{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU",
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "2302b059b0094e94896cff7d6e6f2db0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_126be6dbc52d4d79b3ced479a27f5739",
              "IPY_MODEL_7984e4b259ab4679bc293bd004f9d0b2",
              "IPY_MODEL_2147e1746ebe425f8118d3a722bc967e"
            ],
            "layout": "IPY_MODEL_bb8feea3590c4493a2b3bc0a730279f3"
          }
        },
        "126be6dbc52d4d79b3ced479a27f5739": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7d6ef8ba218b4466ae3d260c27fea432",
            "placeholder": "​",
            "style": "IPY_MODEL_5aa69f7724654f9d9b0471591e543faa",
            "value": "tokenizer_config.json: 100%"
          }
        },
        "7984e4b259ab4679bc293bd004f9d0b2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f716de48c1ee4b9b833f459e41fd7560",
            "max": 49,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_a71c4ada43ac4e088883654f352af207",
            "value": 49
          }
        },
        "2147e1746ebe425f8118d3a722bc967e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_82d32670d7b541579a4e99e349c108d7",
            "placeholder": "​",
            "style": "IPY_MODEL_e6b859fe978640eeb9b52f2959514320",
            "value": " 49.0/49.0 [00:00&lt;00:00, 3.57kB/s]"
          }
        },
        "bb8feea3590c4493a2b3bc0a730279f3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7d6ef8ba218b4466ae3d260c27fea432": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5aa69f7724654f9d9b0471591e543faa": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f716de48c1ee4b9b833f459e41fd7560": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a71c4ada43ac4e088883654f352af207": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "82d32670d7b541579a4e99e349c108d7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e6b859fe978640eeb9b52f2959514320": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "36a39041fcb9418ba77771d31b632cad": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_60e5133645d241e1ac8433041e20ad41",
              "IPY_MODEL_8e155c3522484a2bbe594c8d22efd9c1",
              "IPY_MODEL_8fa10b7f24cb44788c2e5ce43709d05b"
            ],
            "layout": "IPY_MODEL_3cf5897c4d274fad80065df9d477e029"
          }
        },
        "60e5133645d241e1ac8433041e20ad41": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_87201dbab4624b71b4651f47991b762e",
            "placeholder": "​",
            "style": "IPY_MODEL_02404362752c43a2bcba806d851298ec",
            "value": "config.json: 100%"
          }
        },
        "8e155c3522484a2bbe594c8d22efd9c1": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7677487f2fd14c82abe137048356c7bd",
            "max": 462,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_12a9ff1599564a6c85a74825ca06fc06",
            "value": 462
          }
        },
        "8fa10b7f24cb44788c2e5ce43709d05b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0c69059325ec4b1e9671cd1e83574c2b",
            "placeholder": "​",
            "style": "IPY_MODEL_60d25f1eeed44459bcc8e1294dee2616",
            "value": " 462/462 [00:00&lt;00:00, 13.4kB/s]"
          }
        },
        "3cf5897c4d274fad80065df9d477e029": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "87201dbab4624b71b4651f47991b762e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "02404362752c43a2bcba806d851298ec": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "7677487f2fd14c82abe137048356c7bd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "12a9ff1599564a6c85a74825ca06fc06": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "0c69059325ec4b1e9671cd1e83574c2b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "60d25f1eeed44459bcc8e1294dee2616": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "aa72a9c4d048432bb28e3fc494e8440b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_59838d16e4bf4e5eab2054fba0aa5c76",
              "IPY_MODEL_2e030ddedcfc4d2dbe4fd4d9a5d8be07",
              "IPY_MODEL_e3d6729d540842fd8c065d933a2b5448"
            ],
            "layout": "IPY_MODEL_d0b5c3f078134bd1b275f32665cff826"
          }
        },
        "59838d16e4bf4e5eab2054fba0aa5c76": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_cd67b959b37546ec8795448a264eab33",
            "placeholder": "​",
            "style": "IPY_MODEL_e0c7fcfc44744d7f94fe60898b8d4dd8",
            "value": "vocab.txt: 100%"
          }
        },
        "2e030ddedcfc4d2dbe4fd4d9a5d8be07": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_12e7bf8a4cb04be6ac41333ce1f2ca41",
            "max": 213450,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_7961ad44532c4fa8b6a1f99363b0b957",
            "value": 213450
          }
        },
        "e3d6729d540842fd8c065d933a2b5448": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c07eb7ab296d4a8e81dd6c87dace00a3",
            "placeholder": "​",
            "style": "IPY_MODEL_7333a2fab91b4baf99b822d513399b68",
            "value": " 213k/213k [00:00&lt;00:00, 2.93MB/s]"
          }
        },
        "d0b5c3f078134bd1b275f32665cff826": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "cd67b959b37546ec8795448a264eab33": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e0c7fcfc44744d7f94fe60898b8d4dd8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "12e7bf8a4cb04be6ac41333ce1f2ca41": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7961ad44532c4fa8b6a1f99363b0b957": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "c07eb7ab296d4a8e81dd6c87dace00a3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7333a2fab91b4baf99b822d513399b68": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "3881c68bd8064fbe8963a038fce9455c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_9eb17f7511a44254acb3078b2eefd4fa",
              "IPY_MODEL_f4135e59b7aa42f0af35a00726641f0e",
              "IPY_MODEL_5fe8e2f627bf4a0ea1f64818218fb930"
            ],
            "layout": "IPY_MODEL_9b6e0dc1d8fd49528608131220316121"
          }
        },
        "9eb17f7511a44254acb3078b2eefd4fa": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_edb7b73285d44f3a92f7fed42148e82e",
            "placeholder": "​",
            "style": "IPY_MODEL_cdea772afffd4cfca62a01514b8e54cc",
            "value": "special_tokens_map.json: 100%"
          }
        },
        "f4135e59b7aa42f0af35a00726641f0e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_bdf6b240e87f42549843612897670819",
            "max": 112,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_98babaab1ffc47ff98284a7742180c90",
            "value": 112
          }
        },
        "5fe8e2f627bf4a0ea1f64818218fb930": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_8ce2cb82a5f74f7d905bd4c953e3ee63",
            "placeholder": "​",
            "style": "IPY_MODEL_243d39a3150b4d69bb1d90358c3dc09e",
            "value": " 112/112 [00:00&lt;00:00, 1.76kB/s]"
          }
        },
        "9b6e0dc1d8fd49528608131220316121": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "edb7b73285d44f3a92f7fed42148e82e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "cdea772afffd4cfca62a01514b8e54cc": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "bdf6b240e87f42549843612897670819": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "98babaab1ffc47ff98284a7742180c90": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "8ce2cb82a5f74f7d905bd4c953e3ee63": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "243d39a3150b4d69bb1d90358c3dc09e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "cd5a937bd0794a238482e7f0bef529d9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_716f43bca3d94aa88152c22d97b66921",
              "IPY_MODEL_95957a9e2c454ca2ace9964d8d62a865",
              "IPY_MODEL_80a079a8fdda4cf59b9036cda2d67629"
            ],
            "layout": "IPY_MODEL_0652aa8e74fd4548a804db34b8fe8a8b"
          }
        },
        "716f43bca3d94aa88152c22d97b66921": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9e5c99b638a44dce98d632ab8da859d4",
            "placeholder": "​",
            "style": "IPY_MODEL_9c61c8a7a04e4021bd5d8a31a00f2be5",
            "value": "pytorch_model.bin: 100%"
          }
        },
        "95957a9e2c454ca2ace9964d8d62a865": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7eac63f340ae4e7b9b73667b24b34cf4",
            "max": 433286112,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_3458853c665c40a583766717f4f35058",
            "value": 433286112
          }
        },
        "80a079a8fdda4cf59b9036cda2d67629": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_612305bc53854bb9a17481c3d95ecfb1",
            "placeholder": "​",
            "style": "IPY_MODEL_4028065cc4eb4daf9871facde97a3922",
            "value": " 433M/433M [00:06&lt;00:00, 58.1MB/s]"
          }
        },
        "0652aa8e74fd4548a804db34b8fe8a8b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9e5c99b638a44dce98d632ab8da859d4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9c61c8a7a04e4021bd5d8a31a00f2be5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "7eac63f340ae4e7b9b73667b24b34cf4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3458853c665c40a583766717f4f35058": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "612305bc53854bb9a17481c3d95ecfb1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4028065cc4eb4daf9871facde97a3922": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "OzUZExyeT0-5"
      },
      "outputs": [],
      "source": [
        "# This Python 3 environment comes with many helpful analytics libraries installed\n",
        "# It is defined by the kaggle/python Docker image: https://github.com/kaggle/docker-python\n",
        "# For example, here's several helpful packages to load\n",
        "\n",
        "import numpy as np # linear algebra\n",
        "import pandas as pd # data processing, CSV file I/O (e.g. pd.read_csv)\n",
        "\n",
        "# Input data files are available in the read-only \"../input/\" directory\n",
        "# For example, running this (by clicking run or pressing Shift+Enter) will list all files under the input directory\n",
        "\n",
        "import os\n",
        "for dirname, _, filenames in os.walk('/kaggle/input'):\n",
        "    for filename in filenames:\n",
        "        print(os.path.join(dirname, filename))\n",
        "\n",
        "# You can write up to 20GB to the current directory (/kaggle/working/) that gets preserved as output when you create a version using \"Save & Run All\"\n",
        "# You can also write temporary files to /kaggle/temp/, but they won't be saved outside of the current session"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Make sure the file 'treatment-final.xlsx' is in the same directory or provide the full path to the file.\n",
        "data = pd.read_excel('/content/usecase_4_.xlsx')\n",
        "\n",
        "# Display the first few rows to confirm the data is loaded correctly.\n",
        "print(data.head())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5H6jSy8LVLzT",
        "outputId": "5e5c05f8-75a0-4908-ba66-7adb61fd5012"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "    NCT Number                                        Study Title  \\\n",
            "0  NCT00900809  QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...   \n",
            "1  NCT01113515  Clinical Investigation of GalnobaxÂ® for the T...   \n",
            "2  NCT01288573  A Combined Study in Pediatric Cancer Patients ...   \n",
            "3  NCT01336660  A Trial of Equine F (ab')2 Antivenom for Treat...   \n",
            "4  NCT01376167  Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...   \n",
            "\n",
            "                                      Study URL Study Status  \\\n",
            "0  https://clinicaltrials.gov/study/NCT00900809    COMPLETED   \n",
            "1  https://clinicaltrials.gov/study/NCT01113515    COMPLETED   \n",
            "2  https://clinicaltrials.gov/study/NCT01288573    COMPLETED   \n",
            "3  https://clinicaltrials.gov/study/NCT01336660    COMPLETED   \n",
            "4  https://clinicaltrials.gov/study/NCT01376167    COMPLETED   \n",
            "\n",
            "                                       Brief Summary Study Results  \\\n",
            "0  NK cells from patients with malignant diseases...            NO   \n",
            "1  The purpose of this study is to determine safe...           YES   \n",
            "2  This is a multi-site study with plerixafor in ...            NO   \n",
            "3  This study has the objective to demonstrate th...            NO   \n",
            "4  The purpose of this two part study is to test ...           YES   \n",
            "\n",
            "                                          Conditions  \\\n",
            "0                             Acute Myeloid Leukemia   \n",
            "1                                Diabetic Foot Ulcer   \n",
            "2  Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
            "3                        Poisoning by Scorpion Sting   \n",
            "4                                     Malaria, Vivax   \n",
            "\n",
            "                                       Interventions  \\\n",
            "0                  BIOLOGICAL: Neukoplastâ„¢ (NK-92)   \n",
            "1  DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...   \n",
            "2  DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...   \n",
            "3  BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...   \n",
            "4  DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...   \n",
            "\n",
            "                            Primary Outcome Measures  \\\n",
            "0  Determine the safety / maximum tolerated dose ...   \n",
            "1  Safety Outcome, Number of participant with adv...   \n",
            "2  Proportion of patients achieving at least a do...   \n",
            "3  To demonstrate the effectiveness of Alacramyn ...   \n",
            "4  Number of Participants With Recurrence-free Ef...   \n",
            "\n",
            "                          Secondary Outcome Measures  ... Start Date  \\\n",
            "0  Evaluate the therapeutic efficacy of Neukoplas...  ... 2014-05-12   \n",
            "1  Efficacy Outcome, To evaluate the percent chan...  ... 2014-02-20   \n",
            "2  Number of days of apheresis required to reach ...  ... 2014-03-03   \n",
            "3  Effectiveness of Alacramyn NAMO in the treatme...  ... 2018-07-21   \n",
            "4  Number of Participants With Recurrence-free Ef...  ... 2014-04-24   \n",
            "\n",
            "  Primary Completion Date Completion Date First Posted Results First Posted  \\\n",
            "0     2015-06-02 00:00:00      2015-06-02   2009-05-13                  NaT   \n",
            "1     2015-06-27 00:00:00      2015-10-17   2010-04-30           2024-05-20   \n",
            "2     2017-05-09 00:00:00      2017-05-09   2011-02-02                  NaT   \n",
            "3     2018-11-01 00:00:00      2018-11-15   2011-04-18                  NaT   \n",
            "4     2016-11-18 00:00:00      2016-11-18   2011-06-20           2018-04-23   \n",
            "\n",
            "  Last Update Posted                                          Locations  \\\n",
            "0         2022-04-05  UPMC Cancer Center - Hillman Cancer Center, Pi...   \n",
            "1         2024-05-20  VA New England Health Care Division, Providenc...   \n",
            "2         2017-05-16  Investigational Site Number 51, Gent, 9000, Be...   \n",
            "3         2018-12-13  CHU Hassan II de FÃ¨s, FÃ¨s, Morocco|HÃ´pital ...   \n",
            "4         2018-04-23  GSK Investigational Site, Bandarban, Banglades...   \n",
            "\n",
            "  Study Recruitment Rate Duration of Trial  \\\n",
            "0               0.551598               386   \n",
            "1               0.443157               604   \n",
            "2               0.044558              1163   \n",
            "3               7.279202               117   \n",
            "4               1.969008               939   \n",
            "\n",
            "  Primary Completion Duration of Trial  \n",
            "0                                386.0  \n",
            "1                                492.0  \n",
            "2                               1163.0  \n",
            "3                                103.0  \n",
            "4                                939.0  \n",
            "\n",
            "[5 rows x 31 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "_3d3Jy-wVVN7",
        "outputId": "63d2a0e1-0a2c-4160-fffa-915ff7236c1a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "        NCT Number                                        Study Title  \\\n",
              "0      NCT00900809  QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...   \n",
              "1      NCT01113515  Clinical Investigation of GalnobaxÂ® for the T...   \n",
              "2      NCT01288573  A Combined Study in Pediatric Cancer Patients ...   \n",
              "3      NCT01336660  A Trial of Equine F (ab')2 Antivenom for Treat...   \n",
              "4      NCT01376167  Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...   \n",
              "...            ...                                                ...   \n",
              "20671  NCT04883333  A Single and Multiple Ascending-dose Trial of ...   \n",
              "20672  NCT02453087  A Study of Escalating Doses of DCDS0780A in Pa...   \n",
              "20673  NCT03850587  Clinical Trial of YYC301 for Treatment of Oste...   \n",
              "20674  NCT01981187   LGX818 for Patients With BRAFV600 Mutated Tumors   \n",
              "20675  NCT03591887  A Study to Evaluate ABY-035 in Subjects With M...   \n",
              "\n",
              "                                          Study URL Study Status  \\\n",
              "0      https://clinicaltrials.gov/study/NCT00900809    COMPLETED   \n",
              "1      https://clinicaltrials.gov/study/NCT01113515    COMPLETED   \n",
              "2      https://clinicaltrials.gov/study/NCT01288573    COMPLETED   \n",
              "3      https://clinicaltrials.gov/study/NCT01336660    COMPLETED   \n",
              "4      https://clinicaltrials.gov/study/NCT01376167    COMPLETED   \n",
              "...                                             ...          ...   \n",
              "20671  https://clinicaltrials.gov/study/NCT04883333    COMPLETED   \n",
              "20672  https://clinicaltrials.gov/study/NCT02453087    COMPLETED   \n",
              "20673  https://clinicaltrials.gov/study/NCT03850587    COMPLETED   \n",
              "20674  https://clinicaltrials.gov/study/NCT01981187   TERMINATED   \n",
              "20675  https://clinicaltrials.gov/study/NCT03591887    COMPLETED   \n",
              "\n",
              "                                           Brief Summary Study Results  \\\n",
              "0      NK cells from patients with malignant diseases...            NO   \n",
              "1      The purpose of this study is to determine safe...           YES   \n",
              "2      This is a multi-site study with plerixafor in ...            NO   \n",
              "3      This study has the objective to demonstrate th...            NO   \n",
              "4      The purpose of this two part study is to test ...           YES   \n",
              "...                                                  ...           ...   \n",
              "20671  This is a first-in-human study in adult health...            NO   \n",
              "20672  This open-label, multicenter, Phase 1/1b study...            NO   \n",
              "20673  A Multi-center, Double-blinded, Randomized, Ac...            NO   \n",
              "20674  The purpose of this signal seeking study is to...           YES   \n",
              "20675  This randomized, double-blinded dose-finding s...            NO   \n",
              "\n",
              "                                              Conditions  \\\n",
              "0                                 Acute Myeloid Leukemia   \n",
              "1                                    Diabetic Foot Ulcer   \n",
              "2      Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
              "3                            Poisoning by Scorpion Sting   \n",
              "4                                         Malaria, Vivax   \n",
              "...                                                  ...   \n",
              "20671                                 Healthy Volunteers   \n",
              "20672                             Non-Hodgkin's Lymphoma   \n",
              "20673                               Osteoarthritis, Knee   \n",
              "20674               Solid Tumor|Hematologic Malignancies   \n",
              "20675                                   Plaque Psoriasis   \n",
              "\n",
              "                                           Interventions  \\\n",
              "0                      BIOLOGICAL: Neukoplastâ„¢ (NK-92)   \n",
              "1      DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...   \n",
              "2      DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...   \n",
              "3      BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...   \n",
              "4      DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...   \n",
              "...                                                  ...   \n",
              "20671                     DRUG: LEO 153339|DRUG: Placebo   \n",
              "20672  DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...   \n",
              "20673  DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...   \n",
              "20674                                       DRUG: LGX818   \n",
              "20675            BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo   \n",
              "\n",
              "                                Primary Outcome Measures  \\\n",
              "0      Determine the safety / maximum tolerated dose ...   \n",
              "1      Safety Outcome, Number of participant with adv...   \n",
              "2      Proportion of patients achieving at least a do...   \n",
              "3      To demonstrate the effectiveness of Alacramyn ...   \n",
              "4      Number of Participants With Recurrence-free Ef...   \n",
              "...                                                  ...   \n",
              "20671  Number of treatment-emergent adverse events pe...   \n",
              "20672  Number of Participants with Adverse Events, Ba...   \n",
              "20673  100mm Pain VAS, Subjects who have severe pain ...   \n",
              "20674  Clinical Benefit Rate (CBR) for Solid Tumors a...   \n",
              "20675  Proportion of subjects with a â‰¥90% improveme...   \n",
              "\n",
              "                              Secondary Outcome Measures  ... Start Date  \\\n",
              "0      Evaluate the therapeutic efficacy of Neukoplas...  ... 2014-05-12   \n",
              "1      Efficacy Outcome, To evaluate the percent chan...  ... 2014-02-20   \n",
              "2      Number of days of apheresis required to reach ...  ... 2014-03-03   \n",
              "3      Effectiveness of Alacramyn NAMO in the treatme...  ... 2018-07-21   \n",
              "4      Number of Participants With Recurrence-free Ef...  ... 2014-04-24   \n",
              "...                                                  ...  ...        ...   \n",
              "20671  Plasma concentration of LEO 153339 and LEO 159...  ... 2021-05-17   \n",
              "20672  Area Under the Serum Concentration-Time Curve ...  ... 2015-08-04   \n",
              "20673                                                NaN  ... 2018-08-30   \n",
              "20674  Overall Response Rate (ORR) for Solid Tumors a...  ... 2014-01-14   \n",
              "20675  Number of treatment emergent Adverse Events, A...  ... 2018-03-07   \n",
              "\n",
              "      Primary Completion Date Completion Date First Posted  \\\n",
              "0         2015-06-02 00:00:00      2015-06-02   2009-05-13   \n",
              "1         2015-06-27 00:00:00      2015-10-17   2010-04-30   \n",
              "2         2017-05-09 00:00:00      2017-05-09   2011-02-02   \n",
              "3         2018-11-01 00:00:00      2018-11-15   2011-04-18   \n",
              "4         2016-11-18 00:00:00      2016-11-18   2011-06-20   \n",
              "...                       ...             ...          ...   \n",
              "20671     2022-07-18 00:00:00      2022-07-18   2021-05-12   \n",
              "20672     2019-07-12 00:00:00      2019-07-12   2015-05-25   \n",
              "20673     2020-05-12 00:00:00      2020-09-07   2019-02-22   \n",
              "20674     2015-09-01 00:00:00      2015-10-13   2013-11-11   \n",
              "20675     2019-03-27 00:00:00      2021-12-03   2018-07-19   \n",
              "\n",
              "      Results First Posted Last Update Posted  \\\n",
              "0                      NaT         2022-04-05   \n",
              "1               2024-05-20         2024-05-20   \n",
              "2                      NaT         2017-05-16   \n",
              "3                      NaT         2018-12-13   \n",
              "4               2018-04-23         2018-04-23   \n",
              "...                    ...                ...   \n",
              "20671                  NaT         2023-04-26   \n",
              "20672                  NaT         2019-08-29   \n",
              "20673                  NaT         2021-05-11   \n",
              "20674           2021-03-26         2021-03-26   \n",
              "20675                  NaT         2023-06-08   \n",
              "\n",
              "                                               Locations  \\\n",
              "0      UPMC Cancer Center - Hillman Cancer Center, Pi...   \n",
              "1      VA New England Health Care Division, Providenc...   \n",
              "2      Investigational Site Number 51, Gent, 9000, Be...   \n",
              "3      CHU Hassan II de FÃ¨s, FÃ¨s, Morocco|HÃ´pital ...   \n",
              "4      GSK Investigational Site, Bandarban, Banglades...   \n",
              "...                                                  ...   \n",
              "20671  LEO Pharma Investigational Site, Groningen, NZ...   \n",
              "20672  City of Hope National Medical Center, Duarte, ...   \n",
              "20673  Dong-A University Hospital., Busan, Korea, Rep...   \n",
              "20674  Alabama Oncology St. Vincent's Birmingham, Bir...   \n",
              "20675  Rothhaar Studien GmbH, Berlin, 10783, Germany|...   \n",
              "\n",
              "      Study Recruitment Rate Duration of Trial  \\\n",
              "0                   0.551598               386   \n",
              "1                   0.443157               604   \n",
              "2                   0.044558              1163   \n",
              "3                   7.279202               117   \n",
              "4                   1.969008               939   \n",
              "...                      ...               ...   \n",
              "20671               7.693208               427   \n",
              "20672               0.199434              1438   \n",
              "20673               1.074256               739   \n",
              "20674               0.044077               637   \n",
              "20675               0.133504              1367   \n",
              "\n",
              "      Primary Completion Duration of Trial  \n",
              "0                                    386.0  \n",
              "1                                    492.0  \n",
              "2                                   1163.0  \n",
              "3                                    103.0  \n",
              "4                                    939.0  \n",
              "...                                    ...  \n",
              "20671                                427.0  \n",
              "20672                               1438.0  \n",
              "20673                                621.0  \n",
              "20674                                595.0  \n",
              "20675                                385.0  \n",
              "\n",
              "[20676 rows x 31 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-eddbb600-4be7-4347-aaf6-c1dc1f950f10\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>NCT Number</th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study URL</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Primary Outcome Measures</th>\n",
              "      <th>Secondary Outcome Measures</th>\n",
              "      <th>...</th>\n",
              "      <th>Start Date</th>\n",
              "      <th>Primary Completion Date</th>\n",
              "      <th>Completion Date</th>\n",
              "      <th>First Posted</th>\n",
              "      <th>Results First Posted</th>\n",
              "      <th>Last Update Posted</th>\n",
              "      <th>Locations</th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "      <th>Duration of Trial</th>\n",
              "      <th>Primary Completion Duration of Trial</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>NCT00900809</td>\n",
              "      <td>QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT00900809</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>NK cells from patients with malignant diseases...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Acute Myeloid Leukemia</td>\n",
              "      <td>BIOLOGICAL: Neukoplastâ„¢ (NK-92)</td>\n",
              "      <td>Determine the safety / maximum tolerated dose ...</td>\n",
              "      <td>Evaluate the therapeutic efficacy of Neukoplas...</td>\n",
              "      <td>...</td>\n",
              "      <td>2014-05-12</td>\n",
              "      <td>2015-06-02 00:00:00</td>\n",
              "      <td>2015-06-02</td>\n",
              "      <td>2009-05-13</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2022-04-05</td>\n",
              "      <td>UPMC Cancer Center - Hillman Cancer Center, Pi...</td>\n",
              "      <td>0.551598</td>\n",
              "      <td>386</td>\n",
              "      <td>386.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>NCT01113515</td>\n",
              "      <td>Clinical Investigation of GalnobaxÂ® for the T...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT01113515</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this study is to determine safe...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Diabetic Foot Ulcer</td>\n",
              "      <td>DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...</td>\n",
              "      <td>Safety Outcome, Number of participant with adv...</td>\n",
              "      <td>Efficacy Outcome, To evaluate the percent chan...</td>\n",
              "      <td>...</td>\n",
              "      <td>2014-02-20</td>\n",
              "      <td>2015-06-27 00:00:00</td>\n",
              "      <td>2015-10-17</td>\n",
              "      <td>2010-04-30</td>\n",
              "      <td>2024-05-20</td>\n",
              "      <td>2024-05-20</td>\n",
              "      <td>VA New England Health Care Division, Providenc...</td>\n",
              "      <td>0.443157</td>\n",
              "      <td>604</td>\n",
              "      <td>492.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NCT01288573</td>\n",
              "      <td>A Combined Study in Pediatric Cancer Patients ...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT01288573</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a multi-site study with plerixafor in ...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...</td>\n",
              "      <td>DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...</td>\n",
              "      <td>Proportion of patients achieving at least a do...</td>\n",
              "      <td>Number of days of apheresis required to reach ...</td>\n",
              "      <td>...</td>\n",
              "      <td>2014-03-03</td>\n",
              "      <td>2017-05-09 00:00:00</td>\n",
              "      <td>2017-05-09</td>\n",
              "      <td>2011-02-02</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2017-05-16</td>\n",
              "      <td>Investigational Site Number 51, Gent, 9000, Be...</td>\n",
              "      <td>0.044558</td>\n",
              "      <td>1163</td>\n",
              "      <td>1163.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>NCT01336660</td>\n",
              "      <td>A Trial of Equine F (ab')2 Antivenom for Treat...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT01336660</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This study has the objective to demonstrate th...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Poisoning by Scorpion Sting</td>\n",
              "      <td>BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...</td>\n",
              "      <td>To demonstrate the effectiveness of Alacramyn ...</td>\n",
              "      <td>Effectiveness of Alacramyn NAMO in the treatme...</td>\n",
              "      <td>...</td>\n",
              "      <td>2018-07-21</td>\n",
              "      <td>2018-11-01 00:00:00</td>\n",
              "      <td>2018-11-15</td>\n",
              "      <td>2011-04-18</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2018-12-13</td>\n",
              "      <td>CHU Hassan II de FÃ¨s, FÃ¨s, Morocco|HÃ´pital ...</td>\n",
              "      <td>7.279202</td>\n",
              "      <td>117</td>\n",
              "      <td>103.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>NCT01376167</td>\n",
              "      <td>Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT01376167</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this two part study is to test ...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Malaria, Vivax</td>\n",
              "      <td>DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>...</td>\n",
              "      <td>2014-04-24</td>\n",
              "      <td>2016-11-18 00:00:00</td>\n",
              "      <td>2016-11-18</td>\n",
              "      <td>2011-06-20</td>\n",
              "      <td>2018-04-23</td>\n",
              "      <td>2018-04-23</td>\n",
              "      <td>GSK Investigational Site, Bandarban, Banglades...</td>\n",
              "      <td>1.969008</td>\n",
              "      <td>939</td>\n",
              "      <td>939.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>NCT04883333</td>\n",
              "      <td>A Single and Multiple Ascending-dose Trial of ...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT04883333</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a first-in-human study in adult health...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Healthy Volunteers</td>\n",
              "      <td>DRUG: LEO 153339|DRUG: Placebo</td>\n",
              "      <td>Number of treatment-emergent adverse events pe...</td>\n",
              "      <td>Plasma concentration of LEO 153339 and LEO 159...</td>\n",
              "      <td>...</td>\n",
              "      <td>2021-05-17</td>\n",
              "      <td>2022-07-18 00:00:00</td>\n",
              "      <td>2022-07-18</td>\n",
              "      <td>2021-05-12</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2023-04-26</td>\n",
              "      <td>LEO Pharma Investigational Site, Groningen, NZ...</td>\n",
              "      <td>7.693208</td>\n",
              "      <td>427</td>\n",
              "      <td>427.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>NCT02453087</td>\n",
              "      <td>A Study of Escalating Doses of DCDS0780A in Pa...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT02453087</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This open-label, multicenter, Phase 1/1b study...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Non-Hodgkin's Lymphoma</td>\n",
              "      <td>DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...</td>\n",
              "      <td>Number of Participants with Adverse Events, Ba...</td>\n",
              "      <td>Area Under the Serum Concentration-Time Curve ...</td>\n",
              "      <td>...</td>\n",
              "      <td>2015-08-04</td>\n",
              "      <td>2019-07-12 00:00:00</td>\n",
              "      <td>2019-07-12</td>\n",
              "      <td>2015-05-25</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2019-08-29</td>\n",
              "      <td>City of Hope National Medical Center, Duarte, ...</td>\n",
              "      <td>0.199434</td>\n",
              "      <td>1438</td>\n",
              "      <td>1438.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>NCT03850587</td>\n",
              "      <td>Clinical Trial of YYC301 for Treatment of Oste...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT03850587</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>A Multi-center, Double-blinded, Randomized, Ac...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Osteoarthritis, Knee</td>\n",
              "      <td>DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...</td>\n",
              "      <td>100mm Pain VAS, Subjects who have severe pain ...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>...</td>\n",
              "      <td>2018-08-30</td>\n",
              "      <td>2020-05-12 00:00:00</td>\n",
              "      <td>2020-09-07</td>\n",
              "      <td>2019-02-22</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2021-05-11</td>\n",
              "      <td>Dong-A University Hospital., Busan, Korea, Rep...</td>\n",
              "      <td>1.074256</td>\n",
              "      <td>739</td>\n",
              "      <td>621.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20674</th>\n",
              "      <td>NCT01981187</td>\n",
              "      <td>LGX818 for Patients With BRAFV600 Mutated Tumors</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT01981187</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>The purpose of this signal seeking study is to...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Solid Tumor|Hematologic Malignancies</td>\n",
              "      <td>DRUG: LGX818</td>\n",
              "      <td>Clinical Benefit Rate (CBR) for Solid Tumors a...</td>\n",
              "      <td>Overall Response Rate (ORR) for Solid Tumors a...</td>\n",
              "      <td>...</td>\n",
              "      <td>2014-01-14</td>\n",
              "      <td>2015-09-01 00:00:00</td>\n",
              "      <td>2015-10-13</td>\n",
              "      <td>2013-11-11</td>\n",
              "      <td>2021-03-26</td>\n",
              "      <td>2021-03-26</td>\n",
              "      <td>Alabama Oncology St. Vincent's Birmingham, Bir...</td>\n",
              "      <td>0.044077</td>\n",
              "      <td>637</td>\n",
              "      <td>595.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>NCT03591887</td>\n",
              "      <td>A Study to Evaluate ABY-035 in Subjects With M...</td>\n",
              "      <td>https://clinicaltrials.gov/study/NCT03591887</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This randomized, double-blinded dose-finding s...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Plaque Psoriasis</td>\n",
              "      <td>BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo</td>\n",
              "      <td>Proportion of subjects with a â‰¥90% improveme...</td>\n",
              "      <td>Number of treatment emergent Adverse Events, A...</td>\n",
              "      <td>...</td>\n",
              "      <td>2018-03-07</td>\n",
              "      <td>2019-03-27 00:00:00</td>\n",
              "      <td>2021-12-03</td>\n",
              "      <td>2018-07-19</td>\n",
              "      <td>NaT</td>\n",
              "      <td>2023-06-08</td>\n",
              "      <td>Rothhaar Studien GmbH, Berlin, 10783, Germany|...</td>\n",
              "      <td>0.133504</td>\n",
              "      <td>1367</td>\n",
              "      <td>385.0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20676 rows × 31 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-eddbb600-4be7-4347-aaf6-c1dc1f950f10')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-eddbb600-4be7-4347-aaf6-c1dc1f950f10 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-eddbb600-4be7-4347-aaf6-c1dc1f950f10');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-33d053e9-3842-4708-8a16-636598b90b4a\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-33d053e9-3842-4708-8a16-636598b90b4a')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-33d053e9-3842-4708-8a16-636598b90b4a button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_15f3f2e2-e4e4-4d51-b4f6-02e1cdbac80a\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('data')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_15f3f2e2-e4e4-4d51-b4f6-02e1cdbac80a button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('data');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "data"
            }
          },
          "metadata": {},
          "execution_count": 2
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Q6Ipj89GVciP",
        "outputId": "279b64e2-976b-403a-ceff-4e4ee3dd499f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['NCT Number', 'Study Title', 'Study URL', 'Study Status',\n",
              "       'Brief Summary', 'Study Results', 'Conditions', 'Interventions',\n",
              "       'Primary Outcome Measures', 'Secondary Outcome Measures',\n",
              "       'Other Outcome Measures', 'Sponsor', 'Collaborators', 'Sex', 'Age',\n",
              "       'Phases', 'Enrollment', 'Funder Type', 'Study Type', 'Study Design',\n",
              "       'Other IDs', 'Start Date', 'Primary Completion Date', 'Completion Date',\n",
              "       'First Posted', 'Results First Posted', 'Last Update Posted',\n",
              "       'Locations', 'Study Recruitment Rate', 'Duration of Trial',\n",
              "       'Primary Completion Duration of Trial'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 3
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1 = data.drop(['NCT Number','Study URL','Locations','Other IDs','Collaborators','Sponsor','Start Date','Primary Completion Date','Other Outcome Measures'],axis='columns')"
      ],
      "metadata": {
        "id": "y9Hy4WwtVfpj"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data1=data1.drop(['Study Type','Last Update Posted','Results First Posted','First Posted','Funder Type'],axis='columns')"
      ],
      "metadata": {
        "id": "hsvJ5vLZVhg9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "oDDMSZuIVi7o",
        "outputId": "f170ea84-860f-434d-8db3-8f71d3bd1eb5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                             Study Title Study Status  \\\n",
              "0      QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
              "1      Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
              "2      A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
              "3      A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
              "4      Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
              "...                                                  ...          ...   \n",
              "20671  A Single and Multiple Ascending-dose Trial of ...    COMPLETED   \n",
              "20672  A Study of Escalating Doses of DCDS0780A in Pa...    COMPLETED   \n",
              "20673  Clinical Trial of YYC301 for Treatment of Oste...    COMPLETED   \n",
              "20674   LGX818 for Patients With BRAFV600 Mutated Tumors   TERMINATED   \n",
              "20675  A Study to Evaluate ABY-035 in Subjects With M...    COMPLETED   \n",
              "\n",
              "                                           Brief Summary Study Results  \\\n",
              "0      NK cells from patients with malignant diseases...            NO   \n",
              "1      The purpose of this study is to determine safe...           YES   \n",
              "2      This is a multi-site study with plerixafor in ...            NO   \n",
              "3      This study has the objective to demonstrate th...            NO   \n",
              "4      The purpose of this two part study is to test ...           YES   \n",
              "...                                                  ...           ...   \n",
              "20671  This is a first-in-human study in adult health...            NO   \n",
              "20672  This open-label, multicenter, Phase 1/1b study...            NO   \n",
              "20673  A Multi-center, Double-blinded, Randomized, Ac...            NO   \n",
              "20674  The purpose of this signal seeking study is to...           YES   \n",
              "20675  This randomized, double-blinded dose-finding s...            NO   \n",
              "\n",
              "                                              Conditions  \\\n",
              "0                                 Acute Myeloid Leukemia   \n",
              "1                                    Diabetic Foot Ulcer   \n",
              "2      Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
              "3                            Poisoning by Scorpion Sting   \n",
              "4                                         Malaria, Vivax   \n",
              "...                                                  ...   \n",
              "20671                                 Healthy Volunteers   \n",
              "20672                             Non-Hodgkin's Lymphoma   \n",
              "20673                               Osteoarthritis, Knee   \n",
              "20674               Solid Tumor|Hematologic Malignancies   \n",
              "20675                                   Plaque Psoriasis   \n",
              "\n",
              "                                           Interventions  \\\n",
              "0                      BIOLOGICAL: Neukoplastâ„¢ (NK-92)   \n",
              "1      DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...   \n",
              "2      DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...   \n",
              "3      BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...   \n",
              "4      DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...   \n",
              "...                                                  ...   \n",
              "20671                     DRUG: LEO 153339|DRUG: Placebo   \n",
              "20672  DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...   \n",
              "20673  DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...   \n",
              "20674                                       DRUG: LGX818   \n",
              "20675            BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo   \n",
              "\n",
              "                                Primary Outcome Measures  \\\n",
              "0      Determine the safety / maximum tolerated dose ...   \n",
              "1      Safety Outcome, Number of participant with adv...   \n",
              "2      Proportion of patients achieving at least a do...   \n",
              "3      To demonstrate the effectiveness of Alacramyn ...   \n",
              "4      Number of Participants With Recurrence-free Ef...   \n",
              "...                                                  ...   \n",
              "20671  Number of treatment-emergent adverse events pe...   \n",
              "20672  Number of Participants with Adverse Events, Ba...   \n",
              "20673  100mm Pain VAS, Subjects who have severe pain ...   \n",
              "20674  Clinical Benefit Rate (CBR) for Solid Tumors a...   \n",
              "20675  Proportion of subjects with a â‰¥90% improveme...   \n",
              "\n",
              "                              Secondary Outcome Measures  Sex  \\\n",
              "0      Evaluate the therapeutic efficacy of Neukoplas...  ALL   \n",
              "1      Efficacy Outcome, To evaluate the percent chan...  ALL   \n",
              "2      Number of days of apheresis required to reach ...  ALL   \n",
              "3      Effectiveness of Alacramyn NAMO in the treatme...  ALL   \n",
              "4      Number of Participants With Recurrence-free Ef...  ALL   \n",
              "...                                                  ...  ...   \n",
              "20671  Plasma concentration of LEO 153339 and LEO 159...  ALL   \n",
              "20672  Area Under the Serum Concentration-Time Curve ...  ALL   \n",
              "20673                                                NaN  ALL   \n",
              "20674  Overall Response Rate (ORR) for Solid Tumors a...  ALL   \n",
              "20675  Number of treatment emergent Adverse Events, A...  ALL   \n",
              "\n",
              "                             Age         Phases  Enrollment  \\\n",
              "0             ADULT, OLDER_ADULT         PHASE1           7   \n",
              "1             ADULT, OLDER_ADULT  PHASE1|PHASE2          44   \n",
              "2                   CHILD, ADULT  PHASE1|PHASE2          46   \n",
              "3                          CHILD  PHASE2|PHASE3          56   \n",
              "4      CHILD, ADULT, OLDER_ADULT         PHASE2         851   \n",
              "...                          ...            ...         ...   \n",
              "20671         ADULT, OLDER_ADULT         PHASE1         108   \n",
              "20672         ADULT, OLDER_ADULT         PHASE1          66   \n",
              "20673         ADULT, OLDER_ADULT         PHASE2         261   \n",
              "20674         ADULT, OLDER_ADULT         PHASE2          12   \n",
              "20675         ADULT, OLDER_ADULT         PHASE2         108   \n",
              "\n",
              "                                            Study Design Completion Date  \\\n",
              "0      Allocation: NA|Intervention Model: SINGLE_GROU...      2015-06-02   \n",
              "1      Allocation: RANDOMIZED|Intervention Model: PAR...      2015-10-17   \n",
              "2      Allocation: RANDOMIZED|Intervention Model: PAR...      2017-05-09   \n",
              "3      Allocation: RANDOMIZED|Intervention Model: PAR...      2018-11-15   \n",
              "4      Allocation: RANDOMIZED|Intervention Model: PAR...      2016-11-18   \n",
              "...                                                  ...             ...   \n",
              "20671  Allocation: RANDOMIZED|Intervention Model: PAR...      2022-07-18   \n",
              "20672  Allocation: NON_RANDOMIZED|Intervention Model:...      2019-07-12   \n",
              "20673  Allocation: RANDOMIZED|Intervention Model: PAR...      2020-09-07   \n",
              "20674  Allocation: NA|Intervention Model: SINGLE_GROU...      2015-10-13   \n",
              "20675  Allocation: RANDOMIZED|Intervention Model: PAR...      2021-12-03   \n",
              "\n",
              "       Study Recruitment Rate  Duration of Trial  \\\n",
              "0                    0.551598                386   \n",
              "1                    0.443157                604   \n",
              "2                    0.044558               1163   \n",
              "3                    7.279202                117   \n",
              "4                    1.969008                939   \n",
              "...                       ...                ...   \n",
              "20671                7.693208                427   \n",
              "20672                0.199434               1438   \n",
              "20673                1.074256                739   \n",
              "20674                0.044077                637   \n",
              "20675                0.133504               1367   \n",
              "\n",
              "       Primary Completion Duration of Trial  \n",
              "0                                     386.0  \n",
              "1                                     492.0  \n",
              "2                                    1163.0  \n",
              "3                                     103.0  \n",
              "4                                     939.0  \n",
              "...                                     ...  \n",
              "20671                                 427.0  \n",
              "20672                                1438.0  \n",
              "20673                                 621.0  \n",
              "20674                                 595.0  \n",
              "20675                                 385.0  \n",
              "\n",
              "[20676 rows x 17 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-01fb35b0-edc0-41a6-99bf-acbc557adbf2\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Primary Outcome Measures</th>\n",
              "      <th>Secondary Outcome Measures</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Study Design</th>\n",
              "      <th>Completion Date</th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "      <th>Duration of Trial</th>\n",
              "      <th>Primary Completion Duration of Trial</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>NK cells from patients with malignant diseases...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Acute Myeloid Leukemia</td>\n",
              "      <td>BIOLOGICAL: Neukoplastâ„¢ (NK-92)</td>\n",
              "      <td>Determine the safety / maximum tolerated dose ...</td>\n",
              "      <td>Evaluate the therapeutic efficacy of Neukoplas...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>7</td>\n",
              "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
              "      <td>2015-06-02</td>\n",
              "      <td>0.551598</td>\n",
              "      <td>386</td>\n",
              "      <td>386.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Clinical Investigation of GalnobaxÂ® for the T...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this study is to determine safe...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Diabetic Foot Ulcer</td>\n",
              "      <td>DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...</td>\n",
              "      <td>Safety Outcome, Number of participant with adv...</td>\n",
              "      <td>Efficacy Outcome, To evaluate the percent chan...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>44</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2015-10-17</td>\n",
              "      <td>0.443157</td>\n",
              "      <td>604</td>\n",
              "      <td>492.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>A Combined Study in Pediatric Cancer Patients ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a multi-site study with plerixafor in ...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...</td>\n",
              "      <td>DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...</td>\n",
              "      <td>Proportion of patients achieving at least a do...</td>\n",
              "      <td>Number of days of apheresis required to reach ...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>46</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2017-05-09</td>\n",
              "      <td>0.044558</td>\n",
              "      <td>1163</td>\n",
              "      <td>1163.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>A Trial of Equine F (ab')2 Antivenom for Treat...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This study has the objective to demonstrate th...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Poisoning by Scorpion Sting</td>\n",
              "      <td>BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...</td>\n",
              "      <td>To demonstrate the effectiveness of Alacramyn ...</td>\n",
              "      <td>Effectiveness of Alacramyn NAMO in the treatme...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD</td>\n",
              "      <td>PHASE2|PHASE3</td>\n",
              "      <td>56</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2018-11-15</td>\n",
              "      <td>7.279202</td>\n",
              "      <td>117</td>\n",
              "      <td>103.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this two part study is to test ...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Malaria, Vivax</td>\n",
              "      <td>DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>851</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2016-11-18</td>\n",
              "      <td>1.969008</td>\n",
              "      <td>939</td>\n",
              "      <td>939.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>A Single and Multiple Ascending-dose Trial of ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a first-in-human study in adult health...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Healthy Volunteers</td>\n",
              "      <td>DRUG: LEO 153339|DRUG: Placebo</td>\n",
              "      <td>Number of treatment-emergent adverse events pe...</td>\n",
              "      <td>Plasma concentration of LEO 153339 and LEO 159...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>108</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2022-07-18</td>\n",
              "      <td>7.693208</td>\n",
              "      <td>427</td>\n",
              "      <td>427.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>A Study of Escalating Doses of DCDS0780A in Pa...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This open-label, multicenter, Phase 1/1b study...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Non-Hodgkin's Lymphoma</td>\n",
              "      <td>DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...</td>\n",
              "      <td>Number of Participants with Adverse Events, Ba...</td>\n",
              "      <td>Area Under the Serum Concentration-Time Curve ...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>66</td>\n",
              "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
              "      <td>2019-07-12</td>\n",
              "      <td>0.199434</td>\n",
              "      <td>1438</td>\n",
              "      <td>1438.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>Clinical Trial of YYC301 for Treatment of Oste...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>A Multi-center, Double-blinded, Randomized, Ac...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Osteoarthritis, Knee</td>\n",
              "      <td>DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...</td>\n",
              "      <td>100mm Pain VAS, Subjects who have severe pain ...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>261</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2020-09-07</td>\n",
              "      <td>1.074256</td>\n",
              "      <td>739</td>\n",
              "      <td>621.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20674</th>\n",
              "      <td>LGX818 for Patients With BRAFV600 Mutated Tumors</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>The purpose of this signal seeking study is to...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Solid Tumor|Hematologic Malignancies</td>\n",
              "      <td>DRUG: LGX818</td>\n",
              "      <td>Clinical Benefit Rate (CBR) for Solid Tumors a...</td>\n",
              "      <td>Overall Response Rate (ORR) for Solid Tumors a...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>12</td>\n",
              "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
              "      <td>2015-10-13</td>\n",
              "      <td>0.044077</td>\n",
              "      <td>637</td>\n",
              "      <td>595.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>A Study to Evaluate ABY-035 in Subjects With M...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This randomized, double-blinded dose-finding s...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Plaque Psoriasis</td>\n",
              "      <td>BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo</td>\n",
              "      <td>Proportion of subjects with a â‰¥90% improveme...</td>\n",
              "      <td>Number of treatment emergent Adverse Events, A...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>108</td>\n",
              "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
              "      <td>2021-12-03</td>\n",
              "      <td>0.133504</td>\n",
              "      <td>1367</td>\n",
              "      <td>385.0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20676 rows × 17 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-01fb35b0-edc0-41a6-99bf-acbc557adbf2')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-01fb35b0-edc0-41a6-99bf-acbc557adbf2 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-01fb35b0-edc0-41a6-99bf-acbc557adbf2');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-ebbc81e2-51e3-492a-89d5-664de3fabe8d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ebbc81e2-51e3-492a-89d5-664de3fabe8d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-ebbc81e2-51e3-492a-89d5-664de3fabe8d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_25761c2d-73b8-488d-905d-0ea09d3504fc\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('data1')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_25761c2d-73b8-488d-905d-0ea09d3504fc button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('data1');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "data1",
              "summary": "{\n  \"name\": \"data1\",\n  \"rows\": 20676,\n  \"fields\": [\n    {\n      \"column\": \"Study Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20636,\n        \"samples\": [\n          \"CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.\",\n          \"Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy\",\n          \"IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"UNKNOWN\",\n          \"SUSPENDED\",\n          \"COMPLETED\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20528,\n        \"samples\": [\n          \"The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly (over 60 years of age).\",\n          \"The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).\",\n          \"This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-\\u00ce\\u00b4,\\u00ce\\u00b3, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"YES\",\n          \"NO\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 7860,\n        \"samples\": [\n          \"Infection, Bacterial\",\n          \"Connective Tissue Disease-Associated Pulmonary Arterial Hypertension\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 18217,\n        \"samples\": [\n          \"DRUG: siremadlin|DRUG: venetoclax|DRUG: azacitidine\",\n          \"DIETARY_SUPPLEMENT: Probiotic\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20437,\n        \"samples\": [\n          \"Cmax Day 1, Maximum concentration, Day 1 for the first dose (8:00 AM dose)|AUC (AUCDay 3, 0-24hr), Area under the concentration-time curve, Day 3 from 8:00 AM to 8:00 AM from 0 to 24 hr\",\n          \"Phase 1b: Number of Participants With Adverse Events as Per Severity, An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event., Day 1 up to 45.2 months|Phase 2: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\\\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\\\>=90% or to less than (\\\\<) 200 milligrams (mg) per 24 hours. If the serum and urine M-protein were not measurable, a decrease of \\\\>=50% in the difference between involved and uninvolved free light chain (FLC) levels was required in place of the M-protein criteria. If serum and urine M-protein were not measurable, and serum free light assay was also not measurable, \\\\>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow PC percentage was \\\\>=30%. In addition to the above criteria, if present at baseline, a \\\\>=50% reduction in the size of soft tissue plasmacytomas was also required., Day 1 up to 45.2 months\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17646,\n        \"samples\": [\n          \"AUC0-2hr for L-dopa, Area under the Plasma Concentration-time Curve for L-dopa from Time = 0 to Time = 2 hours post dose. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 min|Cmax of L-dopa, Maximum Observed Plasma Concentration of L-dopa from Time = 0 to Time = 2 hours post dose. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Tmax of L-dopa, Time to Reach the Maximum Plasma Concentration (Cmax) of L-dopa, For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Mean Change From Baseline in MDS-UPDRS Score Over 2 Hours for C1, C2, C3 and Change From Baseline at 30, 60, 90, 120 Minutes for C4, in MDS-UPDRS Part III Score, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Maximum score is 132, minimum is zero. High score means worse outcome. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg treatment groups, assessment occurred at pre-dose, 15, 30, 45, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, assessment occurred at pre-dose, 30, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg, assessment occurred at pre-dose, 15, 30, 45, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, assessment occurred at pre-dose, 30, 60, 90 and 120 minutes post-dose.|Time to Response (Defined as Improvement of 30% in MDS-UPDRS Part III Score From Baseline), MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., 2 hours|Cumulative Number of Responders (Defined as Improvement of 30% in MDS-UPDRS Part III Score From Baseline), MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., From time = 0 to 2 hours post-dose|Area Under the Curve (AUC) of Change From Baseline in MDS-UPDRS Part III Scores, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., For L-dopa 35 mg, 70 mg, 140 mg, assessments were made at pre-dose, 15, 30, 45, 60, 90, 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, assessments were made at pre-dose, 50, 60, 90, 120 minutes post-dose.|Mean Maximum Change From Baseline in MDS-UPDRS Part III Score, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. The total of the subscales has a maximum value of 132 and a minimum value of zero. Lower scores indicate better motor function. A negative change from baseline indicates improved motor function., From time = 0 to 2 hours post-dose|Subjective Time to \\\"ON\\\" as Evaluated by the Investigator, Investigators will evaluate subjects' fluctuations in motor functions at 15, 30, 45, 60, 90, 120, and 240 minutes post-dose to determine if they are \\\"ON\\\"., 4 hours|Assessment of Time to \\\"ON\\\" as Evaluated by Subject Self-assessment, Subjects were asked to provide self-assessments at 15, 30, 45, 60, 90, 120, and 240 minutes post-dose as to whether they considered themselves to be \\\"ON\\\"., 4 hours|AUC0-2h for Carbidopa, Area under the concentration time curve for carbidopa, Plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose and AUC calculated from these from time 0 to 120 minutes.|Cmax of Carbidopa, Maximum concentration of carbidopa, For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Tmax of Carbidopa, Time to reach the maximum concentration of carbidopa, For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Duration of Response, Where Response is Defined as an Improvement of 30% in MDS-UPDRS Part III Score From Baseline., MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Maximum score is 132, minimum is zero. High score means worse outcome., 2 hours\",\n          \"Number of subject with adverse events, The toxic effects of the drug would be assessed from adverse events, vital signs and by clinically significant changes in the laboratory evaluations., up to 4 weeks after last dose|Objective response, Evaluation of Response: Clinical responses will be presented patient wise for different dose levels., up to approximately 24 months|AUC0-\\u00e2\\u02c6\\u017e, area under the concentration versus time curve (AUC) from time zero to infinity, up to approximately 4 weeks|AUC0-t, AUC from time zero to the time of the last quantifiable concentration time zero to the time of the last quantifiable concentration, up to approximately 4 weeks|Cmax, maximum observed plasma concentration, up to approximately 4 weeks|tmax, time of the maximum observed plasma concentration, up to approximately 4 weeks|t\\u00c2\\u00bd, apparent terminal elimination half-life, up to approximately 4 weeks|Vz/F, apparent volume of distribution, up to approximately 4 weeks\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"ALL\",\n          \"FEMALE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"ADULT, OLDER_ADULT\",\n          \"CHILD, ADULT\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"PHASE1|PHASE2\",\n          \"PHASE3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3534,\n        \"min\": 1,\n        \"max\": 477102,\n        \"num_unique_values\": 1341,\n        \"samples\": [\n          230,\n          273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Design\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 340,\n        \"samples\": [\n          \"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC\",\n          \"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Completion Date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2014-02-08 00:00:00\",\n        \"max\": \"2024-06-30 00:00:00\",\n        \"num_unique_values\": 3027,\n        \"samples\": [\n          \"2021-05-12 00:00:00\",\n          \"2020-06-25 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Recruitment Rate\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 47.61087701710453,\n        \"min\": 0.0011275127619133577,\n        \"max\": 4816.602870813397,\n        \"num_unique_values\": 17106,\n        \"samples\": [\n          0.9896963123644252,\n          21.433106967464703\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 669,\n        \"min\": -41927,\n        \"max\": 3787,\n        \"num_unique_values\": 2525,\n        \"samples\": [\n          903,\n          106\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Completion Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 527.2636176228543,\n        \"min\": 0.0,\n        \"max\": 3662.0,\n        \"num_unique_values\": 2277,\n        \"samples\": [\n          1207.0,\n          1124.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "target = data1['Study Recruitment Rate']"
      ],
      "metadata": {
        "id": "es1eOvgpVj-c"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "target"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 458
        },
        "id": "SiQ4WNtRVme9",
        "outputId": "a2ca390e-96a6-4bed-b7c8-5cb496f5cb9f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "0        0.551598\n",
              "1        0.443157\n",
              "2        0.044558\n",
              "3        7.279202\n",
              "4        1.969008\n",
              "           ...   \n",
              "20671    7.693208\n",
              "20672    0.199434\n",
              "20673    1.074256\n",
              "20674    0.044077\n",
              "20675    0.133504\n",
              "Name: Study Recruitment Rate, Length: 20676, dtype: float64"
            ],
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0.551598</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>0.443157</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>0.044558</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>7.279202</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>1.969008</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>7.693208</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>0.199434</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>1.074256</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20674</th>\n",
              "      <td>0.044077</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>0.133504</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20676 rows × 1 columns</p>\n",
              "</div><br><label><b>dtype:</b> float64</label>"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8dhCv_oVVoCL",
        "outputId": "316c1c9e-97c4-482a-862b-3f08df6bc4e4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Study Title', 'Study Status', 'Brief Summary', 'Study Results',\n",
              "       'Conditions', 'Interventions', 'Primary Outcome Measures',\n",
              "       'Secondary Outcome Measures', 'Sex', 'Age', 'Phases', 'Enrollment',\n",
              "       'Study Design', 'Completion Date', 'Study Recruitment Rate',\n",
              "       'Duration of Trial', 'Primary Completion Duration of Trial'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "\n",
        "# Example range for binning (e.g., every 5 units within the target variable's range)\n",
        "bin_width = 10  # You can adjust this as needed\n",
        "bins = np.arange(data1['Study Recruitment Rate'].min(), data1['Study Recruitment Rate'].max() + bin_width, bin_width)\n",
        "\n",
        "# Create bins and categorize the target variable\n",
        "data1['Cluster'] = pd.cut(data1['Study Recruitment Rate'], bins=bins, right=False)\n",
        "\n",
        "# Count the number of data points in each cluster\n",
        "cluster_counts = data1['Cluster'].value_counts().sort_index()\n",
        "\n",
        "# Display the clusters\n",
        "print(cluster_counts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "brKRuCxnVpKQ",
        "outputId": "df08ad69-ae55-47d6-fd41-104e3b36c338"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Cluster\n",
            "[0.00113, 10.001)       17665\n",
            "[10.001, 20.001)         1645\n",
            "[20.001, 30.001)          594\n",
            "[30.001, 40.001)          283\n",
            "[40.001, 50.001)          143\n",
            "                        ...  \n",
            "[4770.001, 4780.001)        0\n",
            "[4780.001, 4790.001)        0\n",
            "[4790.001, 4800.001)        0\n",
            "[4800.001, 4810.001)        0\n",
            "[4810.001, 4820.001)        1\n",
            "Name: count, Length: 482, dtype: int64\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns"
      ],
      "metadata": {
        "id": "-cQD5mNpVw0v"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "numerical_cols = ['Study Recruitment Rate', 'Enrollment', 'Duration of Trial','Primary Completion Duration of Trial']\n",
        "\n",
        "# Correlation heatmap\n",
        "plt.figure(figsize=(10, 6))\n",
        "sns.heatmap(data1[numerical_cols].corr(), annot=True, cmap='coolwarm', fmt='.2f')\n",
        "plt.title('Correlation Heatmap')\n",
        "plt.show()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 532
        },
        "id": "8x-IIXWTVrKx",
        "outputId": "73da0671-7f94-4a29-a344-c832c682932b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x600 with 2 Axes>"
            ],
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAA+QAAAL/CAYAAADvOw39AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy81sbWrAAAACXBIWXMAAA9hAAAPYQGoP6dpAACqY0lEQVR4nOzdd3hURdvH8d+mbXqBkEINEDrSBQIqRTAUQSyA4iNFQBQVNKKI0lFBBYRHiqI0CyIqII80kSa9SNfQIqGZBAKkQxKSff/gZXFJAqEkB9jv57rOdbmzc+bcs6xJ5twzc0wWi8UiAAAAAABQqByMDgAAAAAAAHvEgBwAAAAAAAMwIAcAAAAAwAAMyAEAAAAAMAADcgAAAAAADMCAHAAAAAAAAzAgBwAAAADAAAzIAQAAAAAwAANyAAAAAAAMwIAcAAAUqlmzZslkMik6Ovq2tRkdHS2TyaRZs2bdtjYBAChoDMgBALgHREVFqU+fPipXrpxcXV3l7e2txo0ba+LEiTp//rzR4d02c+bM0YQJE4wOw0b37t3l6emZ5/smk0mvvPJKgcYwZcoUbkYAwF3IyegAAADArVm8eLE6duwos9msrl27qnr16srIyND69ev15ptv6s8//9S0adOMDvO2mDNnjvbt26fXXnvNprxMmTI6f/68nJ2djQnMYFOmTJG/v7+6d+9udCgAgBvAgBwAgLvYkSNH9PTTT6tMmTJatWqVgoODre+9/PLLOnz4sBYvXnzL17FYLLpw4YLc3NxyvHfhwgW5uLjIwcG4iXcmk0murq6GXR8AgJvBlHUAAO5iH330kVJSUjR9+nSbwfhloaGh6t+/v/X1xYsXNWrUKJUvX15ms1khISF65513lJ6ebnNeSEiIHn30US1fvlz16tWTm5ubPv/8c61Zs0Ymk0lz587V4MGDVaJECbm7uyspKUmStGXLFrVq1Uo+Pj5yd3dXkyZNtGHDhuv24+eff1bbtm1VvHhxmc1mlS9fXqNGjVJWVpa1TtOmTbV48WIdPXpUJpNJJpNJISEhkvJeQ75q1So9+OCD8vDwkK+vrx577DFFRkba1Bk+fLhMJpMOHz6s7t27y9fXVz4+PurRo4fS0tKuG/vNSE9P17BhwxQaGiqz2axSpUrprbfeyvHvMHPmTDVv3lwBAQEym82qWrWqpk6dalMnJCREf/75p9auXWv9XJo2bSrpynr99evXq1+/fipWrJh8fX3Vp08fZWRkKCEhQV27dpWfn5/8/Pz01ltvyWKx2LQ/duxYNWrUSEWLFpWbm5vq1q2rH3/8MUefLk/N//bbb1WpUiW5urqqbt26+v3332/vhwcA9xAy5AAA3MX+97//qVy5cmrUqFG+6vfq1UuzZ8/WU089pTfeeENbtmzR6NGjFRkZqQULFtjUPXDggJ555hn16dNHvXv3VqVKlazvjRo1Si4uLhowYIDS09Pl4uKiVatWqXXr1qpbt66GDRsmBwcH64By3bp1ql+/fp5xzZo1S56enoqIiJCnp6dWrVqloUOHKikpSR9//LEk6d1331ViYqJOnDihTz75RJKuuXb7t99+U+vWrVWuXDkNHz5c58+f16effqrGjRtrx44d1sH8ZZ06dVLZsmU1evRo7dixQ19++aUCAgL04Ycf5uuzjY+Pz1e97OxstW/fXuvXr9cLL7ygKlWqaO/evfrkk0908OBBLVy40Fp36tSpqlatmtq3by8nJyf973//U9++fZWdna2XX35ZkjRhwgS9+uqr8vT01LvvvitJCgwMtLnmq6++qqCgII0YMUKbN2/WtGnT5Ovrq40bN6p06dL64IMPtGTJEn388ceqXr26unbtaj134sSJat++vZ599lllZGRo7ty56tixo3755Re1bdvW5jpr167V999/r379+slsNmvKlClq1aqVtm7dqurVq+fr8wEAu2IBAAB3pcTERIsky2OPPZav+rt27bJIsvTq1cumfMCAARZJllWrVlnLypQpY5FkWbZsmU3d1atXWyRZypUrZ0lLS7OWZ2dnWypUqGAJDw+3ZGdnW8vT0tIsZcuWtbRs2dJaNnPmTIsky5EjR2zqXa1Pnz4Wd3d3y4ULF6xlbdu2tZQpUyZH3SNHjlgkWWbOnGktq1WrliUgIMBy5swZa9nu3bstDg4Olq5du1rLhg0bZpFkef75523afPzxxy1FixbNca2rdevWzSLpmsfLL79srf/1119bHBwcLOvWrbNp57PPPrNIsmzYsOGan0t4eLilXLlyNmXVqlWzNGnSJEfdy5/11f8uYWFhFpPJZHnxxRetZRcvXrSULFkyRztXx5CRkWGpXr26pXnz5jbll/u6fft2a9nRo0ctrq6ulscffzxHbAAAi4Up6wAA3KUuTxP38vLKV/0lS5ZIkiIiImzK33jjDUnKsda8bNmyCg8Pz7Wtbt262awn37Vrlw4dOqQuXbrozJkzio+PV3x8vFJTU/Xwww/r999/V3Z2dp6x/but5ORkxcfH68EHH1RaWpr279+fr/79W0xMjHbt2qXu3burSJEi1vIaNWqoZcuW1s/i31588UWb1w8++KDOnDlj/ZyvxdXVVStWrMj1uNoPP/ygKlWqqHLlytbPKT4+Xs2bN5ckrV692lr3359LYmKi4uPj1aRJE/39999KTEy8/gfx/3r27CmTyWR93aBBA1ksFvXs2dNa5ujoqHr16unvv/+2OfffMZw7d06JiYl68MEHtWPHjhzXCQsLU926da2vS5curccee0zLly+3WX4AALiEKesAANylvL29JV0awObH0aNH5eDgoNDQUJvyoKAg+fr66ujRozblZcuWzbOtq987dOiQpEsD9bwkJibKz88v1/f+/PNPDR48WKtWrcoxAL6Rgedll/vy72n2l1WpUkXLly9XamqqPDw8rOWlS5e2qXc51nPnzlk/67w4OjqqRYsW+Yrt0KFDioyMVLFixXJ9/9SpU9b/3rBhg4YNG6ZNmzblWM+emJgoHx+ffF3z6r5dPq9UqVI5ys+dO2dT9ssvv+i9997Trl27bNa4/3uAf1mFChVylFWsWFFpaWk6ffq0goKC8hUvANgLBuQAANylvL29Vbx4ce3bt++GzsttIJWb3HZUz+u9y9nvjz/+WLVq1cr1nLzWeyckJKhJkyby9vbWyJEjVb58ebm6umrHjh0aOHDgNTPrt5Ojo2Ou5ZarNjm7VdnZ2brvvvs0fvz4XN+/PEiOiorSww8/rMqVK2v8+PEqVaqUXFxctGTJEn3yySc39Lnk1bfcyv/d33Xr1ql9+/Z66KGHNGXKFAUHB8vZ2VkzZ87UnDlz8n19AEDuGJADAHAXe/TRRzVt2jRt2rRJYWFh16xbpkwZZWdn69ChQ6pSpYq1PC4uTgkJCSpTpsxNx1G+fHlJl24S5DdTfNmaNWt05swZzZ8/Xw899JC1/MiRIznq5vdmwuW+HDhwIMd7+/fvl7+/v012vDCVL19eu3fv1sMPP3zN/vzvf/9Tenq6Fi1aZJPh/veU9svy+7ncqJ9++kmurq5avny5zGaztXzmzJm51r88U+LfDh48KHd39zxnBACAPWMNOQAAd7G33npLHh4e6tWrl+Li4nK8HxUVpYkTJ0qS2rRpI+nSrtz/djlTe/WO2Teibt26Kl++vMaOHauUlJQc758+fTrPcy9naf+dmc3IyNCUKVNy1PXw8MjXFPbg4GDVqlVLs2fPVkJCgrV83759+vXXX62fhRE6deqkkydP6osvvsjx3vnz55Wamiop988lMTEx18Gwh4eHTT9vF0dHR5lMJpv139HR0TY7wf/bpk2bbNaWHz9+XD///LMeeeSRPLP0AGDPyJADAHAXK1++vObMmaPOnTurSpUq6tq1q6pXr66MjAxt3LhRP/zwg7p37y5Jqlmzprp166Zp06ZZp4lv3bpVs2fPVocOHdSsWbObjsPBwUFffvmlWrdurWrVqqlHjx4qUaKETp48qdWrV8vb21v/+9//cj23UaNG8vPzU7du3dSvXz+ZTCZ9/fXXuU4Vr1u3rr7//ntFRETo/vvvl6enp9q1a5drux9//LFat26tsLAw9ezZ0/rYMx8fHw0fPvym+3qrnnvuOc2bN08vvviiVq9ercaNGysrK0v79+/XvHnzrM9+f+SRR+Ti4qJ27dqpT58+SklJ0RdffKGAgADFxMTYtFm3bl1NnTpV7733nkJDQxUQEGDdJO5WtG3bVuPHj1erVq3UpUsXnTp1SpMnT1ZoaKj27NmTo3716tUVHh5u89gzSRoxYsQtxwIA9yIG5AAA3OXat2+vPXv26OOPP9bPP/+sqVOnymw2q0aNGho3bpx69+5trfvll1+qXLlymjVrlhYsWKCgoCANGjRIw4YNu+U4mjZtqk2bNmnUqFGaNGmSUlJSFBQUpAYNGqhPnz55nle0aFH98ssveuONNzR48GD5+fnpP//5jx5++OEcu7z37dtXu3bt0syZM/XJJ5+oTJkyeQ7IW7RooWXLlmnYsGEaOnSonJ2d1aRJE3344YfX3LCuoDk4OGjhwoX65JNP9NVXX2nBggVyd3dXuXLl1L9/f1WsWFHSpQ3pfvzxRw0ePFgDBgxQUFCQXnrpJRUrVkzPP/+8TZtDhw7V0aNH9dFHHyk5OVlNmjS5LQPy5s2ba/r06RozZoxee+01lS1bVh9++KGio6NzHZA3adJEYWFhGjFihI4dO6aqVatq1qxZqlGjxi3HAgD3IpPldu9UAgAAALtjMpn08ssva9KkSUaHAgB3DdaQAwAAAABgAAbkAAAAAAAYgAE5AAAAAAAGYEAOAACAW2axWFg/DuCu9fvvv6tdu3YqXry4TCZTno93/Lc1a9aoTp06MpvNCg0N1axZs274ugzIAQAAAAB2LTU1VTVr1tTkyZPzVf/IkSNq27atmjVrpl27dum1115Tr169tHz58hu6LrusAwAAAADw/0wmkxYsWKAOHTrkWWfgwIFavHix9u3bZy17+umnlZCQoGXLluX7WmTIAQAAAAD3nPT0dCUlJdkc6enpt6XtTZs2qUWLFjZl4eHh2rRp0w2143RbogFgtxY7VzI6BNiJpDX7jQ4BdmLKR+uNDgF2wpKdbXQIsBPr/9fE6BDyVJB/S2579xmNGDHCpmzYsGEaPnz4LbcdGxurwMBAm7LAwEAlJSXp/PnzcnNzy1c7DMgBAAAAAIYwOZsKrO1BgwYpIiLCpsxsNhfY9W4GA3IAAAAAwD3HbDYX2AA8KChIcXFxNmVxcXHy9vbOd3ZcYkAOAAAAADCIg1PBZcgLUlhYmJYsWWJTtmLFCoWFhd1QO2zqBgAAAACwaykpKdq1a5d27dol6dJjzXbt2qVjx45JujT9vWvXrtb6L774ov7++2+99dZb2r9/v6ZMmaJ58+bp9ddfv6HrkiEHAAAAABjC5Hxn5Ii3b9+uZs2aWV9fXnverVs3zZo1SzExMdbBuSSVLVtWixcv1uuvv66JEyeqZMmS+vLLLxUeHn5D12VADgAAAACwa02bNpXFYsnz/VmzZuV6zs6dO2/pugzIAQAAAACGuFvXkN8ud8b8AAAAAAAA7AwZcgAAAACAIQryOeR3AwbkAAAAAABDMGUdAAAAAAAUOjLkAAAAAABD2PuUdTLkAAAAAAAYgAw5AAAAAMAQrCEHAAAAAACFjgw5AAAAAMAQJkcy5AAAAAAAoJCRIQcAAAAAGMKBDDkAAAAAAChsZMgBAAAAAIYwOdh3hpwBOQAAAADAECZH+560bd+9BwAAAADAIGTIAQAAAACGYFM3AAAAAABQ6MiQAwAAAAAMYe+bupEhBwAAAADAAGTIAQAAAACGYA05AAAAAAAodGTIAQAAAACGMNl5hpwBOQAAAADAECYH+560bd+9BwAAAADAIGTIAQAAAACG4LFnAAAAAACg0JEhBwAAAAAYgseeAQAAAACAQkeGHAAAAABgCNaQAwAAAACAQkeGHAAAAABgCHt/DjkDcgAAAACAIZiyDgAAAAAACh0ZcgAAAACAIXjsGQAAAAAAKHRkyAEAAAAAhmANOQAAAAAAKHRkyAEAAAAAhrD3x57Zd+8BAAAAADAIGXIAAAAAgCHsfQ05A3IAAAAAgCHsfUDOlHUAAAAAAAxAhhwAAAAAYAgy5LBbTZs21WuvvWZ0GAWme/fu6tChg9FhAAAAAECuyJDfQU6fPq2hQ4dq8eLFiouLk5+fn2rWrKmhQ4eqcePGkiSTyaQFCxbcEQPN6OholS1b1vraz89P9913n9577z09+OCDBkZ2ycSJE2WxWKyvmzZtqlq1amnChAnGBfUvw4cP18KFC7Vr167r1hsxYoQkycHBQcWLF1fr1q01ZswYFSlSJN/X6969uxISErRw4cJbiBpXK/JAPZV7o6d86lSXa/EAbX+yr+IWrbz2OQ/VV9Wxb8uzagVdOB6jw6On6sRXC2zqlHmpi8pF9JQ5qJiS9uzXn6+NUuK2vQXZFdwFtq78VhuWTVdKYryCSlVW62cHq2S5GrnW/WPtPO3e+LNOnTwkSQouU00PP/m6Tf0F09/W7g0Lbc4rX/0BPRfxZYH1AXeXnl3KqF3LIHl6OGrv/iSNm3pYJ2Iu5Fm/ZlVvPfN4SVUK9ZR/EbPe+eAvrdty5pbbxb2v57MhavdIkLw8nLQ3MkljpxzSiZjzedavWc1HXZ4opUrlPeVf1KxB7+/Tus25fNdusF0UPh57hjvGk08+qZ07d2r27Nk6ePCgFi1apKZNm+rMmZw/XO4kv/32m2JiYvT777+rePHievTRRxUXF1dg18vMzMxXPR8fH/n6+hZYHIWpWrVqiomJ0bFjxzRz5kwtW7ZML730ktFhQZKjh7uS9hzQvn4j8lXfLaSk7l/0uc6s2aL19R7TkU9n677P35N/ywesdYI7tlaVjwfp0HuTtb7+40res18NFk+XS7H834DBvWff1iVa/v0YNW3/svoMm6/AUpX0zfheSknK/XdE9IGtqt6grbq9NVs9350rnyJB+npcTyWds/35HFr9Qb3xyTrr8VSfcYXRHdwFujxRUk+2La6xUw+pz5u7dP5CtsYNry4X57ynl7q6OupwdKrGfx51W9vFve3ZJ0vpqUdLaOyUQ3phwE6dv5Cl8SPvu+Z3ws3VUYePpGj8Z4dua7tAYWNAfodISEjQunXr9OGHH6pZs2YqU6aM6tevr0GDBql9+/aSpJCQEEnS448/LpPJZH2d29Ts1157TU2bNrW+Tk1NVdeuXeXp6ang4GCNG2f7B9fIkSNVvXr1HHHVqlVLQ4YMuWbsRYsWVVBQkKpXr6533nlHSUlJ2rJli/X9ffv2qXXr1vL09FRgYKCee+45xcfHW9/Pzs7WRx99pNDQUJnNZpUuXVrvv/++pEtZeJPJpO+//15NmjSRq6urvv32Ww0fPly1atWyiWPChAnWz+Tqz6V79+5au3atJk6cKJPJJJPJpOjoaK1Zs0Ymk0nLly9X7dq15ebmpubNm+vUqVNaunSpqlSpIm9vb3Xp0kVpaWk2MY8ePVply5aVm5ubatasqR9//NH6/uV2V65cqXr16snd3V2NGjXSgQMHJEmzZs3SiBEjtHv3bms8s2bNyvMzdnJyUlBQkEqUKKEWLVqoY8eOWrFihfX9rKws9ezZ0xpPpUqVNHHiROv7w4cP1+zZs/Xzzz9br7dmzRpJ0vHjx9WpUyf5+vqqSJEieuyxxxQdHX3Nf3NccXr57zo4bILifv4tX/XLvPC0zh85oci3PlTK/r91dMq3iv1pucr2726tU/a1Hjo+fZ5OzJ6vlMgo7e07TFlpF1Sq+5MF1AvcDTYtn6U6D3VU7QefVECJUD3adYScXVy1c91PudZ/8oWxqt+8i4JLV1Gx4HJq3+M9WSzZ+vuvTTb1HJ1d5OVTzHq4efgURndwF+jUroS++uGY1m89q6ijaXp/wgEVLWLWgw398zxny45z+vLbo7lmKm+lXdzbOrYvoa/mHdX6LWcUFZ2q9z7Zf93vxOY/zuqLb6L1+zW+azfTLgqfg6OpwI67AQPyO4Snp6c8PT21cOFCpaen51pn27ZtkqSZM2cqJibG+jo/3nzzTa1du1Y///yzfv31V61Zs0Y7duywvv/8888rMjLSps2dO3dqz5496tGjR76ucf78eX311VeSJBcXF0mXbjQ0b95ctWvX1vbt27Vs2TLFxcWpU6dO1vMGDRqkMWPGaMiQIfrrr780Z84cBQYG2rT99ttvq3///oqMjFR4eHi++33ZxIkTFRYWpt69eysmJkYxMTEqVaqU9f3hw4dr0qRJ2rhxo3WAOmHCBM2ZM0eLFy/Wr7/+qk8//dRaf/To0frqq6/02Wef6c8//9Trr7+u//znP1q7dq3Ndd99912NGzdO27dvl5OTk55//nlJUufOnfXGG29YM98xMTHq3LlzvvoSHR2t5cuXWz9j6dINgpIlS+qHH37QX3/9paFDh+qdd97RvHnzJEkDBgxQp06d1KpVK+v1GjVqpMzMTIWHh8vLy0vr1q3Thg0b5OnpqVatWikjI+OGP2dcn2/DWopfZTsgOr1ivfwa1pIkmZyd5VOnmuJXbrxSwWJR/KqN8m1YuxAjxZ3k4sUM/XP0T5Wr2sha5uDgoHJVw3Qiale+2shMP6/srIs5BtzR+7fqo/6N9OmgVvrlq+FKSzl3GyPH3So40FVFi7ho++4Ea1lqWpYiDyarWiWvO65d3L2KB7rKv4hZ23Zd+dmTmpalvw4mqXpl7zuuXeB2Yw35HcLJyUmzZs1S79699dlnn6lOnTpq0qSJnn76adWocWm9X7FixSRJvr6+CgoKynfbKSkpmj59ur755hs9/PDDkqTZs2erZMmS1jolS5ZUeHi4Zs6cqfvvv1/SpYF/kyZNVK5cuWu236hRIzk4OCgtLU0Wi0V169a1XmfSpEmqXbu2PvjgA2v9GTNmqFSpUjp48KCCg4M1ceJETZo0Sd26dZMklS9fXg888IDNNV577TU98cQT+e7z1Xx8fOTi4iJ3d/dcP7v33nvPuk6/Z8+eGjRokKKioqx9f+qpp7R69WoNHDhQ6enp+uCDD/Tbb78pLCxMklSuXDmtX79en3/+uZo0aWJt9/3337e+fvvtt9W2bVtduHBBbm5u8vT0tGa+r2fv3r3y9PRUVlaWLly4tMZu/Pjx1vednZ2t68wlqWzZstq0aZPmzZunTp06ydPTU25ubkpPT7e53jfffKPs7Gx9+eWXMpku3UWcOXOmfH19tWbNGj3yyCM2caSnp+e4YZRpyZaziXt7+WUO9Fd6XLxNWXpcvJx9vOTgapazn48cnJyUfurMVXXOyKPStf9fxL0rLfmcLNlZ8vQualPu4e2v+Jgj+WpjxY/j5OUboHLVrgzqQ6s/qCp1HpFfsRI6e+q4Vv70ib755AX1eneuHBwcb2sfcHcp6ucsSTqXYHtz9mxChor4ueR2iqHt4u51+d/9XILtksRzt/idKKh2cfuxyzruGE8++aT++ecfLVq0SK1atdKaNWtUp06da05lzo+oqChlZGSoQYMG1rIiRYqoUqVKNvV69+6t7777ThcuXFBGRobmzJljzehey/fff6+dO3fqp59+UmhoqGbNmiVn50u/cHfv3q3Vq1dbZwB4enqqcuXK1rgiIyOVnp5uHcDnpV69ejfa7Rty+aaHJAUGBsrd3d3mRkRgYKBOnTolSTp8+LDS0tLUsmVLm3599dVXioqKyrPd4OBgSbK2cyMqVaqkXbt2adu2bRo4cKDCw8P16quv2tSZPHmy6tatq2LFisnT01PTpk3TsWPHrtnu7t27dfjwYXl5eVn7UaRIEV24cCFHX6RLMwN8fHxsjnnZZ2+4PwAK17rF07Rv6xJ1fmWSnJ3N1vL7GrRV5drNFViykqrUaaEu/T/TP0f2Knr/VgOjhRFaNimm5XMbWQ8nR/5ERMFo2SRAv857wHo4Odn3YAyXNnUrqONuQIb8DuPq6qqWLVuqZcuWGjJkiHr16qVhw4ape/fueZ7j4OBgs5u4lP+Nz/6tXbt2MpvNWrBggVxcXJSZmamnnnrquueVKlVKFSpUUIUKFXTx4kU9/vjj2rdvn8xms1JSUtSuXTt9+OGHOc4LDg7W33//na/YPDw8bF7frj5fdvkGgnRpJ/t/v75clp2dLenSjANJWrx4sUqUKGFTz2w227y+ul1J1nZuhIuLi0JDQyVJY8aMUdu2bTVixAiNGjVKkjR37lwNGDBA48aNU1hYmLy8vPTxxx/brOXPTUpKiurWratvv/02x3uXZ2T826BBgxQREWFTtqpI3Rvujz1Lj4uXOdB27Zo50F+ZicnKvpCujPhzyr54UeaAolfVKar0WNvMOuyHu5efTA6OOTZwS02Kl6fPtddCblg2XeuXfKGuA2YoqFSla9YtElBK7p5+OnvqqMpVDbvluHH3WL/1rP46cGUpm7PzpT9k/XxddObcld+vRXxddOhIyk1f53Jbt7td3D3Wbz2jvw5ut752sX7XnHXm3JWZE36+Ljr8981/J87+f1u3u13gdrs7bhvYsapVqyo1NdX62tnZWVlZWTZ1ihUrppiYGJuyfz9Kq3z58nJ2drYZnJ07d04HDx60OcfJyUndunXTzJkzNXPmTD399NNyc3O7oXifeuopOTk5acqUKZKkOnXq6M8//1RISIhCQ0NtDg8PD1WoUEFubm5aufLaj4m6WrFixRQbG2szKL/e48NcXFxyfHY3o2rVqjKbzTp27FiOPv17Xfr13Eo8gwcP1tixY/XPP/9IkjZs2KBGjRqpb9++ql27tkJDQ3NkuHO7Xp06dXTo0CEFBATk6IuPT86Nncxms7y9vW0OpqvfmITNu1S0eUObMv+HG+nc5l2SJEtmphJ3/Cn/5v8aDJlMKtosTAmbdxZipLiTODm5qHiZajoSeWX/gezsbP0duVkly9fK87z1S7/U7/+bqv9EfKESZe+77nUSz8YqLTVBnj4BtyNs3EXOn8/SydgL1iP6eJrOnM1Q3Rq+1jrubo6qUtFLfx5IvunrxMRdKJB2cfc4fz5LJ2MuWI8jx9IUfzZd9Wr6Weu4uzmqakVv7dufdNPX+SfuQoG0i9vP5GAqsONuwF/Sd4gzZ86oefPm+uabb7Rnzx4dOXJEP/zwgz766CM99thj1nohISFauXKlYmNjde7cpU0qmjdvru3bt+urr77SoUOHNGzYMO3bt896jqenp3r27Kk333xTq1at0r59+9S9e3c55DKNo1evXlq1apWWLVuWr+nqVzOZTOrXr5/GjBmjtLQ0vfzyyzp79qyeeeYZbdu2TVFRUVq+fLl69OihrKwsubq6auDAgXrrrbesU743b96s6dOnX/M6TZs21enTp/XRRx8pKipKkydP1tKlS695TkhIiLZs2aLo6GjFx8ffVKZakry8vDRgwAC9/vrrmj17tqKiorRjxw59+umnmj17dr7bCQkJ0ZEjR7Rr1y7Fx8fnuZlfbsLCwlSjRg3r2vwKFSpo+/btWr58uQ4ePKghQ4bk2PQvJCREe/bs0YEDBxQfH6/MzEw9++yz8vf312OPPaZ169bpyJEjWrNmjfr166cTJ07kOx575ujhLu+aleVd89JSDPeyJeVds7JcS11aolDpvQjVnHllhsjRaXPlXraUKo9+Ux6VyqnMi10U3LG1jkycZa1zZMJMlerZSSWe6yDPyuVUffJwOXm46fjs+YXaN9xZwsK764+1P2jXhgU6/U+UFn89XJnp51X7gUv7a8z/YqB++/HKEzTWL/lCqxdM1GM93pevfwklJ55WcuJppV+4dJM3/UKqfp33kY5H7dK5+BP6+69NmvtpXxUJKK3Q6g/kGgPsy7z/nVS3TqXUuH4RlSvjrsGvVdSZs+lat/nKbJ0JI+/TE22Cra/dXB0UWtZDoWUvzWwLDjQrtKyHAvzNN9Qu7MsPi06qW+fSaly/qMqV8dDgiMo5v2vv1dATbYtbX+f8rrkqtKyHAouZb6hdwGhMWb9DeHp6qkGDBvrkk08UFRWlzMxMlSpVSr1799Y777xjrTdu3DhFREToiy++UIkSJRQdHa3w8HANGTJEb731li5cuKDnn39eXbt21d69e63nffzxx9bp415eXnrjjTeUmJiYI44KFSqoUaNGOnv2rM2a8xvRrVs3vfvuu5o0aZLeeustbdiwQQMHDtQjjzyi9PR0lSlTRq1atbLeEBgyZIicnJw0dOhQ/fPPPwoODtaLL754zWtUqVJFU6ZM0QcffKBRo0bpySef1IABAzRt2rQ8zxkwYIC6deumqlWr6vz58zpyJH8bIeVm1KhRKlasmEaPHq2///5bvr6+qlOnjs2/1fU8+eSTmj9/vpo1a6aEhATNnDnzmksTrvb666+re/fuGjhwoPr06aOdO3eqc+fOMplMeuaZZ9S3b1+bmxS9e/fWmjVrVK9ePaWkpGj16tVq2rSpfv/9dw0cOFBPPPGEkpOTVaJECT388MPy9mYH0vzwqVtdYSu/tr6uOvbSd+D4V/O1p+cgmYOLya3UlT9Wz0ef0Lb2fVR13CCFvNpVF07Eam+fwYpfsd5aJ+aHpXIpVkQVh/WTOaiYknZHauujvZRxKu9Hu+DeV71+G6Umn9XqhZ8qJfG0gkpV0X9e/8I6ZT3x7D822YBtq79T1sVMzZvS36adJu1fVrMOr8rBwVFxxw9o14aFupCWLC/fYipfrbGaP95fTs5seARpzvwTcnN11Jt9K8jTw0l7IxM1YMSfysi8MjuteJCrfLyvLM+qFOqlT9+/sn/Kqz3LS5KWrozTB/89mO92YV++/em4XF0d9dYrFS99J/5K1BvD9tp8J0oEucn3X9+1yqFe+nR0Levrfr0uLe1bsjJWH0w4kO92Yby7JZNdUEyWqxfiwq5ZLBZVqFBBffv2zbFWGMjNYudrr0kFbpekNfuNDgF2YspH669fCbgNLDc5Ww+4Uev/1+T6lQxy9IUOBdZ2mWkLC6zt24UMOaxOnz6tuXPnKjY2Nt/PHgcAAACAm3W37IZeUBiQwyogIED+/v6aNm2a/Pz8rn8CAAAAAOCmMSCHFasXAAAAABQme19DzoAcAAAAAGAIe5+ybt+9BwAAAADAIGTIAQAAAADGMNn3lHUy5AAAAAAAGIAMOQAAAADAEPa+qRsZcgAAAAAADECGHAAAAABgCHZZBwAAAAAAhY4MOQAAAADAEPa+hpwBOQAAAADAEExZBwAAAAAAhY4MOQAAAADAEPY+ZZ0MOQAAAAAABmBADgAAAAAwhMnBVGDHzZg8ebJCQkLk6uqqBg0aaOvWrdesP2HCBFWqVElubm4qVaqUXn/9dV24cCHf12NADgAAAACwe99//70iIiI0bNgw7dixQzVr1lR4eLhOnTqVa/05c+bo7bff1rBhwxQZGanp06fr+++/1zvvvJPvazIgBwAAAAAYw8Gh4I4bNH78ePXu3Vs9evRQ1apV9dlnn8nd3V0zZszItf7GjRvVuHFjdenSRSEhIXrkkUf0zDPPXDerbtP9G44SAAAAAIA7XHp6upKSkmyO9PT0XOtmZGTojz/+UIsWLaxlDg4OatGihTZt2pTrOY0aNdIff/xhHYD//fffWrJkidq0aZPvGBmQAwAAAAAMYTKZCuwYPXq0fHx8bI7Ro0fnGkd8fLyysrIUGBhoUx4YGKjY2Nhcz+nSpYtGjhypBx54QM7OzipfvryaNm3KlHUAAAAAwJ3P5OBQYMegQYOUmJhocwwaNOi2xb5mzRp98MEHmjJlinbs2KH58+dr8eLFGjVqVL7b4DnkAAAAAIB7jtlsltlszlddf39/OTo6Ki4uzqY8Li5OQUFBuZ4zZMgQPffcc+rVq5ck6b777lNqaqpeeOEFvfvuu3LIxzp2MuQAAAAAAEPcKY89c3FxUd26dbVy5UprWXZ2tlauXKmwsLBcz0lLS8sx6HZ0dJQkWSyWfF2XDDkAAAAAwO5FRESoW7duqlevnurXr68JEyYoNTVVPXr0kCR17dpVJUqUsK5Db9euncaPH6/atWurQYMGOnz4sIYMGaJ27dpZB+bXw4AcAAAAAGCMm3g8WUHp3LmzTp8+raFDhyo2Nla1atXSsmXLrBu9HTt2zCYjPnjwYJlMJg0ePFgnT55UsWLF1K5dO73//vv5vqbJkt9cOgDkYrFzJaNDgJ1IWrPf6BBgJ6Z8tN7oEGAnLNnZRocAO7H+f02MDiFPZ0a+UGBtFx06rcDavl3IkAMAAAAADHGja73vNXfO/AAAAAAAAOwIGXIAAAAAgCFMJvvOETMgBwAAAAAYgynrAAAAAACgsJEhBwAAAAAYwnQHPfbMCPbdewAAAAAADEKGHAAAAABgCB57BgAAAAAACh0ZcgAAAACAMez8sWf23XsAAAAAAAxChhwAAAAAYAjWkAMAAAAAgEJHhhwAAAAAYAw7fw45A3IAAAAAgCFMJqasAwAAAACAQkaGHAAAAABgDDufsm7fvQcAAAAAwCBkyAEAAAAAhuCxZwAAAAAAoNCRIQcAAAAAGMNk3zli++49AAAAAAAGIUMOAAAAADCGna8hZ0AOAAAAADCEiSnrAAAAAACgsJEhB3BLktbsNzoE2AnvppWNDgF2ovSAVUaHAAD2w86nrJMhBwAAAADAAGTIAQAAAACGMDnYd47YvnsPAAAAAIBByJADAAAAAIxhYg05AAAAAAAoZGTIAQAAAADGsPM15AzIAQAAAADGYMo6AAAAAAAobGTIAQAAAACG4LFnAAAAAACg0JEhBwAAAAAYw2TfOWL77j0AAAAAAAYhQw4AAAAAMIYDu6wDAAAAAIBCRoYcAAAAAGAIk52vIWdADgAAAAAwBlPWAQAAAABAYSNDDgAAAAAwhp1PWbfv3gMAAAAAYBAy5AAAAAAAY5hYQw4AAAAAAAoZGXIAAAAAgDEc7DtHbN+9BwAAAADAIGTIAQAAAADGsPNd1hmQAwAAAACM4cCmbgAAAAAAoJCRIQcAAAAAGMPOp6zbd+8BAAAAADAIGXIAAAAAgDFMrCEHAAAAAACFjAw5AAAAAMAYDvadI7bv3gMAAAAAYBAy5AAAAAAAY9j5GnIG5AAAAAAAY/DYMwAAAAAAUNjIkAMAAAAAjMGmbgAAAAAAoLCRIQcAAAAAGMPON3UjQw4AAAAAgAHIkAMAAAAAjMEu6wAAAAAAoLCRIQcAAAAAGMPO15AzIAcAAAAAGIPHngEAAAAAgMJGhhwAAAAAYAiLnU9ZJ0MOAAAAAIAByJADAAAAAIzBY88AAAAAAMDkyZMVEhIiV1dXNWjQQFu3br1m/YSEBL388ssKDg6W2WxWxYoVtWTJknxfjww5AAAAAMAYd1CG/Pvvv1dERIQ+++wzNWjQQBMmTFB4eLgOHDiggICAHPUzMjLUsmVLBQQE6Mcff1SJEiV09OhR+fr65vuaDMgBAAAAAHZv/Pjx6t27t3r06CFJ+uyzz7R48WLNmDFDb7/9do76M2bM0NmzZ7Vx40Y5OztLkkJCQm7omnfO7QgAAAAAgF2xmEwFdqSnpyspKcnmSE9PzzWOjIwM/fHHH2rRooW1zMHBQS1atNCmTZtyPWfRokUKCwvTyy+/rMDAQFWvXl0ffPCBsrKy8t1/BuRAIVqzZo1MJpMSEhIkSbNmzbqhKS0AAADAPcXkUGDH6NGj5ePjY3OMHj061zDi4+OVlZWlwMBAm/LAwEDFxsbmes7ff/+tH3/8UVlZWVqyZImGDBmicePG6b333st395myDrvUvXt3zZ49O0d5eHi4li1bZkBExmvatKlq1aqlCRMmGB3KXWfrym+1Ydl0pSTGK6hUZbV+drBKlquRa90/1s7T7o0/69TJQ5Kk4DLV9PCTr9vUXzD9be3esNDmvPLVH9BzEV8WWB9w5yvyQD2Ve6OnfOpUl2vxAG1/sq/iFq289jkP1VfVsW/Ls2oFXTgeo8Ojp+rEVwts6pR5qYvKRfSUOaiYkvbs15+vjVLitr0F2RXcBVo29FDbhzzl4+moY7GZmr0oQX+fyMyzfv3qrurY0lv+fk6KO3NR3y1L1O4DV7JQ9aq5qkUDD4WUcJGXu4Pe+e8pHY3Juz3YD75rKEiDBg1SRESETZnZbL5t7WdnZysgIEDTpk2To6Oj6tatq5MnT+rjjz/WsGHD8tUGGXLYrVatWikmJsbm+O67726qLYvFoosXL97mCHE32Ld1iZZ/P0ZN27+sPsPmK7BUJX0zvpdSks7kWj/6wFZVb9BW3d6arZ7vzpVPkSB9Pa6nks7F2dQLrf6g3vhknfV4qs+4wugO7mCOHu5K2nNA+/qNyFd9t5CSun/R5zqzZovW13tMRz6drfs+f0/+LR+w1gnu2FpVPh6kQ+9N1vr6jyt5z341WDxdLsWKFFQ3cBdoeJ+bnm3ro/krkzV40ikdi8nU28/7y9sj9z8bK5R20StPF9Ga7Wl699NT2v7XeUX8p6hKBl7J+7i6mHQgOkNzlyYWVjdwF+C7BkmSyVRgh9lslre3t82R14Dc399fjo6Oiouz/ZssLi5OQUFBuZ4THBysihUrytHR0VpWpUoVxcbGKiMjI1/dZ0AOu2U2mxUUFGRz+Pn5SZJMJpO+/PJLPf7443J3d1eFChW0aNEi67mXp54vXbpUdevWldls1vr165Wenq5+/fopICBArq6ueuCBB7Rt27Z8xzR8+HDVqlVLM2bMUOnSpeXp6am+ffsqKytLH330kYKCghQQEKD333/f5ryEhAT16tVLxYoVk7e3t5o3b67du3fnaPfrr79WSEiIfHx89PTTTys5OVnSpRkDa9eu1cSJE2UymWQymRQdHX0Ln6792LR8luo81FG1H3xSASVC9WjXEXJ2cdXOdT/lWv/JF8aqfvMuCi5dRcWCy6l9j/dksWTr779s1yY5OrvIy6eY9XDz8CmM7uAOdnr57zo4bILifv4tX/XLvPC0zh85oci3PlTK/r91dMq3iv1pucr2726tU/a1Hjo+fZ5OzJ6vlMgo7e07TFlpF1Sq+5MF1AvcDVo/6KnV21L1+x9pOnnqomYsTFB6hkVN6rnnWr9VYw/tOZSuxetS9M/pi/pxRbKi/8nUI2Ge1jrrd57XglXJ2nc497WbsE9813AncXFxUd26dbVy5ZXZZ9nZ2Vq5cqXCwsJyPadx48Y6fPiwsrOzrWUHDx5UcHCwXFxc8nVdBuRAHkaMGKFOnTppz549atOmjZ599lmdPXvWps7bb7+tMWPGKDIyUjVq1NBbb72ln376SbNnz9aOHTsUGhqq8PDwHOddS1RUlJYuXaply5bpu+++0/Tp09W2bVudOHFCa9eu1YcffqjBgwdry5Yt1nM6duyoU6dOaenSpfrjjz9Up04dPfzwwzbXjYqK0sKFC/XLL7/ol19+0dq1azVmzBhJ0sSJExUWFqbevXtbZwuUKlXqFj/Be9/Fixn65+ifKle1kbXMwcFB5aqG6UTUrny1kZl+XtlZF3MMuKP3b9VH/Rvp00Gt9MtXw5WWcu42Rg574NuwluJX2d7oOb1ivfwa1pIkmZyd5VOnmuJXbrxSwWJR/KqN8m1YuxAjxZ3E0VEqW9zZZjBjsUj7otJVoXTuf1yGlnbRvsMXbMr2HLqg0DzqAxLfNfyLg0PBHTcoIiJCX3zxhWbPnq3IyEi99NJLSk1Nte663rVrVw0aNMha/6WXXtLZs2fVv39/HTx4UIsXL9YHH3ygl19+Of/dv+EogXvEL7/8Ik9PT5vjgw8+sL7fvXt3PfPMMwoNDdUHH3yglJQUbd261aaNkSNHqmXLlipfvrzMZrOmTp2qjz/+WK1bt1bVqlX1xRdfyM3NTdOnT893XNnZ2ZoxY4aqVq2qdu3aqVmzZjpw4IAmTJigSpUqqUePHqpUqZJWr14tSVq/fr22bt2qH374QfXq1VOFChU0duxY+fr66scff7Rpd9asWapevboefPBBPffcc9Y7gD4+PnJxcZG7u7t1tsC/p95clttOlZkZ9nsHOi35nCzZWfL0LmpT7uHtr5TE+Hy1seLHcfLyDVC5alcG9aHVH9TjvT5UtzdnqkXHAYo+sE3ffPKCsrPzv2MnYA70V3qc7fcwPS5ezj5ecnA1y8XfTw5OTko/deaqOmdkDvIvzFBxB/Fyd5Cjo0mJKdk25UnJWfLxyvl7QZJ8PR1z1E9MyZavJ39mIm9813An6ty5s8aOHauhQ4eqVq1a2rVrl5YtW2bd6O3YsWOKiYmx1i9VqpSWL1+ubdu2qUaNGurXr5/69++f6yPS8sKmbrBbzZo109SpU23KihS5sm6yRo0rm2x5eHjI29tbp06dsqlfr149639HRUUpMzNTjRs3tpY5Ozurfv36ioyMzHdcISEh8vLysr4ODAyUo6OjHP51ly8wMNAay+7du5WSkqKiRW0HhefPn1dUVFSe7QYHB+foz/WMHj1aI0bYrl99osdQPdVz+A21g0vWLZ6mfVuXqPtbX8nZ+cp6pvsatLX+d2DJSgosWUn/fbulovdvVbmquU+ZAgAAuBtZTCajQ7Dxyiuv6JVXXsn1vTVr1uQoCwsL0+bNm2/6egzIYbc8PDwUGhqa5/vOzs42r00mk836kMtt3G65XfdasaSkpCg4ODjXHxD/fqRafvpzPbntVLnwD/udJubu5SeTg2OODdxSk+Ll6XPtDOOGZdO1fskX6jpghoJKVbpm3SIBpeTu6aezp44yIEe+pcfFyxxo+z00B/orMzFZ2RfSlRF/TtkXL8ocUPSqOkWVHpu/GR649ySnZSsryyKfqzKO3l6OSkzOfZZOQkpWjvo+ng5KSLmx3zGwL3zXgEuY3wHcJuXLl5eLi4s2bNhgLcvMzNS2bdtUtWrVArtunTp1FBsbKycnJ4WGhtoc/v75n3bq4uKirKxrT4nObadKZ5fb9+iIu42Tk4uKl6mmI5FX1ulmZ2fr78jNKlm+Vp7nrV/6pX7/31T9J+ILlSh733Wvk3g2VmmpCfL0CbgdYcNOJGzepaLNG9qU+T/cSOc275IkWTIzlbjjT/k3/9dNHpNJRZuFKWHzzkKMFHeSrCzpyD+Zqlb+ys92k0mqXt6sQ8dy3zH48LEMm/qSVD3UrMN51Ackvmv4lwJ8Dvnd4O6IEigA6enpio2NtTni428+K+Th4aGXXnpJb775ppYtW6a//vpLvXv3Vlpamnr27HkbI7fVokULhYWFqUOHDvr1118VHR2tjRs36t1339X27dvz3U5ISIi2bNmi6OhoxcfH33D23F6FhXfXH2t/0K4NC3T6nygt/nq4MtPPq/YDT0iS5n8xUL/9eOWRZeuXfKHVCybqsR7vy9e/hJITTys58bTSL6RKktIvpOrXeR/peNQunYs/ob//2qS5n/ZVkYDSCq3+QK4xwD44erjLu2ZledesLElyL1tS3jUry7VUsCSp0nsRqjnzQ2v9o9Pmyr1sKVUe/aY8KpVTmRe7KLhjax2ZOMta58iEmSrVs5NKPNdBnpXLqfrk4XLycNPx2fMLtW+4syxdl6Jm93vowTruKl7MST0e85XZxaS1f6RJkl7s6KfO4d7W+ss2pKpGRVe1ecBTwcWc9MTDXipXwkW/bkqx1vFwM6lMsLNK/P/jqYL9nVQm2DlHthP2he8awJR12LFly5YpODjYpqxSpUrav3//Tbc5ZswYZWdn67nnnlNycrLq1aun5cuXWx+nVhBMJpOWLFmid999Vz169NDp06cVFBSkhx56yLoBRX4MGDBA3bp1U9WqVXX+/HkdOXJEISEhBRb3vaJ6/TZKTT6r1Qs/VUriaQWVqqL/vP6Fdcp64tl/ZHK4sjZq2+rvlHUxU/Om9Ldpp0n7l9Wsw6tycHBU3PED2rVhoS6kJcvLt5jKV2us5o/3l5Oz/S4PgORTt7rCVn5tfV117DuSpONfzdeenoNkDi4mt1JXfqadjz6hbe37qOq4QQp5tasunIjV3j6DFb9ivbVOzA9L5VKsiCoO6ydzUDEl7Y7U1kd7KeOqjd5gXzbvPS8vTwc91cJLPl6OOhqTqQ9nxivp/6cFF/V1lMVisdY/dCxDk+eeVcdHvNUp3Fux8Rc1/pszOhF30VqnbhU39el45Xfhq10u7dny029Jmr8yuZB6hjsN3zVIkuUuyWQXFJPl399yALhB323gRwgKh3fTykaHADsxZ8Aqo0MAgNvq29EljA4hTylb/ldgbXs2aFdgbd8u9n07AgAAAAAAgzBlHQAAAABgCHufsm7fvQcAAAAAwCBkyAEAAAAAxjCZrl/nHkaGHAAAAAAAA5AhBwAAAAAYgzXkAAAAAACgsJEhBwAAAAAYwmLna8gZkAMAAAAAjMGUdQAAAAAAUNjIkAMAAAAADGGRfU9ZJ0MOAAAAAIAByJADAAAAAAxhYQ05AAAAAAAobGTIAQAAAADGIEMOAAAAAAAKGxlyAAAAAIAhLCb73mWdATkAAAAAwBBs6gYAAAAAAAodGXIAAAAAgDHsfMo6GXIAAAAAAAxAhhwAAAAAYAjWkAMAAAAAgEJHhhwAAAAAYAiLWEMOAAAAAAAKGRlyAAAAAIAh7H0NOQNyAAAAAIAxeOwZAAAAAAAobGTIAQAAAACGsNh5jti+ew8AAAAAgEHIkAMAAAAADGFhDTkAAAAAAChsZMgBAAAAAIaw98ee2XfvAQAAAAAwCBlyAAAAAIAhLLLvNeQMyAEAAAAAhmDKOgAAAAAAKHRkyAEAAAAAhuCxZwAAAAAAoNCRIQcAAAAAGMLeN3UjQw4AAAAAgAHIkAMAAAAADMEu6wAAAAAAoNCRIQcAAAAAGMLe15AzIAcAAAAAGIIp6wAAAAAAoNCRIQcAAAAAGMLep6yTIQcAAAAAwABkyAEAAAAAhmANOQAAAAAAKHRkyAEAAAAAhmANOQAAAAAAKHRkyAHckikfrTc6BNiJ0gNWGR0C7ESXsc2NDgF2ovYrdYwOAXbjO6MDyJPFZN8ZcgbkAAAAAABDWCz2PSBnyjoAAAAAAAYgQw4AAAAAMITFznPE9t17AAAAAAAMQoYcAAAAAGAIHnsGAAAAAAAKHRlyAAAAAIAhyJADAAAAAIBCR4YcAAAAAGAIe8+QMyAHAAAAABjC3gfkTFkHAAAAAMAAZMgBAAAAAIawWMiQAwAAAACAQkaGHAAAAABgCNaQAwAAAACAQseAHAAAAABgCItMBXbcjMmTJyskJESurq5q0KCBtm7dmq/z5s6dK5PJpA4dOtzQ9RiQAwAAAADs3vfff6+IiAgNGzZMO3bsUM2aNRUeHq5Tp05d87zo6GgNGDBADz744A1fkwE5AAAAAMAQd1KGfPz48erdu7d69OihqlWr6rPPPpO7u7tmzJiR5zlZWVl69tlnNWLECJUrV+6Gr8mAHAAAAABwz0lPT1dSUpLNkZ6enmvdjIwM/fHHH2rRooW1zMHBQS1atNCmTZvyvMbIkSMVEBCgnj173lSMDMgBAAAAAIawWEwFdowePVo+Pj42x+jRo3ONIz4+XllZWQoMDLQpDwwMVGxsbK7nrF+/XtOnT9cXX3xx0/3nsWcAAAAAAENkF+BjzwYNGqSIiAibMrPZfFvaTk5O1nPPPacvvvhC/v7+N90OA3IAAAAAwD3HbDbnewDu7+8vR0dHxcXF2ZTHxcUpKCgoR/2oqChFR0erXbt21rLs7GxJkpOTkw4cOKDy5ctf97pMWQcAAAAAGOJO2dTNxcVFdevW1cqVK61l2dnZWrlypcLCwnLUr1y5svbu3atdu3ZZj/bt26tZs2batWuXSpUqla/rkiEHAAAAANi9iIgIdevWTfXq1VP9+vU1YcIEpaamqkePHpKkrl27qkSJEho9erRcXV1VvXp1m/N9fX0lKUf5tTAgBwAAAAAYwmIpuDXkN6pz5846ffq0hg4dqtjYWNWqVUvLli2zbvR27NgxOTjc3knmDMgBAAAAAJD0yiuv6JVXXsn1vTVr1lzz3FmzZt3w9RiQAwAAAAAMcaNrve81bOoGAAAAAIAByJADAAAAAAxxJ60hNwIDcgAAAACAIZiyDgAAAAAACh0ZcgAAAACAIex9yjoZcgAAAAAADECGHAAAAABgiGyjAzAYGXIAAAAAAAxAhhwAAAAAYAjWkAMAAAAAgEJHhhwAAAAAYAh7fw45A3IAAAAAgCGYsg4AAAAAAAodGXIAAAAAgCHsfco6GXIAAAAAAAxAhhwAAAAAYIhsi9ERGIsMOQAAAAAABiBDDgAAAAAwBGvIAQAAAABAoSNDDgAAAAAwhL0/h5wBOQAAAADAEBY2dQMAAAAAAIWNDDkAAAAAwBDZbOoG2K9Zs2bJ19fX6DAkSQsXLlRoaKgcHR312muv3ZY2mzZtekNtrVmzRiaTSQkJCbfl+gAAAADyRoYcBa579+6aPXu2JMnJyUlFihRRjRo19Mwzz6h79+5ycCic+0IhISF67bXXbAaonTt3Vps2bQrl+tfTp08f9ejRQ/369ZOXl5fNe2vWrFGzZs2uef7q1avVtGlTm7L58+fL2dn5doeKPPTsUkbtWgbJ08NRe/cnadzUwzoRcyHP+jWreuuZx0uqUqin/IuY9c4Hf2ndljO33C7uXS0beqjtQ57y8XTUsdhMzV6UoL9PZOZZv351V3Vs6S1/PyfFnbmo75YlaveBdOv79aq5qkUDD4WUcJGXu4Pe+e8pHY3Juz3YhyIP1FO5N3rKp051uRYP0PYn+ypu0cprn/NQfVUd+7Y8q1bQheMxOjx6qk58tcCmTpmXuqhcRE+Zg4opac9+/fnaKCVu21uQXcFdwL1xS3k2bydHLx9l/nNMifNnKfNYVJ71PR5qLY/GLeTo66/s1GSd37NFSb/MlS5e+tnl3qiFPBq3lGMRf0nSxdgTSl4+X+n7dxdKf3Dj7H1TNzLkKBStWrVSTEyMoqOjtXTpUjVr1kz9+/fXo48+qosXL950uxaL5ZbOd3NzU0BAwE2ff7ukpKTo1KlTCg8PV/HixXMMyBs1aqSYmBjr0alTJ+tnevlo1KiRtX5GRoYkqUiRIjnaQsHo8kRJPdm2uMZOPaQ+b+7S+QvZGje8ulyc8/4l4+rqqMPRqRr/ed5/eNxMu7g3NbzPTc+29dH8lckaPOmUjsVk6u3n/eXtkfuv8gqlXfTK00W0Znua3v30lLb/dV4R/ymqkoFX7sW7uph0IDpDc5cmFlY3cBdw9HBX0p4D2tdvRL7qu4WU1P2LPteZNVu0vt5jOvLpbN33+Xvyb/mAtU5wx9aq8vEgHXpvstbXf1zJe/arweLpcilWpKC6gbuAa62G8unwnJKX/6TT495R5j9HVbTP23Lw9M61vludRvJ+9GklL/9Jp8a8oYTvP5dbrTB5t+1srZOVeFZJv3yn0+Pe1enx7yr90J8q0nOAnIJKFla3gBvCgByFwmw2KygoSCVKlFCdOnX0zjvv6Oeff9bSpUs1a9YsSVJ0dLRMJpN27dplPS8hIUEmk0lr1qyRdGVK9dKlS1W3bl2ZzWatX79eUVFReuyxxxQYGChPT0/df//9+u2336ztNG3aVEePHtXrr78uk8kkk+nSYCa3KetTp05V+fLl5eLiokqVKunrr7+2ed9kMunLL7/U448/Lnd3d1WoUEGLFi26Zv/PnTunrl27ys/PT+7u7mrdurUOHTpk7dPlQXPz5s1t+nuZi4uLgoKCrIebm5v1Mw0KCtJnn32m+vXr68svv1TZsmXl6upq7fe/ZwR8/fXXqlevnry8vBQUFKQuXbro1KlT14wd+dOpXQl99cMxrd96VlFH0/T+hAMqWsSsBxv653nOlh3n9OW3R7Vuc86s+K20i3tT6wc9tXpbqn7/I00nT13UjIUJSs+wqEk991zrt2rsoT2H0rV4XYr+OX1RP65IVvQ/mXokzNNaZ/3O81qwKln7Dqfn2gbs0+nlv+vgsAmK+/m361eWVOaFp3X+yAlFvvWhUvb/raNTvlXsT8tVtn93a52yr/XQ8enzdGL2fKVERmlv32HKSrugUt2fLKBe4G7g2bSt0jat0vmta3Ux7qQSf5guS0aG3Bs0zbW+S0hFZRw5qPM7NirrXLzSD+zV+R0b5Vy6vLVO+p87lB65S1nxsco6HavkJfNkSb8glzKhhdQr3CiLpeCOuwEDchimefPmqlmzpubPn3/D57799tsaM2aMIiMjVaNGDaWkpKhNmzZauXKldu7cqVatWqldu3Y6duyYpEtTt0uWLKmRI0daM8q5WbBggfr376833nhD+/bts04jX716tU29ESNGqFOnTtqzZ4/atGmjZ599VmfPns0z3u7du2v79u1atGiRNm3aJIvFojZt2igzM1ONGjXSgQMHJEk//fRTjmx3fh0+fFg//fST5s+fb3NT498yMzM1atQo7d69WwsXLlR0dLS6d+9+w9eCreBAVxUt4qLtuxOsZalpWYo8mKxqlW5+hkJBtYu7j6OjVLa4s83A2WKR9kWlq0Jpl1zPCS3ton2HbZc27Dl0QaF51Adulm/DWopftcmm7PSK9fJrWEuSZHJ2lk+daopfufFKBYtF8as2yrdh7UKMFHcUR0c5lyyr9IP7rpRZLEo/tE/OZSrkekpG9EE5lyprHYA7Fg2QuWotpUfuyv0aJpNca4fJZDYrI/rQbe4AcHuwhhyGqly5svbs2XPD540cOVItW7a0vi5SpIhq1qxpfT1q1CgtWLBAixYt0iuvvKIiRYrI0dHRmhnOy9ixY9W9e3f17dtXkhQREaHNmzdr7NixNmu4u3fvrmeeeUaS9MEHH+i///2vtm7dqlatWuVo89ChQ1q0aJE2bNhgHWh/++23KlWqlBYuXKiOHTtap80XKVLkmvFdS0ZGhr766isVK1YszzrPP/+89b/LlSun//73v7r//vuVkpIiT0/PPM+7LD09Xenptpm07KwMOTja9x/4Rf0urdM/l5BhU342IUNF/G7+symodnH38XJ3kKOjSYkp2TblSclZKl7MnOs5vp6OOeonpmTL15N78bi9zIH+So+LtylLj4uXs4+XHFzNcvbzkYOTk9JPnbmqzhl5VCpXmKHiDuLg4S2To6Oykm2XzGQnJ8oloHiu55zfsVEOHl7yf3W4ZJJMjk5K3bBCKb/9bFPPKbiU/PuPlMnJWZaMCzo7Y7wuxp0sqK7gFlnYZR0wjsVisU4fvxH16tWzeZ2SkqIBAwaoSpUq8vX1laenpyIjI60Z8vyKjIxU48aNbcoaN26syMhIm7IaNWpY/9vDw0Pe3t55Tv2OjIyUk5OTGjRoYC0rWrSoKlWqlKPdW1GmTJlrDsYl6Y8//lC7du1UunRpeXl5qUmTJpKU789p9OjR8vHxsTmOH/rmlmO/27RsUkzL5zayHk6O/CgFAKCguZSvIs8WHZT44wydHveOzs4YJ3PV2vJs+bhNvYun/tHpsW8rfsIQpW74Tb5dXpJTYAmDosb1ZFsK7rgbkCGHoSIjI1W2bFlJsu62bvnXgo/MzNx3+/Xw8LB5PWDAAK1YsUJjx45VaGio3Nzc9NRTT1k3N7vdrt653GQyKTs7O4/ahePqz+RqqampCg8PV3h4uL799lsVK1ZMx44dU3h4eL4/p0GDBikiIsKmrHWXbTcd891q/daz+uvADutrZ+dL310/XxedOXflO1vE10WHjqTc9HUut3W728XdJzktW1lZFvlcld329nJUYnJWruckpGTlqO/j6aCEFGN/VuHekx4XL3Og7b4W5kB/ZSYmK/tCujLizyn74kWZA4peVaeo0mNtM+uwH9mpSbJkZV3aXf1f5Q5ePspKSsj1HK82nXR++zqlbbm0lPBizHGZXFzl06mXUn5beGXRcFaWsuLjlCUp88QRuZQuJ4+HWinxh+kF2SXgppDWgWFWrVqlvXv36sknL23ocjm7++/13Xmthb7ahg0b1L17dz3++OO67777FBQUpOjoaJs6Li4uysrK/Q/Xy6pUqaINGzbkaLtq1ar5iiOvNi9evKgtW7ZYy86cOaMDBw7cUrs3av/+/Tpz5ozGjBmjBx98UJUrV77hDd3MZrO8vb1tDnucrn7+fJZOxl6wHtHH03TmbIbq1vC11nF3c1SVil7680DyTV8nJu5CgbSLu09WlnTkn0xVK39lerrJJFUvb9ahY7nfUDt8LMOmviRVDzXrcB71gZuVsHmXijZvaFPm/3Ajndu8S5JkycxU4o4/5d887EoFk0lFm4UpYfPOQowUd5SsrEuD5YrVr5SZTDJXqKbMo7mv9zY5u9gkbiRJ+UmImBxkcuIxsHcqi8VUYMfdgAw5CkV6erpiY2OVlZWluLg4LVu2TKNHj9ajjz6qrl27Srr0CLKGDRtqzJgxKlu2rE6dOqXBgwfnq/0KFSpo/vz5ateunUwmk4YMGZIjYx0SEqLff/9dTz/9tMxms/z9c+5S/eabb6pTp06qXbu2WrRoof/973+aP3++zY7tN6pChQp67LHH1Lt3b33++efy8vLS22+/rRIlSuixxx676XZvVOnSpeXi4qJPP/1UL774ovbt26dRo0YV2vXvdfP+d1LdOpXSiZjziom7oF5dyujM2XSt23wl+zNh5H36fXO85i+5dNPJzdVBJYLdrO8HB5oVWtZDSckXdSo+Pd/twj4sXZeiPh39dORkpqKOZ6hVY0+ZXUxa+0eaJOnFjn46l5Sl75cnSZKWbUjV4Bf81eYBT+08cEFhNdxUroSLpi9IsLbp4WaSv6+TfL0v3Z8P9r/0Z0FCclaO9eewH44e7vIILW197V62pLxrVlbG2URdOB6jSu9FyLVEoHb3GChJOjptrsr0fVaVR7+p47N+kn+zhgru2Frb2vextnFkwkzVnPGhEv7Yp8RtexTSr5ucPNx0fPaNb+yKe0fKmsXy6/KSMo//rcyjh+XRpLVMLmalbVkrSfLt8pKyEs8pefFcSZd2UPdo2kaZJ6OVefSwnPyD5NW6o9L/3GHNjnu1ffrSLuvn4mVydZNbncZyKV9FZz8fY1g/gWthQI5CsWzZMgUHB8vJyUl+fn6qWbOm/vvf/6pbt27WqeqSNGPGDPXs2VN169ZVpUqV9NFHH+mRRx65bvvjx4/X888/r0aNGsnf318DBw5UUlKSTZ2RI0eqT58+Kl++vNLT03PeYZXUoUMHTZw4UWPHjlX//v1VtmxZzZw5U02bNr2l/s+cOdP63PWMjAw99NBDWrJkSY6p7wWpWLFimjVrlt555x3997//VZ06dTR27Fi1b9++0GK4l82Zf0Juro56s28FeXo4aW9kogaM+FMZmVe+Z8WDXOXjfeXfvFKolz59/8p+BK/2vLRr7NKVcfrgvwfz3S7sw+a95+Xl6aCnWnjJx8tRR2My9eHMeCX9/8C5qK+jzc+1Q8cyNHnuWXV8xFudwr0VG39R4785oxNxF6116lZxU5+OftbXr3a59Ezon35L0vyVzMKwVz51qyts5ZVHflYd+44k6fhX87Wn5yCZg4vJrVSw9f3z0Se0rX0fVR03SCGvdtWFE7Ha22ew4lest9aJ+WGpXIoVUcVh/WQOKqak3ZHa+mgvZZzK+7GPuPdd2LVZiZ7e8mr1lBy9fZV58qjOfD5G2SmXNnpz9PO3eXZV8ooFskjybt1Jjj5FlJWapPQ/dyhp8ffWOg6e3vJ9tq8cvX2VfT5NF2OO6eznY5R+cG9hdw/5dLc8nqygmCy5jUoAIJ8efGyd0SHATpSuym7MKBxdxjY3OgTYidqv1DE6BNiJ4p98Z3QIeVqyI/c9o26HNnXu/KUKZMgBAAAAAIbI5rFnAAAAAACgsJEhBwAAAAAYwt4XUDMgBwAAAAAY4m55PFlBYco6AAAAAAAGIEMOAAAAADBEtp1PWSdDDgAAAACAAciQAwAAAAAMYe+bupEhBwAAAADAAGTIAQAAAACGsIhd1gEAAAAAQCEjQw4AAAAAMIS977LOgBwAAAAAYAg2dQMAAAAAAIWODDkAAAAAwBBkyAEAAAAAQKEjQw4AAAAAMES2hceeAQAAAACAQkaGHAAAAABgCNaQAwAAAACAQkeGHAAAAABgCHvPkDMgBwAAAAAYItvOB+RMWQcAAAAAwABkyAEAAAAAhrDw2DMAAAAAAFDYyJADAAAAAAxh75u6kSEHAAAAAMAAZMgBAAAAAIZgl3UAAAAAAFDoyJADAAAAAAxh72vIGZADAAAAAAxh7wNypqwDAAAAAGAAMuQAAAAAAEOwqRsAAAAAACh0ZMgBAAAAAIZgDTkAAAAAACh0DMgBAAAAAIbIzi6442ZMnjxZISEhcnV1VYMGDbR169Y8637xxRd68MEH5efnJz8/P7Vo0eKa9XPDgBwAAAAAYPe+//57RUREaNiwYdqxY4dq1qyp8PBwnTp1Ktf6a9as0TPPPKPVq1dr06ZNKlWqlB555BGdPHky39dkQA4AAAAAMITFUnDHjRo/frx69+6tHj16qGrVqvrss8/k7u6uGTNm5Fr/22+/Vd++fVWrVi1VrlxZX375pbKzs7Vy5cp8X5MBOQAAAADgnpOenq6kpCSbIz09Pde6GRkZ+uOPP9SiRQtrmYODg1q0aKFNmzbl63ppaWnKzMxUkSJF8h0jA3IAAAAAgCEKMkM+evRo+fj42ByjR4/ONY74+HhlZWUpMDDQpjwwMFCxsbH56svAgQNVvHhxm0H99fDYMwAAAACAIbIL8LFngwYNUkREhE2Z2WwukGuNGTNGc+fO1Zo1a+Tq6prv8xiQAwAAAADuOWazOd8DcH9/fzk6OiouLs6mPC4uTkFBQdc8d+zYsRozZox+++031ahR44ZiZMo6AAAAAMAQFoulwI4b4eLiorp169psyHZ5g7awsLA8z/voo480atQoLVu2TPXq1bvh/pMhBwAAAADYvYiICHXr1k316tVT/fr1NWHCBKWmpqpHjx6SpK5du6pEiRLWdegffvihhg4dqjlz5igkJMS61tzT01Oenp75uiYDcgAAAACAIW7m8WQFpXPnzjp9+rSGDh2q2NhY1apVS8uWLbNu9Hbs2DE5OFyZZD516lRlZGToqaeesmln2LBhGj58eL6uyYAcAAAAAABJr7zyil555ZVc31uzZo3N6+jo6Fu+HgNyAAAAAIAhsrONjsBYbOoGAAAAAIAByJADAAAAAAxxJ60hNwIDcgAAAACAIbLtfEDOlHUAAAAAAAxAhhzALbHY+04cAO45tV+pY3QIsBM7J+0wOgTYieKfGB1B3ux9yjoZcgAAAAAADECGHAAAAABgCEuBLiI3FWDbtwcZcgAAAAAADECGHAAAAABgCHZZBwAAAAAAhY4MOQAAAADAEPa+yzoDcgAAAACAIbLtfM46U9YBAAAAADAAGXIAAAAAgCHsfco6GXIAAAAAAAxAhhwAAAAAYAgy5AAAAAAAoNCRIQcAAAAAGCLbzlPkZMgBAAAAADAAGXIAAAAAgCEs2UZHYCwG5AAAAAAAQ1iYsg4AAAAAAAobGXIAAAAAgCGy7XzKOhlyAAAAAAAMQIYcAAAAAGAI1pADAAAAAIBCR4YcAAAAAGCIbPtOkJMhBwAAAADACGTIAQAAAACGsNh5ipwBOQAAAADAEHa+pxtT1gEAAAAAMAIZcgAAAACAIbLtfMo6GXIAAAAAAAxAhhwAAAAAYAiLnS8iJ0MOAAAAAIAByJADAAAAAAxhyTY6AmORIQcAAAAAwABkyAEAAAAAhsi28zXkDMgBAAAAAIZgUzcAAAAAAFDoyJADAAAAAAyRnU2GHAAAAAAAFDIy5AAAAAAAQ9j5EnIy5AAAAAAAGIEMOQAAAADAEBbWkAMAAAAAgMJGhhwAAAAAYIhsO19EzoAcAAAAAGAIpqwDAAAAAIBCR4YcAAAAAGAIMuQAAAAAAKDQkSEHAAAAABjCzhPkZMgBAAAAADACGXIAAAAAgCFYQw4AAAAAAAodGXIAAAAAgCEsFjLkBS4kJEQTJkwojEvZjdv1mZpMJi1cuPCW27lbRUdHy2QyadeuXUaHov3796thw4ZydXVVrVq1bkubw4cPv+G27P07AQAAgMKTnW0psONucEMZ8u7du2v27NmSJGdnZ5UuXVpdu3bVO++8IyenvJvatm2bPDw8bi3SQpaRkaEJEybo22+/1aFDh+Tu7q5KlSqpV69e+s9//iNnZ2ejQ7whw4cP18KFC3MMPGNiYuTn51eg1541a5Z69OghSXJwcJC3t7cqVqyotm3bqn///vLx8SnQ61/WvXt3JSQk2Aw2S5UqpZiYGPn7+xdKDNcybNgweXh46MCBA/L09Mzxvslkuu75w4cPtykbMGCAXn311dsZJq6h57MhavdIkLw8nLQ3MkljpxzSiZjzedavWc1HXZ4opUrlPeVf1KxB7+/Tus1nbrld3LtaNvRQ24c85ePpqGOxmZq9KEF/n8jMs3796q7q2NJb/n5OijtzUd8tS9TuA+nW9+tVc1WLBh4KKeEiL3cHvfPfUzoak3d7sB/ujVvKs3k7OXr5KPOfY0qcP0uZx6LyrO/xUGt5NG4hR19/Zacm6/yeLUr6Za508dL3yb1RC3k0binHIpd+316MPaHk5fOVvn93ofQHd6YiD9RTuTd6yqdOdbkWD9D2J/sqbtHKa5/zUH1VHfu2PKtW0IXjMTo8eqpOfLXApk6Zl7qoXERPmYOKKWnPfv352iglbttbkF0BbtoNZ8hbtWqlmJgYHTp0SG+88YaGDx+ujz/+ONe6GRkZkqRixYrJ3d391iK9CZevfzPnhYeHa8yYMXrhhRe0ceNGbd26VS+//LI+/fRT/fnnn7c5UuMEBQXJbDYX+HW8vb0VExOjEydOaOPGjXrhhRf01VdfqVatWvrnn39uqe3MzJv/49HR0VFBQUHXvKFUWKKiovTAAw+oTJkyKlq0aI73Y2JirMeECROsn+nlY8CAAda6FotFFy9elKenZ65t4fZ79slSeurREho75ZBeGLBT5y9kafzI++TinPeNFDdXRx0+kqLxnx26re3i3tTwPjc929ZH81cma/CkUzoWk6m3n/eXt0fuv8orlHbRK08X0ZrtaXr301Pa/td5RfynqEoGXvl55+pi0oHoDM1dmlhY3cBdwLVWQ/l0eE7Jy3/S6XHvKPOfoyra5205eHrnWt+tTiN5P/q0kpf/pFNj3lDC95/LrVaYvNt2ttbJSjyrpF++0+lx7+r0+HeVfuhPFek5QE5BJQurW7gDOXq4K2nPAe3rNyJf9d1CSur+RZ/rzJotWl/vMR35dLbu+/w9+bd8wFonuGNrVfl4kA69N1nr6z+u5D371WDxdLkUK1JQ3cAtslgsBXbcDW54QG42mxUUFKQyZcropZdeUosWLbRo0SJJlzKQHTp00Pvvv6/ixYurUqVKknJOrzaZTPr888/16KOPyt3dXVWqVNGmTZt0+PBhNW3aVB4eHmrUqJGioq7ciY2KitJjjz2mwMBAeXp66v7779dvv/1mE1tISIhGjRqlrl27ytvbWy+88IKaN2+uV155xabe6dOn5eLiopUrc78DN2HCBP3+++9auXKlXn75ZdWqVUvlypVTly5dtGXLFlWoUEGSlJ6ern79+ikgIECurq564IEHtG3bNms7a9askclk0vLly1W7dm25ubmpefPmOnXqlJYuXaoqVarI29tbXbp0UVpamvW8pk2b6pVXXtErr7wiHx8f+fv7a8iQIdf8UiUkJKhXr14qVqyYvL291bx5c+3efemu86xZszRixAjt3r1bJpNJJpNJs2bNsv5b/DtjvHfvXjVv3lxubm4qWrSoXnjhBaWkpFjfv/xvPHbsWAUHB6to0aJ6+eWXrzsoNplMCgoKUnBwsKpUqaKePXtq48aNSklJ0VtvvWXzb3j1VPxatWrZZH5NJpOmTp2q9u3by8PDQ++//76ysrLUs2dPlS1bVm5ubqpUqZImTpxoPWf48OGaPXu2fv75Z+tnsGbNmlynrK9du1b169eX2WxWcHCw3n77bV28eNHm36dfv3566623VKRIEQUFBeXITF8tOztbI0eOVMmSJWU2m1WrVi0tW7bMpk9//PGHRo4cKZPJlGt7QUFB1sPHx8f6mQYFBWn//v3y8vLS0qVLVbduXZnNZq1fvz7HlPVt27apZcuW8vf3l4+Pj5o0aaIdO3ZcM3bkT8f2JfTVvKNav+WMoqJT9d4n+1W0iFkPNsx79sXmP87qi2+i9XsuWfFbaRf3ptYPemr1tlT9/keaTp66qBkLE5SeYVGTernf8G7V2EN7DqVr8boU/XP6on5ckazofzL1SNiVGTjrd57XglXJ2nc4Pdc2YJ88m7ZV2qZVOr91rS7GnVTiD9NlyciQe4OmudZ3CamojCMHdX7HRmWdi1f6gb06v2OjnEuXt9ZJ/3OH0iN3KSs+VlmnY5W8ZJ4s6RfkUia0kHqFO9Hp5b/r4LAJivv5t+tXllTmhad1/sgJRb71oVL2/62jU75V7E/LVbZ/d2udsq/10PHp83Ri9nylREZpb99hykq7oFLdnyygXgC35pbXkLu5udlkoleuXKkDBw5oxYoV+uWXX/I87/LAedeuXapcubK6dOmiPn36aNCgQdq+fbssFovNQDolJUVt2rTRypUrtXPnTrVq1Urt2rXTsWPHbNodO3asatasqZ07d2rIkCHq1auX5syZo/T0K39sfPPNNypRooSaN2+ea2zffvutWrRoodq1a+d4z9nZ2Tr9/q233tJPP/2k2bNna8eOHQoNDVV4eLjOnj1rc87w4cM1adIkbdy4UcePH1enTp00YcIEzZkzR4sXL9avv/6qTz/91Oac2bNny8nJSVu3btXEiRM1fvx4ffnll3l+nh07drQO9P/44w/VqVNHDz/8sM6ePavOnTvrjTfeULVq1azZ1M6dO+doIzU1VeHh4fLz89O2bdv0ww8/6LfffstxQ2P16tWKiorS6tWrNXv2bM2aNcs6wL8RAQEBevbZZ7Vo0SJlZWXd0LnDhw/X448/rr179+r5559Xdna2SpYsqR9++EF//fWXhg4dqnfeeUfz5s2TdGnqdqdOnawzPGJiYtSoUaMc7Z48eVJt2rTR/fffr927d2vq1KmaPn263nvvPZt6s2fPloeHh7Zs2aKPPvpII0eO1IoVK/KMd+LEiRo3bpzGjh2rPXv2KDw8XO3bt9ehQ5cyozExMapWrZreeOONHNnuG/H2229rzJgxioyMVI0aNXK8n5ycrG7dumn9+vXavHmzKlSooDZt2ig5OfmmrodLige6yr+IWdt2nbOWpaZl6a+DSapeOfeMkpHt4u7j6CiVLe5sM3C2WKR9UemqUNol13NCS7to3+ELNmV7Dl1QaB71AUmSo6OcS5ZV+sF9V8osFqUf2ifnMhVyPSUj+qCcS5W1DsAdiwbIXLWW0iN35X4Nk0mutcNkMpuVEZ33DCHgar4Nayl+1SabstMr1suvYS1JksnZWT51qil+5cYrFSwWxa/aKN+GOf+ux53Bkm0psONucNPzdC0Wi1auXKnly5fbrFH18PDQl19+KReXa//C79Gjhzp16iRJGjhwoMLCwjRkyBCFh4dLkvr3729ddyxJNWvWVM2aNa2vR40apQULFmjRokU2A8bmzZvrjTfesL4uUaKEXnnlFf3888/W682aNUvdu3fPc03uoUOH1LRp02vGn5qaqqlTp2rWrFlq3bq1JOmLL77QihUrNH36dL355pvWuu+9954aN24sSerZs6cGDRqkqKgolStXTpL01FNPafXq1Ro4cKD1nFKlSumTTz6RyWRSpUqVtHfvXn3yySfq3bt3jljWr1+vrVu36tSpU9bp52PHjtXChQv1448/6oUXXpCnp6ecnJwUFBSUZ5/mzJmjCxcu6KuvvrLedJg0aZLatWunDz/8UIGBgZIkPz8/TZo0SY6OjqpcubLatm2rlStX5hrb9VSuXFnJyck6c+aMAgIC8n1ely5dbL4fkjRixJXpTmXLltWmTZs0b948derUSZ6ennJzc1N6evo1P4MpU6aoVKlSmjRpkkwmkypXrqx//vlHAwcO1NChQ+XgcOkeVo0aNTRs2DBJUoUKFTRp0iStXLlSLVu2zLXdsWPHauDAgXr66aclSR9++KFWr16tCRMmaPLkydZp856enteM73pGjhyZZwySctyEmjZtmnx9fbV27Vo9+uij120/PT3d5uaWJGVnZcjB0b7/wC/id6n/5xJsZ4qcS8iwvncntYu7j5e7gxwdTUpMybYpT0rOUvFiuS878vV0zFE/MSVbvp488RR5c/DwlsnRUVnJtssYspMT5RJQPNdzzu/YKAcPL/m/OlwySSZHJ6VuWKGU3362qecUXEr+/UfK5OQsS8YFnZ0xXhfjThZUV3APMgf6Kz0u3qYsPS5ezj5ecnA1y9nPRw5OTko/deaqOmfkUalcYYYK5NsN/1b+5Zdf5OnpKVdXV7Vu3VqdO3e2mV573333XXcwLskme3d5oHfffffZlF24cEFJSUmSLmXIBwwYoCpVqsjX11eenp6KjIzMkSGvV6+ezWtXV1c999xzmjFjhiRpx44d2rdvn7p3755nbPlZbxAVFaXMzEzrQFu6lD2vX7++IiMjr9lXd3d362D8ctmpU6dszmnYsKHNDYOwsDAdOnQo10zy7t27lZKSoqJFi8rT09N6HDlyxGba//VERkaqZs2aNhvwNW7cWNnZ2Tpw4IC1rFq1anJ0dLS+Dg4OzhF/fl3+rK+3YdnVrv53lqTJkyerbt26KlasmDw9PTVt2rQc34/riYyMVFhYmE08jRs3VkpKik6cOGEtuzr7fK3PICkpSf/884/Nd+Vyu1d/V25Vbp/Lv8XFxal3796qUKGCfHx85O3trZSUlHx/TqNHj5aPj4/NceLwt7cj9LtKyyYB+nXeA9bDyYn13ADsl0v5KvJs0UGJP87Q6XHv6OyMcTJXrS3Plo/b1Lt46h+dHvu24icMUeqG3+Tb5SU5BZYwKGoAdwoy5DeoWbNmmjp1qlxcXFS8ePEcm2Hldzf1f+9Sfnnwk1tZdvalu/sDBgzQihUrNHbsWIWGhsrNzU1PPfVUjo3bcrt+r169VKtWLZ04cUIzZ85U8+bNVaZMmTxjq1ixovbv35+vfuTH1f26eod2k8lk7efNSElJUXBwsNasWZPjPV9f35tuNy+3M/7IyEh5e3tbNx5zcHDIcUMkt/XpV/87z507VwMGDNC4ceMUFhYmLy8vffzxx9qyZctNxXU9t/vf8Ha53v9/3bp105kzZzRx4kSVKVNGZrNZYWFh+d4AcdCgQYqIiLApa/V0wXzGd7L1W8/or4Pbra9dnC/d2/TzddaZc1c+Sz9fFx3+OyXH+fl19v/but3t4u6TnJatrCyLfK7Kbnt7OSoxOfclPwkpWTnq+3g6KCHF+J9VuHNlpybJkpV1aXf1f5U7ePkoKykh13O82nTS+e3rlLZltSTpYsxxmVxc5dOpl1J+W3hpfYUkZWUpKz5OWZIyTxyRS+ly8niolRJ/mF6QXcI9JD0uXuZA2z1UzIH+ykxMVvaFdGXEn1P2xYsyBxS9qk5RpcfaZtaBO8UNZ8g9PDwUGhqq0qVLF+rO1Bs2bFD37t31+OOP67777lNQUJCio6Pzde59992nevXq6YsvvtCcOXP0/PPPX7N+ly5d9Ntvv2nnzp053svMzFRqaqrKly8vFxcXbdiwwea9bdu2qWrVqjfUt9xcPZC8vN7335npy+rUqaPY2Fg5OTkpNDTU5rj8OC8XF5frrtOuUqWKdu/erdTUVGvZhg0b5ODgYN2g73Y6deqU5syZow4dOlinghcrVkwxMTHWOklJSTpy5Mh129qwYYMaNWqkvn37qnbt2goNDc0xOyC/n8GmTZtsbgps2LBBXl5eKlny5naC9fb2VvHixW2+K5fbvR3flRuxYcMG9evXT23atFG1atVkNpsVH5//X1Bms1ne3t42hz1OVz9/PksnYy5YjyPH0hR/Nl31al55hKC7m6OqVvTWvv1JN32df+IuFEi7uPtkZUlH/slUtfJXpqebTFL18mYdOpb7DbXDxzJs6ktS9VCzDudRH5AkZWVdGixXrH6lzGSSuUI1ZR7Nfb23ydkl5+zC/NykNjnI5HR3PUYWxkrYvEtFmze0KfN/uJHObd4lSbJkZipxx5/ybx52pYLJpKLNwpSwOeff9bgzZFssBXbcDe6ahWQVKlTQ/PnztWvXLu3evVtdunS5oYxkr169NGbMGFksFj3++OPXrPvaa6+pcePGevjhhzV58mTt3r1bf//9t+bNm6eGDRvq0KFD8vDw0EsvvaQ333xTy5Yt019//aXevXsrLS1NPXv2vNXu6tixY4qIiNCBAwf03Xff6dNPP1X//v1zrduiRQuFhYWpQ4cO+vXXXxUdHa2NGzfq3Xff1fbtl7J4ISEhOnLkiHbt2qX4+Pgc64Al6dlnn5Wrq6u6deumffv2afXq1Xr11Vf13HPPWZcV3CyLxaLY2FjFxMQoMjJSM2bMUKNGjeTj46MxY8ZY6zVv3lxff/211q1bp71796pbt2653oS4WoUKFbR9+3YtX75cBw8e1JAhQ2x2vL/8GezZs0cHDhxQfHx8rpn3vn376vjx43r11Ve1f/9+/fzzzxo2bJgiIiKsNw1uxptvvqkPP/xQ33//vQ4cOKC3335bu3btyvPftKBUqFBBX3/9tSIjI7VlyxY9++yzcnNzK9QY7lU/LDqpbp1Lq3H9oipXxkODIyrrzNl0rdt85YbHhPdq6Im2V9Zgurk6KLSsh0LLXprZEBzoqtCyHgr815rg/LQL+7B0XYqa3e+hB+u4q3gxJ/V4zFdmF5PW/nHpKR0vdvRT5/Arm/0t25CqGhVd1eYBTwUXc9ITD3upXAkX/brpyuwKDzeTygQ7q8T/Pwot2N9JZYKdc2TWYV9S1iyWR8Nmcrv/ITkFFJfPU8/L5GJW2pa1kiTfLi/Jq+3T1vrpf+6QR+MWcq0dJscixWSueJ+8WndU+p87rNlxr7ZPy6VcZTn6+cspuNSl1+Wr6PwfG3KNAfbB0cNd3jUry7tmZUmSe9mS8q5ZWa6lgiVJld6LUM2ZH1rrH502V+5lS6ny6DflUamcyrzYRcEdW+vIxFnWOkcmzFSpnp1U4rkO8qxcTtUnD5eTh5uOz55fqH0D8sv4hy/n0/jx4/X888+rUaNG8vf318CBA63ry/PjmWee0WuvvaZnnnlGrq6u16xrNpu1YsUKffLJJ/r88881YMAA6+PZ+vXrp+rVL901HjNmjLKzs/Xcc88pOTlZ9erV0/Lly+Xn53fN9vOja9euOn/+vOrXry9HR0f1799fL7zwQq51TSaTlixZonfffVc9evTQ6dOnFRQUpIceesg6kH7yySc1f/58NWvWTAkJCZo5c2aOdfTu7u5avny5+vfvr/vvv1/u7u568sknNX78+FvuT1JSkoKDg2UymeTt7a1KlSqpW7du6t+/v7y9r/wBOWjQIB05ckSPPvqofHx8NGrUqHxlyPv06aOdO3eqc+fOMplMeuaZZ9S3b18tXbrUWqd3795as2aN6tWrp5SUFK1evVohISE27ZQoUUJLlizRm2++qZo1a6pIkSLq2bOnBg8efEv979evnxITE/XGG2/o1KlTqlq1qhYtWmR9hF5hmT59ul544QXVqVNHpUqV0gcffHDTO7rD1rc/HZerq6PeeqWiPD2ctPevRL0xbK8yMq/cnS0R5CZf7yvZoMqhXvp0dC3r6369Lj3+Z8nKWH0w4UC+24V92Lz3vLw8HfRUCy/5eDnqaEymPpwZr6T/n4Je1NfRJkt56FiGJs89q46PeKtTuLdi4y9q/DdndCLuymMc61ZxU5+OV35nvdrl0nN6f/otSfNX8vQFe3Vh12YlenrLq9VTcvT2VebJozrz+Rhlp1za6M3Rz//KNHRJySsWyCLJu3UnOfoUUVZqktL/3KGkxd9b6zh4esv32b5y9PZV9vk0XYw5prOfj1H6wb2F3T3cQXzqVlfYyq+tr6uOfUeSdPyr+drTc5DMwcXk9v+Dc0k6H31C29r3UdVxgxTyalddOBGrvX0GK37FemudmB+WyqVYEVUc1k/moGJK2h2prY/2UsapvB8xCmPdLWu9C4rJcrc8Mf0WRUdHq3z58tq2bZvq1KljdDjX1LRpU9WqVSvH87iBO9ED7dYaHQLsRJnqPK8YhePjC9yoROHYOWmH0SHATrTNPHD9SgbpOiTm+pVu0lejgq9fyWB3TYb8ZmVmZurMmTMaPHiwGjZseMcPxgEAAAAA9uGeH5Bv2LBBzZo1U8WKFfXjjz8aHQ4AAAAA4P9l2/mU9Xt+QN60adN8PVf8TpLb48sAAAAAAPeWe35ADgAAAAC4M9n7pm481wQAAAAAAEmTJ09WSEiIXF1d1aBBA23duvWa9X/44QdVrlxZrq6uuu+++7RkyZIbuh4DcgAAAACAISwWS4EdN+r7779XRESEhg0bph07dqhmzZoKDw/XqVOncq2/ceNGPfPMM+rZs6d27typDh06qEOHDtq3b1++r8mAHAAAAABg98aPH6/evXurR48eqlq1qj777DO5u7trxowZudafOHGiWrVqpTfffFNVqlTRqFGjVKdOHU2aNCnf12RADgAAAAAwhCU7u8CO9PR0JSUl2Rzp6em5xpGRkaE//vhDLVq0sJY5ODioRYsW2rRpU67nbNq0yaa+JIWHh+dZPzcMyAEAAAAAhsjOthTYMXr0aPn4+Ngco0ePzjWO+Ph4ZWVlKTAw0KY8MDBQsbGxuZ4TGxt7Q/Vzwy7rAAAAAIB7zqBBgxQREWFTZjabDYomdwzIAQAAAACGuJnN1/LLbDbnewDu7+8vR0dHxcXF2ZTHxcUpKCgo13OCgoJuqH5umLIOAAAAALBrLi4uqlu3rlauXGkty87O1sqVKxUWFpbrOWFhYTb1JWnFihV51s8NGXIAAAAAgCEs2QWXIb9RERER6tatm+rVq6f69etrwoQJSk1NVY8ePSRJXbt2VYkSJazr0Pv3768mTZpo3Lhxatu2rebOnavt27dr2rRp+b4mA3IAAAAAgN3r3LmzTp8+raFDhyo2Nla1atXSsmXLrBu3HTt2TA4OVyaZN2rUSHPmzNHgwYP1zjvvqEKFClq4cKGqV6+e72uaLAU5aR/APe+BdmuNDgF2okz1UKNDgJ34+MIAo0OAndg5aYfRIcBOtM08YHQIeXqq/98F1vaPE8sVWNu3C2vIAQAAAAAwAFPWAQAAAACGyLZkGx2CoRiQAwAAAAAMcSdt6mYEpqwDAAAAAGAAMuQAAAAAAEOQIQcAAAAAAIWODDkAAAAAwBD2/hRuMuQAAAAAABiADDkAAAAAwBDZ2fb92DMy5AAAAAAAGIAMOQAAAADAEPa+yzoDcgAAAACAISwWpqwDAAAAAIBCRoYcAAAAAGAIe5+yToYcAAAAAAADkCEHAAAAABiCDDkAAAAAACh0ZMgBAAAAAIbIZpd1AAAAAABQ2MiQAwAAAAAMYe9ryBmQAwAAAAAMYclmyjoAAAAAAChkZMgBAAAAAIaw9ynrZMgBAAAAADAAGXIAAAAAgCEsPPYMAAAAAAAUNjLkAAAAAABDZLOGHAAAAAAAFDYy5AAAAAAAQ9j7c8gZkAMAAAAADMFjzwAAAAAAQKEjQw4AAAAAMASPPQMAAAAAAIWODDkAAAAAwBCsIQcAAAAAAIWODDkAAAAAwBD2/tgzMuQAAAAAABjAZLFY7HvSPgAUsvT0dI0ePVqDBg2S2Ww2Ohzcw/iuobDwXUNh4buGew0DcgAoZElJSfLx8VFiYqK8vb2NDgf3ML5rKCx811BY+K7hXsOUdQAAAAAADMCAHAAAAAAAAzAgBwAAAADAAAzIAaCQmc1mDRs2jM1oUOD4rqGw8F1DYeG7hnsNm7oBAAAAAGAAMuQAAAAAABiAATkAAAAAAAZgQA4AAAAAgAEYkAMAAAAAYAAnowMAAHtw8eJFrVmzRlFRUerSpYu8vLz0zz//yNvbW56enkaHBwDXlZSUlO+63t7eBRgJANw72GUdAArY0aNH1apVKx07dkzp6ek6ePCgypUrp/79+ys9PV2fffaZ0SECwHU5ODjIZDJds47FYpHJZFJWVlYhRYV70aJFi/Jdt3379gUYCVDwyJADQAHr37+/6tWrp927d6to0aLW8scff1y9e/c2MDLci44dO6ZSpUrlGDhZLBYdP35cpUuXNigy3O1Wr15tdAiwEx06dMhXPW7+4F7AgBwACti6deu0ceNGubi42JSHhITo5MmTBkWFe1XZsmUVExOjgIAAm/KzZ8+qbNmy/PGKm9akSROjQ4CdyM7ONjoEoNAwIAeAApadnZ3rIOjEiRPy8vIyICLcyy5PGb5aSkqKXF1dDYgI97K0tDQdO3ZMGRkZNuU1atQwKCIAuLswIAeAAvbII49owoQJmjZtmqRLU+xSUlI0bNgwtWnTxuDocK+IiIiQdOn7NWTIELm7u1vfy8rK0pYtW1SrVi2DosO95vTp0+rRo4eWLl2a6/vMxMDtlJqaqrVr1+Z686dfv34GRQXcHgzIAaCAjRs3TuHh4apataouXLigLl266NChQ/L399d3331ndHi4R+zcuVPSpQz53r17bZZIuLi4qGbNmhowYIBR4eEe89prrykhIUFbtmxR06ZNtWDBAsXFxem9997TuHHjjA4P95CdO3eqTZs2SktLU2pqqooUKaL4+Hi5u7srICCAATnueuyyDgCF4OLFi/r++++1e/dupaSkqE6dOnr22Wfl5uZmdGi4x/To0UMTJ07ksVMoUMHBwfr5559Vv359eXt7a/v27apYsaIWLVqkjz76SOvXrzc6RNwjmjZtqooVK+qzzz6Tj4+Pdu/eLWdnZ/3nP/9R//799cQTTxgdInBLGJADQAH7/fff1ahRIzk52U5KunjxojZu3KiHHnrIoMgA4OZ4e3trz549CgkJUZkyZTRnzhw1btxYR44cUbVq1ZSWlmZ0iLhH+Pr6asuWLapUqZJ8fX21adMmValSRVu2bFG3bt20f/9+o0MEbomD0QEAwL2uWbNmOnv2bI7yxMRENWvWzICIcC9LTU3VkCFD1KhRI4WGhqpcuXI2B3A7VKpUSQcOHJAk1axZU59//rlOnjypzz77TMHBwQZHh3uJs7OzHBwuDVkCAgJ07NgxSZKPj4+OHz9uZGjAbcEacgAoYHnten3mzBl5eHgYEBHuZb169dLatWv13HPPKTg4ONfvHnCr+vfvr5iYGEnSsGHD1KpVK3377bdycXHRrFmzjA0O95TatWtr27ZtqlChgpo0aaKhQ4cqPj5eX3/9tapXr250eMAtY8o6ABSQy+vafv75Z7Vq1Upms9n6XlZWlvbs2aNKlSpp2bJlRoWIe5Cvr68WL16sxo0bGx0K7EhaWpr279+v0qVLy9/f3+hwcA/Zvn27kpOT1axZM506dUpdu3bVxo0bVaFCBc2YMUM1a9Y0OkTglpAhB4AC4uPjI+lShtzLy8tmAzcXFxc1bNhQvXv3Nio83KP8/PxUpEgRo8OAnXF3d1edOnWMDgP3oHr16ln/OyAggJvYuOeQIQeAAjZixAgNGDCA6ekoFN98841+/vlnzZ492+ZZ5MCtioiI0KhRo+Th4WF97n1exo8fX0hRAcDdjQE5AAD3kNq1aysqKkoWi0UhISFydna2eX/Hjh0GRYa7XbNmzbRgwQL5+vqqadOmee5PYDKZtGrVqkKODveSOnXqaOXKlfLz81Pt2rWvuRcGP9Nwt2PKOgAUgh9//FHz5s3TsWPHlJGRYfMef0zgdurQoYPRIeAetXr1aut/r1mzxrhAcM977LHHrPuu8DMN9zoy5ABQwP773//q3XffVffu3TVt2jT16NFDUVFR2rZtm15++WW9//77RocIAPmWmZkpNzc37dq1i12uUaCysrK0YcMG1ahRQ76+vkaHAxQInkMOAAVsypQpmjZtmj799FO5uLjorbfe0ooVK9SvXz8lJiYaHR7uQQkJCfryyy81aNAgnT17VtKlmRgnT540ODLcC5ydnVW6dGllZWUZHQrucY6OjnrkkUd07tw5o0MBCgwDcgAoYMeOHVOjRo0kSW5ubkpOTpYkPffcc/ruu++MDA33oD179qhixYr68MMPNXbsWCUkJEiS5s+fr0GDBhkbHO4Z7777rt555x3rDR+goFSvXl1///230WEABYYBOQAUsKCgIOsfraVLl9bmzZslSUeOHBGrhnC7RUREqHv37jp06JBcXV2t5W3atNHvv/9uYGS4F/z+++/KzMzUpEmT9Pvvv6t48eKqVKmS6tSpY3MAt8t7772nAQMG6JdfflFMTIySkpJsDuBux6ZuAFDAmjdvrkWLFql27drq0aOHXn/9df3444/avn27nnjiCaPDwz1m27Zt+vzzz3OUlyhRQrGxsQZEhHtJs2bNFBMTw0ZbKHAjR47UG2+8oTZt2kiS2rdvb7PbusVikclkYukE7nps6gYABSw7O1vZ2dlycrp0D3Tu3LnauHGjKlSooD59+sjFxcXgCHEvCQgI0PLly1W7dm15eXlp9+7dKleunFas+L/27jQ66irP//inKvtOWBIJICQQDBBWgWFpQMAGAYmA2Mi+K2qLAkHBv4KAIDqCEukeRmV1BtBBWqHlCAoZaJamxYQEZZMEJCwBJLIECNnq/4BjxjLgQuqXWyner3M4h7r39+DzICep7+9+772fa9SoUcrKyjIdERWY3W5Xdna2IiIiTEeBh/Py8tLp06d14MCBX3yuU6dO5ZQIsAYFOQAYdPLkSdWoUcN0DHiQMWPG6Pz58/rwww9VuXJlpaeny8vLS3369FHHjh311ltvmY6ICsxut+vMmTOqVq2a6SjwcLz8wZ2CghwADMjOztbs2bO1ePFiXb161XQceJCLFy+qf//+2rNnjy5fvqyoqChlZ2erbdu22rBhg4KCgkxHRAVmt9vVo0ePkjuib2Xt2rXllAieipc/uFOwhxwALPLDDz/oySef1Oeffy5fX19NmTJFf/7zn/Xyyy/rjTfeUJMmTbR06VLTMeFhwsLC9Pnnn2v79u1KT09Xbm6uWrRoofvvv990NHiIkJAQBQQEmI6BO0D9+vWd9o3fDCf9o6JjhRwALPL444/rs88+0yOPPKKNGzdq//796t69u+x2u1588UW1adPGdEQA+F1oI0Z5sdvteuuttxQWFvaLzw0fPrycEgHWoCAHAIvcfffdWrZsmbp06aJjx44pJiZGU6ZM0Zw5c0xHg4f78ssvlZycrLNnz6q4uNhpbv78+YZSwRP8eNAWBTmsxssf3CloWQcAi5w6dUoNGjSQJNWpU0f+/v4aMmSI4VTwdHPmzNGLL76oe+65R5GRkU7tnr/W+gn8GtZxUF74fYU7BQU5AFjE4XCUXHUm3VhZYt8lrLZgwQItWbJEI0aMMB0FHig5OVmVK1c2HQN3AF7+4E5ByzoAWMRutys+Pr6kKE9PT1dcXFype8dTUlJMxIOHql69urZt26bY2FjTUQAAwK+gIAcAi8yYMeM3PTd9+nSLk+BO8vrrr+vUqVPcNw4AQAVAQQ4AgAcpLi5Wr169dPjwYTVs2FA+Pj5O89wPDQCA+7CbDgAAAFxn/PjxSk5OVv369VWlShWFhYU5/QNu18SJE3XlyhVJ0rZt21RYWGg4EQBUfKyQAwDgQUJCQrR69Wr16tXLdBR4GB8fH504cUKRkZFcfwZLtWjRQps3b1Z4eLhmzpypxMREBQYGmo4FWIKCHAAAD1K7dm1t3LhRcXFxpqPAw8TGxupPf/qTunXrps6dO+tvf/ubwsPDb/psx44dyzkdPElAQIC+/fZb1axZk5c/8HgU5AAAeJClS5fqs88+09KlS1lRgkt9/PHHGjdunM6ePSubzXbLa6lsNpuKiorKOR08Sdu2bRUcHKw//OEPmjFjhhITExUcHHzTZ6dNm1bO6QDXoiAHAIutWLFCAwYMkJ+fn9N4fn6+Vq9erWHDhhlKBk/UvHlzZWRkyOFwqE6dOqUOdeOaPZRVbm6uQkNDdejQoVuuWnJeAcri0KFDmj59ujIyMpSSkqKGDRuWXCH6Uzabjd9pqPAoyAHAYrdqtzt//rwiIiJYSYJL/dp1e1yzB1fYunWr2rdvf9MiCXAlu92u7OxsWtbhsSjIAcBidrtdZ86cUbVq1ZzG09LS1LlzZ+Xk5BhKBgC3r6ioSB9//LEOHDggSWrYsKEeeugheXl5GU4GABUHrzUBwCLNmzeXzWaTzWZT165dnVaSioqKdPToUT3wwAMGEwLA7Tly5Ih69eqlEydO6J577pEkvfrqq6pVq5Y+/fRT1a1b13BCeJKMjAy99dZbTi9/nnnmGX7O4BEoyAHAIn369JEk7d27V927d3c6kMbX11d16tTRww8/bCgdPEl4eLhsNttvepaODLjC+PHjFRMTo127dqly5cqSbmzDGTJkiMaPH69PP/3UcEJ4io0bNyohIUHNmjVT+/btJUk7duxQo0aNtH79ev3xj380nBAoG1rWAcBiy5cv14ABA+Tv7286CjzU8uXLf/Ozw4cPtzAJ7hRBQUH65z//qcaNGzuNp6WlqX379srNzTWUDJ6mefPm6t69u+bOnes0PmXKFG3atIlD3VDhUZADQDnJz8/X2bNnVVxc7DR+9913G0oEALencuXK+vvf/6527do5je/YsUO9e/emEwMu4+/vr3379ik2NtZp/PDhw2rSpIny8vIMJQNcg5Z1ALDYt99+q1GjRmnnzp1O4w6Hg/t64RKXLl36zc+GhoZamAR3igcffFCPPfaYFi9erNatW0uSdu/erXHjxikhIcFwOniSatWqae/evaUK8r1793LyOjwCBTkAWGzEiBHy9vbW3//+d1WvXv037/UFfqtKlSr96s8VL4DgSklJSRo+fLjatm1bctd9YWGhEhIStGDBAsPp4EnGjh2rxx57TJmZmSUdGTt27NBrr72miRMnGk4HlB0t6wBgsaCgIH311VeKi4szHQUeauvWrb/52U6dOlmYBHeaI0eOlJx83aBBA9WrV89wIngah8Oht956S/PmzdOpU6ckSVFRUZo8ebLGjx/PS25UeBTkAGCxVq1a6c0339Qf/vAH01EAAKiwLl++LEkKCQkxnARwHQpyALDYli1b9OKLL2rOnDlq3LhxSXvnj9jTC1e7cOGCFi9eXLJy2ahRI40aNUphYWGGkwEAgJ+iIAcAi9ntdkkq1VbHnl5YYc+ePerevbsCAgJKDtv68ssvde3aNW3atEktWrQwnBAAAPyIghwALPZr+3vZ0wtX6tChg+rVq6d3331X3t43zm4tLCzUmDFjlJmZqW3bthlOCAAAfkRBDgCABwkICFBqamqpQwT379+vli1b6urVq4aSAQCAn+PaMwAoB//4xz/0n//5n8rMzNT//M//qEaNGnr//fcVHR3NYW9wqdDQUB0/frxUQZ6VlcVBSHCpCxcu6F//+pfOnj2r4uJip7lhw4YZSgUAFQsFOQBY7KOPPtLQoUM1ePBgpaSk6Pr165Kkixcvas6cOdqwYYPhhPAkAwYM0OjRo/XGG2843dk7efJkDRw40HA6eIr169dr8ODBys3NVWhoqNMZGTabjYIcLrV582Zt3rz5pi9/lixZYigV4Bq0rAOAxZo3b64JEyZo2LBhCgkJUVpammJiYpSamqoePXooOzvbdER4kPz8fE2ePFmLFi1SYWGhJMnHx0dPPPGE5s6dKz8/P8MJ4Qnq16+vnj17as6cOQoMDDQdBx5sxowZmjlzplq2bKnq1auXOiD1b3/7m6FkgGtQkAOAxQIDA7V//37VqVPHqSDPzMxUw4YNlZeXZzoiPERRUZF27Nihxo0by8/PTxkZGZKkunXrUjTBpYKCgrRv3z7FxMSYjgIPV716db3++usaOnSo6SiAJeymAwCAp7vrrrt05MiRUuPbt2/nyyxcysvLS926ddOFCxcUGBioxo0bq3HjxhTjcLnu3btrz549pmPgDpCfn1+y/QbwROwhBwCLjR07Vs8884yWLFkim82mU6dOadeuXUpMTNRLL71kOh48THx8vDIzMxUdHW06CjxYr169NHnyZO3fv1+NGzeWj4+P03xCQoKhZPA0Y8aM0cqVK/l7CY9FyzoAWMzhcGjOnDl69dVXS66c8vPzU2JiombNmmU4HTzNZ599pqlTp2rWrFm69957FRQU5DQfGhpqKBk8id1+6yZLm82moqKickwDT/bMM89oxYoVatKkiZo0aVLq5c/8+fMNJQNcg4IcAMpJfn6+jhw5otzcXDVs2FDBwcGmI8ED/bRQ+unhRw6Hg0IJQIXTuXPnW87ZbDZt2bKlHNMArkdBDgCAB9m6desvznfq1KmckgAAgF9DQQ4AFsvLy9Pbb7+t5OTkm96hmpKSYigZANy+rVu36o033tCBAwckSQ0bNtTkyZPVoUMHw8ngqU6cOCFJqlmzpuEkgOtwqBsAWGz06NHatGmT+vfvr9atW5e6QxVwtQsXLuhf//rXTV8ADRs2zFAqeJL/+q//0siRI9WvXz+NHz9ekrRjxw517dpVy5Yt06BBgwwnhKcoLi7WK6+8onnz5ik3N1eSFBISokmTJun//b//94vnGQAVASvkAGCxsLAwbdiwQe3btzcdBXeA9evXa/DgwcrNzVVoaKjTCyCbzaacnByD6eApGjRooMcee0wTJkxwGp8/f77efffdklVzoKymTp2qxYsXa8aMGSV/R7dv366XX35ZY8eO1ezZsw0nBMqGghwALNawYUOtXr1aTZo0MR0Fd4D69eurZ8+emjNnDvePwzJ+fn765ptvVK9ePafxI0eOKD4+Xnl5eYaSwdNERUVp0aJFpa7S++STT/Tkk0/q5MmThpIBrkGPBwBYbN68eXr++ef13XffmY6CO8DJkyc1fvx4inFYqlatWtq8eXOp8S+++EK1atUykAieKicnR3FxcaXG4+Li6PiBR2APOQBYrGXLlsrLy1NMTIwCAwNL3aHKFwq4Uvfu3bVnzx7FxMSYjgIPNmnSJI0fP1579+5Vu3btJN3YQ75s2TItWLDAcDp4kqZNm2rhwoVKSkpyGl+4cKGaNm1qKBXgOhTkAGCxgQMH6uTJk5ozZ44iIyM51A2W6tWrlyZPnqz9+/ercePGpV4A/bztE7gdTzzxhO666y7NmzdPH374oaQb+8o/+OADPfTQQ4bTwZO8/vrr6tWrl7744gu1bdtWkrRr1y5lZWVpw4YNhtMBZccecgCwWGBgoHbt2sWbfJSLXzpx2GazqaioqBzTAEDZnTp1Sn/5y1908OBBSTde/jz55JOKiooynAwoO1bIAcBicXFxunbtmukYuEP8/JozAKjooqKiOE0dHosVcgCw2KZNmzRjxgzNnj37pi3EoaGhhpLBk/Ts2VOrVq1SWFiYJGnu3LkaN26cKlWqJEk6f/68OnTooP379xtMiYqscuXKOnz4sKpWrarw8PBf3H7D2Rgoi/T0dMXHx8tutys9Pf0Xn+UGE1R0FOQAYLEfW4h//uXV4XDQQgyX8fLy0unTpxURESHpxouevXv3lhzudubMGUVFRfHzhtu2fPlyPfroo/Lz89OyZct+sSAfPnx4OSaDp7Hb7crOzlZERITsdrtsNptuVrLwNxSegJZ1ALBYcnKy6Qi4A/z8yyrv2+FqPy2yR4wYYS4IPN7Ro0dVrVq1kv8DnoyCHAAsFh0drVq1at10hTwrK8tQKgC4fT/vyPjR+fPnFRERwaolyqR27dol///uu+/Url07eXs7ly2FhYXauXOn07NARXTro1gBAC4RHR2tc+fOlRrPyclRdHS0gUTwRDabrdRLH67Yg1Vu1YFx/fp1+fr6lnMaeLLOnTvf9EyCixcvqnPnzgYSAa7FCjkAWOzHveI/l5ubK39/fwOJ4IkcDodGjBghPz8/SVJeXp7GjRunoKAgSTcKJaCskpKSJN142fPee+8pODi4ZK6oqEjbtm1TXFycqXjwQLf6G3r+/PmS329ARUZBDgAWmThxoqQbX1xfeuklBQYGlswVFRVp9+7datasmaF08DQ/P0RryJAhpZ4ZNmxYecWBh3rzzTcl3SiSFi1aJC8vr5I5X19f1alTR4sWLTIVDx6kX79+km78Df3py0bpxt/Q9PR0tWvXzlQ8wGUoyAHAIqmpqZJufHHdt2+fUxunr6+vmjZtqsTERFPx4GGWLl1qOgLuAD8esNW5c2etXbtW4eHhhhPBU/14haPD4VBISIgCAgJK5nx9fdWmTRuNHTvWVDzAZbj2DAAsNnLkSC1YsID7xgEA+J1mzJihxMRE2tPhsSjIAQAA8LudOHFC69at0/Hjx5Wfn+80N3/+fEOpAKBioWUdACzQr18/LVu2TKGhoSX74G5l7dq15ZQKAFxj8+bNSkhIUExMjA4ePKj4+HgdO3ZMDodDLVq0MB0PHmbNmjX68MMPb/ryJyUlxVAqwDW49gwALBAWFlZyKmxYWNgv/gOAimbq1KlKTEzUvn375O/vr48++khZWVnq1KmTHnnkEdPx4EGSkpI0cuRIRUZGKjU1Va1bt1aVKlWUmZmpHj16mI4HlBkt6wAAAPhdQkJCtHfvXtWtW1fh4eHavn27GjVqpLS0ND300EM6duyY6YjwEHFxcZo+fboGDhyokJAQpaWlKSYmRtOmTVNOTo4WLlxoOiJQJqyQAwAA4HcJCgoqaR2uXr26MjIySua+//57U7HggY4fP15yvVlAQIAuX74sSRo6dKhWrVplMhrgEuwhBwCLRUdHl7Sv30xmZmY5pgGAsmvTpo22b9+uBg0aqGfPnpo0aZL27duntWvXqk2bNqbjwYPcddddysnJUe3atXX33Xfrn//8p5o2baqjR4+KRl94AgpyALDYs88+6/S5oKBAqamp+uyzzzR58mQzoQCgDObPn6/c3FxJN66lys3N1QcffKDY2FhOWIdLdenSRevWrVPz5s01cuRITZgwQWvWrNGePXt+9dBUoCJgDzkAGPKXv/xFe/bs0dKlS01HAYDfrKioSDt27FCTJk1UqVIl03Hg4YqLi1VcXCxv7xvriKtXr9bOnTsVGxurxx9/XL6+voYTAmVDQQ4AhmRmZqpZs2a6dOmS6SgA8Lv4+/vrwIEDio6ONh0FHqywsFBz5szRqFGjVLNmTdNxAEtwqBsAGLJmzRpVrlzZdAwA+N3i4+M5/wKW8/b21uuvv67CwkLTUQDLsIccACzWvHlzp0PdHA6HsrOzde7cOf31r381mAwAbs8rr7yixMREzZo1S/fee6+CgoKc5kNDQw0lg6fp2rWrtm7dqjp16piOAliClnUAsNiMGTOcPtvtdlWrVk333Xef4uLiDKUCgNtnt/9fk+XPXzjabDYVFRWZiAUPtGjRIs2YMUODBw++6cufhIQEQ8kA16AgBwALFRYWauXKlerevbsiIyNNxwEAl9i6desvznfq1KmcksDT/fTlz8/x8geegIIcACwWGBioAwcOqHbt2qajAAAAwI2whxwALNa6dWulpqZSkAPwGNu2bfvF+Y4dO5ZTEgCo2CjIAcBiTz75pCZNmqQTJ07cdP9bkyZNDCUDgNtz3333lRr76V5y2ojhKjNnzvzF+WnTppVTEsAatKwDgMVutv/NZrNx+BGACuvixYtOnwsKCpSamqqXXnpJs2fPVteuXQ0lg6dp3ry50+eCggIdPXpU3t7eqlu3rlJSUgwlA1yDFXIAsNjRo0dNRwAAlwoLCys19sc//lG+vr6aOHGivvrqKwOp4IlSU1NLjV26dEkjRoxQ3759DSQCXIsVcgAAALjEwYMH1bJlS+Xm5pqOAg+3b98+9e7dW8eOHTMdBSgTVsgBwGKvvvqqIiMjNWrUKKfxJUuW6Ny5c3r++ecNJQOA25Oenu702eFw6PTp05o7d66aNWtmJhTuKBcvXiy1dQKoiFghBwCL1alTRytXrlS7du2cxnfv3q1HH32UlnYAFY7dbi85C+On2rRpoyVLliguLs5QMniapKQkp88/vvx5//331alTJ61cudJQMsA1KMgBwGL+/v46cOCAoqOjncYzMzPVsGFD5eXlGUoGALfnu+++c/pst9tVrVo1+fv7G0oET/Xzv50//qx16dJFU6dOVUhIiKFkgGvQsg4AFqtVq5Z27NhR6kvFjh07FBUVZSgVANy+2rVrm46AOwRdZPB0FOQAYLGxY8fq2WefVUFBgbp06SJJ2rx5s5577jlNmjTJcDoA+H2Ki4u1bNkyrV27VseOHZPNZlN0dLT69++voUOHOt1HDriCw+HQ+fPnZbPZVKVKFdNxAJeiZR0ALOZwODRlyhQlJSUpPz9f0o029ueff17Tpk0znA4AfjuHw6HevXtrw4YNatq0qeLi4uRwOHTgwAHt27dPCQkJ+vjjj03HhIfIzs7Wc889p3Xr1uny5cuSpNDQUPXt27fkwFSgoqMgB4BykpubqwMHDiggIECxsbHy8/MzHQkAfpelS5fqmWee0SeffKLOnTs7zW3ZskV9+vTRwoULNWzYMEMJ4SkuXbqkZs2aKTc3V4MHDy55+bN//36tWrVK4eHhSklJUXBwsOmoQJlQkANAOTly5IgyMjLUsWNHBQQEyOFw0NoJoELp1q2bunTpoilTptx0fs6cOdq6das2btxYzsngaWbNmqUVK1Zo586dqlatmtPc2bNn1b59e40cOVIvvPCCoYSAa9hNBwAAT3f+/Hl17dpV9evXV8+ePXX69GlJ0ujRo9lDDqBCSU9P1wMPPHDL+R49eigtLa0cE8FTffrpp3rhhRdKFeOSFBERoalTp2r9+vUGkgGuRUEOABabMGGCfHx8dPz4cQUGBpaMDxgwQJ999pnBZADw++Tk5Pzivt3IyEj98MMP5ZgInurw4cNq167dLefbtWunQ4cOlWMiwBqcsg4AFtu0aZM2btyomjVrOo3HxsaWussXANxZUVGRvL1v/fXRy8tLhYWF5ZgInurSpUuqVKnSLecrVaqkS5culV8gwCIU5ABgsStXrjitjP8oJyeHg90AVCgOh0MjRoy45e+u69evl3MieCqHwyG7/dbNvDabTRyFBU9AQQ4AFuvQoYNWrFihWbNmSbrxJaK4uFivv/56qVOKAcCdDR8+/Fef4YR1uILD4VD9+vVvefgpxTg8BaesA4DFvv76a3Xt2lUtWrTQli1blJCQoG+++UY5OTnasWOH6tatazoiAABuZfny5b/pud/ykghwZxTkAFAOLl68qIULFyotLU25ublq0aKFnnrqKVWvXt10NAAAABhCQQ4AhuTl5WnhwoVKTEw0HQUAAAAGUJADgIXOnTun3bt3y9fXV127dpWXl5cKCgr017/+Va+++qoKCwv1/fffm44JAAAAAyjIAcAi27dv14MPPqhLly7JZrOpZcuWWrp0qfr06SNvb2+NHz9ew4cPV0BAgOmoAAAAMICCHAAsct999ykqKkovvPCCli9frnnz5ik2NlazZ89W//79TccDAACAYRTkAGCRKlWq6B//+IcaNmyoa9euKTg4WGvXrtVDDz1kOhoAAADcAPeQA4BFfvjhB1WtWlWSFBAQoMDAQMXHxxtOBQBAxVFUVKRly5Zp8+bNOnv2rIqLi53mt2zZYigZ4BoU5ABgof379ys7O1uS5HA4dOjQIV25csXpmSZNmpiIBgCA23vmmWe0bNky9erVS/Hx8bLZbKYjAS5FyzoAWMRut8tms+lmv2Z/HLfZbCoqKjKQDgAA91e1alWtWLFCPXv2NB0FsAQr5ABgkaNHj5qOAABAhebr66t69eqZjgFYhhVyAAAAAG5p3rx5yszM1MKFC2lXh0eiIAcAAADglvr27avk5GRVrlxZjRo1ko+Pj9P82rVrDSUDXIOWdQAAAABuqVKlSurbt6/pGIBlWCEHAAAAAMAAVsgBAAAAuLVz587p0KFDkqR77rlH1apVM5wIcA276QAA4OmmT5+u7777znQMAAAqnCtXrmjUqFGqXr26OnbsqI4dOyoqKkqjR4/W1atXTccDyoyCHAAs9sknn6hu3brq2rWrVq5cqevXr5uOBABAhTBx4kRt3bpV69ev14ULF3ThwgV98skn2rp1qyZNmmQ6HlBm7CEHgHKQmpqqpUuXatWqVSosLNSjjz6qUaNGqVWrVqajAQDgtqpWrao1a9bovvvucxpPTk7Wn/70J507d85MMMBFWCEHgHLQvHlzJSUl6dSpU1q8eLFOnDih9u3bq0mTJlqwYIEuXrxoOiIAAG7n6tWrioyMLDUeERFByzo8AgU5AJQjh8OhgoIC5efny+FwKDw8XAsXLlStWrX0wQcfmI4HAIBbadu2raZPn668vLySsWvXrmnGjBlq27atwWSAa9CyDgDl4KuvvippWffz89OwYcM0ZswY1atXT5L09ttv65VXXtGZM2cMJwUAwH18/fXX6t69u65fv66mTZtKktLS0uTv76+NGzeqUaNGhhMCZUNBDgAWa9y4sQ4ePKhu3bpp7Nix6t27t7y8vJye+f777xUREaHi4mJDKQEAcE9Xr17Vf//3f+vgwYOSpAYNGmjw4MEKCAgwnAwoOwpyALDYrFmzNGrUKNWoUcN0FAAAALgRCnIAAAAAbmPdunXq0aOHfHx8tG7dul98NiEhoZxSAdagIAcAC0ycOPE3Pzt//nwLkwAAULHY7XZlZ2crIiJCdvutz6C22WwqKioqx2SA63mbDgAAnig1NdXpc0pKigoLC3XPPfdIkg4fPiwvLy/de++9JuIBAOC2fnqeCmerwNNx7RkAWCA5ObnkX+/evdWpUyedOHFCKSkpSklJUVZWljp37qxevXqZjgoAgNtasWKFrl+/Xmo8Pz9fK1asMJAIcC1a1gHAYjVq1NCmTZtKXc3y9ddfq1u3bjp16pShZAAAuDcvLy+dPn1aERERTuPnz59XREQELeuo8FghBwCLXbp0SefOnSs1fu7cOV2+fNlAIgAAKgaHwyGbzVZq/MSJEwoLCzOQCHAt9pADgMX69u2rkSNHat68eWrdurUkaffu3Zo8ebL69etnOB0AAO6nefPmstlsstls6tq1q7y9/69sKSoq0tGjR/XAAw8YTAi4BgU5AFhs0aJFSkxM1KBBg1RQUCBJ8vb21ujRo/Xv//7vhtMBAOB++vTpI0nau3evunfvruDg4JI5X19f1alTRw8//LChdIDrsIccAMrJlStXlJGRIUmqW7eugoKCDCcCAMC9LV++XAMGDJC/v7/pKIAlKMgBAAAAuK0LFy5ozZo1ysjI0OTJk1W5cmWlpKQoMjJSNWrUMB0PKBMKcgCwWOfOnW96IM2PtmzZUo5pAACoONLT03X//fcrLCxMx44d06FDhxQTE6MXX3xRx48f5+ozVHicsg4AFmvWrJmaNm1a8q9hw4bKz89XSkqKGjdubDoeAABua8KECRoxYoS+/fZbp7b1nj17atu2bQaTAa7BoW4AYLE333zzpuMvv/yycnNzyzkNAAAVx549e/TOO++UGq9Ro4ays7MNJAJcixVyADBkyJAhWrJkiekYAAC4LT8/P126dKnU+OHDh1WtWjUDiQDXoiAHAEN27drFqbEAAPyChIQEzZw5s+TaUJvNpuPHj+v555/n2jN4BA51AwCL9evXz+mzw+HQ6dOntWfPHr300kuaPn26oWQAALi3ixcvqn///tqzZ48uX76sqKgoZWdnq23bttqwYQNXiKLCoyAHAIuNGDHC6ZR1u92uatWqqUuXLurWrZvBZAAAVAzbt29Xenq6cnNz1aJFC91///2mIwEuQUEOAAAAAIABnLIOABaLiYnRl19+qSpVqjiNX7hwQS1atFBmZqahZAAAuJ+kpKTf/Oz48eMtTAJYjxVyALCY3W5Xdna2IiIinMbPnDmju+++W9evXzeUDAAA9xMdHf2bnrPZbLzURoXHCjkAWGTdunUl/9+4caPCwsJKPhcVFWnz5s2qU6eOgWQAALivo0ePmo4AlBtWyAHAInb7jZslbTabfv6r1sfHR3Xq1NG8efP04IMPmogHAECF8uPf0p8elApUdNxDDgAWKS4uVnFxse6++26dPXu25HNxcbGuX7+uQ4cOUYwDAPArFi9erPj4ePn7+8vf31/x8fF67733TMcCXIKWdQCwGK13AADcnmnTpmn+/Pl6+umn1bZtW0nSrl27NGHCBB0/flwzZ840nBAoG1rWAcAiu3bt0vnz551WwVesWKHp06frypUr6tOnj95++235+fkZTAkAgPuqVq2akpKSNHDgQKfxVatW6emnn9b3339vKBngGrSsA4BFZs6cqW+++abk8759+zR69Gjdf//9mjJlitavX69XX33VYEIAANxbQUGBWrZsWWr83nvvVWFhoYFEgGtRkAOARfbu3auuXbuWfF69erX+7d/+Te+++64mTpyopKQkffjhhwYTAgDg3oYOHar/+I//KDX+zjvvaPDgwQYSAa7FHnIAsMgPP/ygyMjIks9bt25Vjx49Sj63atVKWVlZJqIBAFBhLF68WJs2bVKbNm0kSbt379bx48c1bNgwTZw4seS5+fPnm4oI3DYKcgCwSGRkpI4ePapatWopPz9fKSkpmjFjRsn85cuX5ePjYzAhAADu7euvv1aLFi0kSRkZGZKkqlWrqmrVqvr6669LnuMqNFRUFOQAYJGePXtqypQpeu211/Txxx8rMDBQHTp0KJlPT09X3bp1DSYEAMC9JScnm44AWIqCHAAsMmvWLPXr10+dOnVScHCwli9fLl9f35L5JUuWqFu3bgYTAgAAwCSuPQMAi128eFHBwcHy8vJyGs/JyVFwcLBTkQ4AAP5PXl6e3n77bSUnJ+vs2bMqLi52mk9JSTGUDHANVsgBwGJhYWE3Ha9cuXI5JwEAoGIZPXq0Nm3apP79+6t169bsFYfHYYUcAAAAgFsKCwvThg0b1L59e9NRAEtwDzkAAAAAt1SjRg2FhISYjgFYhoIcAAAAgFuaN2+enn/+eX333XemowCWYA85AAAAALfUsmVL5eXlKSYmRoGBgfLx8XGaz8nJMZQMcA0KcgAAAABuaeDAgTp58qTmzJmjyMhIDnWDx+FQNwAAAABuKTAwULt27VLTpk1NRwEswR5yAAAAAG4pLi5O165dMx0DsAwFOQAAAAC3NHfuXE2aNEn/+7//q/Pnz+vSpUtO/4CKjpZ1AAAAAG7Jbr+xfvjzveMOh0M2m01FRUUmYgEuw6FuAAAAANxScnKy6QiApVghBwAAAADAAFbIAQAAALitCxcuaPHixTpw4IAkqVGjRho1apTCwsIMJwPKjhVyAAAAAG5pz5496t69uwICAtS6dWtJ0pdffqlr165p06ZNatGiheGEQNlQkAMAAABwSx06dFC9evX07rvvytv7RnNvYWGhxowZo8zMTG3bts1wQqBsKMgBAAAAuKWAgAClpqYqLi7OaXz//v1q2bKlrl69aigZ4BrcQw4AAADALYWGhur48eOlxrOyshQSEmIgEeBaFOQAAAAA3NKAAQM0evRoffDBB8rKylJWVpZWr16tMWPGaODAgabjAWXGKesAAAAA3NIbb7whm82mYcOGqbCwUJLk4+OjJ554QnPnzjWcDig79pADAAAAcGtXr15VRkaGJKlu3boKDAw0nAhwDQpyAAAAAG6lqKhI33zzjWJjYxUQEOA0d+3aNX377beKj4+X3c4OXFRs/AQDAAAAcCvvv/++Ro0aJV9f31JzPj4+GjVqlFauXGkgGeBaFOQAAAAA3MrixYuVmJgoLy+vUnPe3t567rnn9M477xhIBrgWBTkAAAAAt3Lo0CG1adPmlvOtWrXSgQMHyjERYA0KcgAAAABu5cqVK7p06dIt5y9fvqyrV6+WYyLAGhTkAAAAANxKbGysdu7cecv57du3KzY2thwTAdagIAcAAADgVgYNGqQXX3xR6enppebS0tI0bdo0DRo0yEAywLW49gwAAACAWykoKFC3bt20fft23X///YqLi5MkHTx4UF988YXat2+vzz//XD4+PoaTAmVDQQ4AAADA7RQUFOjNN9/UypUr9e2338rhcKh+/foaNGiQnn322ZteiQZUNBTkAAAAAAAYwB5yAAAAAAAMoCAHAAAAAMAACnIAAAAAAAygIAcAAAAAwAAKcgAAAABuKTk52XQEwFKcsg4AAADALfn5+almzZoaOXKkhg8frlq1apmOBLgUK+QAAAAA3NLJkyf15z//WWvWrFFMTIy6d++uDz/8UPn5+aajAS7BCjkAAAAAt5eSkqKlS5dq1apVkqRBgwZp9OjRatq0qeFkwO2jIAcAAABQIZw6dUrvvPOO5s6dK29vb+Xl5alt27ZatGiRGjVqZDoe8LvRsg4AAADAbRUUFGjNmjXq2bOnateurY0bN2rhwoU6c+aMjhw5otq1a+uRRx4xHRO4LayQAwAAAHBLTz/9tFatWiWHw6GhQ4dqzJgxio+Pd3omOztbUVFRKi4uNpQSuH3epgMAAAAAwM3s379fb7/9tvr16yc/P7+bPlO1alWuR0OFRcs6AAAAALdTUFCg2rVrq02bNrcsxiXJ29tbnTp1KsdkgOtQkAMAAABwOz4+Pvroo49MxwAsRUEOAAAAwC316dNHH3/8sekYgGXYQw4AAADALcXGxmrmzJnasWOH7r33XgUFBTnNjx8/3lAywDU4ZR0AAACAW4qOjr7lnM1mU2ZmZjmmAVyPghwAAAAAAAPYQw4AAAAAgAHsIQcAAADgtk6cOKF169bp+PHjys/Pd5qbP3++oVSAa1CQAwAAAHBLmzdvVkJCgmJiYnTw4EHFx8fr2LFjcjgcatGihel4QJnRsg4AAADALU2dOlWJiYnat2+f/P399dFHHykrK0udOnXSI488YjoeUGYc6gYAAADALYWEhGjv3r2qW7euwsPDtX37djVq1EhpaWl66KGHdOzYMdMRgTJhhRwAAACAWwoKCirZN169enVlZGSUzH3//femYgEuwx5yAAAAAG6pTZs22r59uxo0aKCePXtq0qRJ2rdvn9auXas2bdqYjgeUGS3rAAAAANxSZmamcnNz1aRJE125ckWTJk3Szp07FRsbq/nz56t27dqmIwJlQkEOAAAAAIABtKwDAAAAcHu5ubkqLi52GgsNDTWUBnANDnUDAAAA4JaOHj2qXr16KSgoSGFhYQoPD1d4eLgqVaqk8PBw0/GAMmOFHAAAAIBbGjJkiBwOh5YsWaLIyEjZbDbTkQCXYg85AAAAALcUHBysr776Svfcc4/pKIAlaFkHAAAA4JZatWqlrKws0zEAy9CyDgAAAMAtvffeexo3bpxOnjyp+Ph4+fj4OM03adLEUDLANSjIAQAAALilc+fOKSMjQyNHjiwZs9lscjgcstlsKioqMpgOKDv2kAMAAABwSw0bNlSDBg303HPP3fRQt9q1axtKBrgGBTkAAAAAtxQUFKS0tDTVq1fPdBTAEhzqBgAAAMAtdenSRWlpaaZjAJZhDzkAAAAAt9S7d29NmDBB+/btU+PGjUsd6paQkGAoGeAatKwDAAAAcEt2+60bejnUDZ6AghwAAAAAAAPYQw4AAAAAgAHsIQcAAADgNpKSkvTYY4/J399fSUlJv/js+PHjyykVYA1a1gEAAAC4jejoaO3Zs0dVqlRRdHT0LZ+z2WzKzMwsx2SA61GQAwAAAABgAHvIAQAAALidgoIC1a1bVwcOHDAdBbAMBTkAAAAAt+Pj46O8vDzTMQBLUZADAAAAcEtPPfWUXnvtNRUWFpqOAliCPeQAAAAA3FLfvn21efNmBQcHq3HjxgoKCnKaX7t2raFkgGtw7RkAAAAAt1SpUiU9/PDDpmMAlmGFHAAAAAAAA9hDDgAAAMCtFBcX67XXXlP79u3VqlUrTZkyRdeuXTMdC3A5CnIAAAAAbmX27Nl64YUXFBwcrBo1amjBggV66qmnTMcCXI6WdQAAAABuJTY2VomJiXr88cclSV988YV69eqla9euyW5nTRGeg4IcAAAAgFvx8/PTkSNHVKtWrZIxf39/HTlyRDVr1jSYDHAtXi8BAAAAcCuFhYXy9/d3GvPx8VFBQYGhRIA1uPYMAAAAgFtxOBwaMWKE/Pz8Ssby8vI0btw4p7vIuYccFR0FOQAAAAC3Mnz48FJjQ4YMMZAEsBZ7yAEAAAAAMIA95AAAAAAAGEBBDgAAAACAARTkAAAAAAAYQEEOAAAAAIABFOQAAAAAABhAQQ4AAAAAgAEU5AAAAAAAGEBBDgAAAACAAf8fyN1gxuC+v5kAAAAASUVORK5CYII=\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Display unique categories for each feature in the dataset\n",
        "for column in data1.columns:\n",
        "    unique_values = data1[column].unique()\n",
        "    num_unique = len(unique_values)\n",
        "\n",
        "    if num_unique < 20:  # Display categories if they are fewer than 20 for better readability\n",
        "        print(f\"Column: {column}\")\n",
        "        print(f\"Unique Categories ({num_unique}): {unique_values}\")\n",
        "        print(\"-\" * 40)\n",
        "    else:\n",
        "        print(f\"Column: {column} has {num_unique} unique categories (not displayed).\")\n",
        "        print(\"-\" * 40)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JLAl7vgcVteH",
        "outputId": "02d5a7eb-54dc-478c-8fb9-7acdb01d8941"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Column: Study Title has 20636 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Study Status\n",
            "Unique Categories (8): ['COMPLETED' 'UNKNOWN' 'TERMINATED' 'ACTIVE_NOT_RECRUITING' 'RECRUITING'\n",
            " 'SUSPENDED' 'ENROLLING_BY_INVITATION' 'NOT_YET_RECRUITING']\n",
            "----------------------------------------\n",
            "Column: Brief Summary has 20528 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Study Results\n",
            "Unique Categories (2): ['NO' 'YES']\n",
            "----------------------------------------\n",
            "Column: Conditions has 7860 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Interventions has 18217 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Primary Outcome Measures has 20437 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Secondary Outcome Measures has 17647 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Sex\n",
            "Unique Categories (4): ['ALL' 'FEMALE' 'MALE' nan]\n",
            "----------------------------------------\n",
            "Column: Age\n",
            "Unique Categories (6): ['ADULT, OLDER_ADULT' 'CHILD, ADULT' 'CHILD' 'CHILD, ADULT, OLDER_ADULT'\n",
            " 'ADULT' 'OLDER_ADULT']\n",
            "----------------------------------------\n",
            "Column: Phases\n",
            "Unique Categories (5): ['PHASE1' 'PHASE1|PHASE2' 'PHASE2|PHASE3' 'PHASE2' 'PHASE3']\n",
            "----------------------------------------\n",
            "Column: Enrollment has 1341 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Study Design has 340 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Completion Date has 3028 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Study Recruitment Rate has 17106 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Duration of Trial has 2525 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Primary Completion Duration of Trial has 2278 unique categories (not displayed).\n",
            "----------------------------------------\n",
            "Column: Cluster has 52 unique categories (not displayed).\n",
            "----------------------------------------\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1.drop(['Cluster'],axis='columns',inplace=True)\n",
        "\n",
        "# Split the 'System Design' column into multiple components using | as a separator\n",
        "split_columns = data1['Study Design'].str.split('|', expand=True)\n",
        "\n",
        "# Extract the keys (e.g., \"Allocation\", \"Intervention Model\") and their values\n",
        "for col in split_columns.columns:\n",
        "    key_value = split_columns[col].str.split(':', expand=True)\n",
        "    key = key_value[0].str.strip()  # Extract the key and strip any whitespace\n",
        "    value = key_value[1].str.strip()  # Extract the value and strip any whitespace\n",
        "    data1[key[0]] = value\n",
        "\n",
        "# Drop the original 'System Design' column after splitting\n",
        "data1 = data1.drop(columns=['Study Design'])\n"
      ],
      "metadata": {
        "id": "AYaXaPFfWCVv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data1.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2eIiThIvWEjc",
        "outputId": "ed4381ea-1e5a-4b67-dba6-8979c0f5f391"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Study Title', 'Study Status', 'Brief Summary', 'Study Results',\n",
              "       'Conditions', 'Interventions', 'Primary Outcome Measures',\n",
              "       'Secondary Outcome Measures', 'Sex', 'Age', 'Phases', 'Enrollment',\n",
              "       'Completion Date', 'Study Recruitment Rate', 'Duration of Trial',\n",
              "       'Primary Completion Duration of Trial', 'Allocation',\n",
              "       'Intervention Model', 'Masking', 'Primary Purpose'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "ltB4Ij8CWGQu",
        "outputId": "b8619fb3-671d-4cea-9a17-81a0528358eb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                             Study Title Study Status  \\\n",
              "0      QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
              "1      Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
              "2      A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
              "3      A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
              "4      Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
              "...                                                  ...          ...   \n",
              "20671  A Single and Multiple Ascending-dose Trial of ...    COMPLETED   \n",
              "20672  A Study of Escalating Doses of DCDS0780A in Pa...    COMPLETED   \n",
              "20673  Clinical Trial of YYC301 for Treatment of Oste...    COMPLETED   \n",
              "20674   LGX818 for Patients With BRAFV600 Mutated Tumors   TERMINATED   \n",
              "20675  A Study to Evaluate ABY-035 in Subjects With M...    COMPLETED   \n",
              "\n",
              "                                           Brief Summary Study Results  \\\n",
              "0      NK cells from patients with malignant diseases...            NO   \n",
              "1      The purpose of this study is to determine safe...           YES   \n",
              "2      This is a multi-site study with plerixafor in ...            NO   \n",
              "3      This study has the objective to demonstrate th...            NO   \n",
              "4      The purpose of this two part study is to test ...           YES   \n",
              "...                                                  ...           ...   \n",
              "20671  This is a first-in-human study in adult health...            NO   \n",
              "20672  This open-label, multicenter, Phase 1/1b study...            NO   \n",
              "20673  A Multi-center, Double-blinded, Randomized, Ac...            NO   \n",
              "20674  The purpose of this signal seeking study is to...           YES   \n",
              "20675  This randomized, double-blinded dose-finding s...            NO   \n",
              "\n",
              "                                              Conditions  \\\n",
              "0                                 Acute Myeloid Leukemia   \n",
              "1                                    Diabetic Foot Ulcer   \n",
              "2      Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
              "3                            Poisoning by Scorpion Sting   \n",
              "4                                         Malaria, Vivax   \n",
              "...                                                  ...   \n",
              "20671                                 Healthy Volunteers   \n",
              "20672                             Non-Hodgkin's Lymphoma   \n",
              "20673                               Osteoarthritis, Knee   \n",
              "20674               Solid Tumor|Hematologic Malignancies   \n",
              "20675                                   Plaque Psoriasis   \n",
              "\n",
              "                                           Interventions  \\\n",
              "0                      BIOLOGICAL: Neukoplastâ„¢ (NK-92)   \n",
              "1      DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...   \n",
              "2      DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...   \n",
              "3      BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...   \n",
              "4      DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...   \n",
              "...                                                  ...   \n",
              "20671                     DRUG: LEO 153339|DRUG: Placebo   \n",
              "20672  DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...   \n",
              "20673  DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...   \n",
              "20674                                       DRUG: LGX818   \n",
              "20675            BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo   \n",
              "\n",
              "                                Primary Outcome Measures  \\\n",
              "0      Determine the safety / maximum tolerated dose ...   \n",
              "1      Safety Outcome, Number of participant with adv...   \n",
              "2      Proportion of patients achieving at least a do...   \n",
              "3      To demonstrate the effectiveness of Alacramyn ...   \n",
              "4      Number of Participants With Recurrence-free Ef...   \n",
              "...                                                  ...   \n",
              "20671  Number of treatment-emergent adverse events pe...   \n",
              "20672  Number of Participants with Adverse Events, Ba...   \n",
              "20673  100mm Pain VAS, Subjects who have severe pain ...   \n",
              "20674  Clinical Benefit Rate (CBR) for Solid Tumors a...   \n",
              "20675  Proportion of subjects with a â‰¥90% improveme...   \n",
              "\n",
              "                              Secondary Outcome Measures  Sex  \\\n",
              "0      Evaluate the therapeutic efficacy of Neukoplas...  ALL   \n",
              "1      Efficacy Outcome, To evaluate the percent chan...  ALL   \n",
              "2      Number of days of apheresis required to reach ...  ALL   \n",
              "3      Effectiveness of Alacramyn NAMO in the treatme...  ALL   \n",
              "4      Number of Participants With Recurrence-free Ef...  ALL   \n",
              "...                                                  ...  ...   \n",
              "20671  Plasma concentration of LEO 153339 and LEO 159...  ALL   \n",
              "20672  Area Under the Serum Concentration-Time Curve ...  ALL   \n",
              "20673                                                NaN  ALL   \n",
              "20674  Overall Response Rate (ORR) for Solid Tumors a...  ALL   \n",
              "20675  Number of treatment emergent Adverse Events, A...  ALL   \n",
              "\n",
              "                             Age         Phases  Enrollment Completion Date  \\\n",
              "0             ADULT, OLDER_ADULT         PHASE1           7      2015-06-02   \n",
              "1             ADULT, OLDER_ADULT  PHASE1|PHASE2          44      2015-10-17   \n",
              "2                   CHILD, ADULT  PHASE1|PHASE2          46      2017-05-09   \n",
              "3                          CHILD  PHASE2|PHASE3          56      2018-11-15   \n",
              "4      CHILD, ADULT, OLDER_ADULT         PHASE2         851      2016-11-18   \n",
              "...                          ...            ...         ...             ...   \n",
              "20671         ADULT, OLDER_ADULT         PHASE1         108      2022-07-18   \n",
              "20672         ADULT, OLDER_ADULT         PHASE1          66      2019-07-12   \n",
              "20673         ADULT, OLDER_ADULT         PHASE2         261      2020-09-07   \n",
              "20674         ADULT, OLDER_ADULT         PHASE2          12      2015-10-13   \n",
              "20675         ADULT, OLDER_ADULT         PHASE2         108      2021-12-03   \n",
              "\n",
              "       Study Recruitment Rate  Duration of Trial  \\\n",
              "0                    0.551598                386   \n",
              "1                    0.443157                604   \n",
              "2                    0.044558               1163   \n",
              "3                    7.279202                117   \n",
              "4                    1.969008                939   \n",
              "...                       ...                ...   \n",
              "20671                7.693208                427   \n",
              "20672                0.199434               1438   \n",
              "20673                1.074256                739   \n",
              "20674                0.044077                637   \n",
              "20675                0.133504               1367   \n",
              "\n",
              "       Primary Completion Duration of Trial      Allocation  \\\n",
              "0                                     386.0              NA   \n",
              "1                                     492.0      RANDOMIZED   \n",
              "2                                    1163.0      RANDOMIZED   \n",
              "3                                     103.0      RANDOMIZED   \n",
              "4                                     939.0      RANDOMIZED   \n",
              "...                                     ...             ...   \n",
              "20671                                 427.0      RANDOMIZED   \n",
              "20672                                1438.0  NON_RANDOMIZED   \n",
              "20673                                 621.0      RANDOMIZED   \n",
              "20674                                 595.0              NA   \n",
              "20675                                 385.0      RANDOMIZED   \n",
              "\n",
              "      Intervention Model                                            Masking  \\\n",
              "0           SINGLE_GROUP                                               NONE   \n",
              "1               PARALLEL  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)   \n",
              "2               PARALLEL                                               NONE   \n",
              "3               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "4               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "...                  ...                                                ...   \n",
              "20671           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20672           PARALLEL                                               NONE   \n",
              "20673           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20674       SINGLE_GROUP                                                      \n",
              "20675           PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "\n",
              "      Primary Purpose  \n",
              "0           TREATMENT  \n",
              "1           TREATMENT  \n",
              "2           TREATMENT  \n",
              "3           TREATMENT  \n",
              "4           TREATMENT  \n",
              "...               ...  \n",
              "20671       TREATMENT  \n",
              "20672       TREATMENT  \n",
              "20673       TREATMENT  \n",
              "20674       TREATMENT  \n",
              "20675       TREATMENT  \n",
              "\n",
              "[20676 rows x 20 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-9766335e-2346-4f75-b74b-65ef2ee29f4c\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Primary Outcome Measures</th>\n",
              "      <th>Secondary Outcome Measures</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Completion Date</th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "      <th>Duration of Trial</th>\n",
              "      <th>Primary Completion Duration of Trial</th>\n",
              "      <th>Allocation</th>\n",
              "      <th>Intervention Model</th>\n",
              "      <th>Masking</th>\n",
              "      <th>Primary Purpose</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>NK cells from patients with malignant diseases...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Acute Myeloid Leukemia</td>\n",
              "      <td>BIOLOGICAL: Neukoplastâ„¢ (NK-92)</td>\n",
              "      <td>Determine the safety / maximum tolerated dose ...</td>\n",
              "      <td>Evaluate the therapeutic efficacy of Neukoplas...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>7</td>\n",
              "      <td>2015-06-02</td>\n",
              "      <td>0.551598</td>\n",
              "      <td>386</td>\n",
              "      <td>386.0</td>\n",
              "      <td>NA</td>\n",
              "      <td>SINGLE_GROUP</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Clinical Investigation of GalnobaxÂ® for the T...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this study is to determine safe...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Diabetic Foot Ulcer</td>\n",
              "      <td>DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...</td>\n",
              "      <td>Safety Outcome, Number of participant with adv...</td>\n",
              "      <td>Efficacy Outcome, To evaluate the percent chan...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>44</td>\n",
              "      <td>2015-10-17</td>\n",
              "      <td>0.443157</td>\n",
              "      <td>604</td>\n",
              "      <td>492.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>A Combined Study in Pediatric Cancer Patients ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a multi-site study with plerixafor in ...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...</td>\n",
              "      <td>DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...</td>\n",
              "      <td>Proportion of patients achieving at least a do...</td>\n",
              "      <td>Number of days of apheresis required to reach ...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>46</td>\n",
              "      <td>2017-05-09</td>\n",
              "      <td>0.044558</td>\n",
              "      <td>1163</td>\n",
              "      <td>1163.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>A Trial of Equine F (ab')2 Antivenom for Treat...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This study has the objective to demonstrate th...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Poisoning by Scorpion Sting</td>\n",
              "      <td>BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...</td>\n",
              "      <td>To demonstrate the effectiveness of Alacramyn ...</td>\n",
              "      <td>Effectiveness of Alacramyn NAMO in the treatme...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD</td>\n",
              "      <td>PHASE2|PHASE3</td>\n",
              "      <td>56</td>\n",
              "      <td>2018-11-15</td>\n",
              "      <td>7.279202</td>\n",
              "      <td>117</td>\n",
              "      <td>103.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this two part study is to test ...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Malaria, Vivax</td>\n",
              "      <td>DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>Number of Participants With Recurrence-free Ef...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>851</td>\n",
              "      <td>2016-11-18</td>\n",
              "      <td>1.969008</td>\n",
              "      <td>939</td>\n",
              "      <td>939.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>A Single and Multiple Ascending-dose Trial of ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a first-in-human study in adult health...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Healthy Volunteers</td>\n",
              "      <td>DRUG: LEO 153339|DRUG: Placebo</td>\n",
              "      <td>Number of treatment-emergent adverse events pe...</td>\n",
              "      <td>Plasma concentration of LEO 153339 and LEO 159...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>108</td>\n",
              "      <td>2022-07-18</td>\n",
              "      <td>7.693208</td>\n",
              "      <td>427</td>\n",
              "      <td>427.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>A Study of Escalating Doses of DCDS0780A in Pa...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This open-label, multicenter, Phase 1/1b study...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Non-Hodgkin's Lymphoma</td>\n",
              "      <td>DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...</td>\n",
              "      <td>Number of Participants with Adverse Events, Ba...</td>\n",
              "      <td>Area Under the Serum Concentration-Time Curve ...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>66</td>\n",
              "      <td>2019-07-12</td>\n",
              "      <td>0.199434</td>\n",
              "      <td>1438</td>\n",
              "      <td>1438.0</td>\n",
              "      <td>NON_RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>Clinical Trial of YYC301 for Treatment of Oste...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>A Multi-center, Double-blinded, Randomized, Ac...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Osteoarthritis, Knee</td>\n",
              "      <td>DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...</td>\n",
              "      <td>100mm Pain VAS, Subjects who have severe pain ...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>261</td>\n",
              "      <td>2020-09-07</td>\n",
              "      <td>1.074256</td>\n",
              "      <td>739</td>\n",
              "      <td>621.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20674</th>\n",
              "      <td>LGX818 for Patients With BRAFV600 Mutated Tumors</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>The purpose of this signal seeking study is to...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Solid Tumor|Hematologic Malignancies</td>\n",
              "      <td>DRUG: LGX818</td>\n",
              "      <td>Clinical Benefit Rate (CBR) for Solid Tumors a...</td>\n",
              "      <td>Overall Response Rate (ORR) for Solid Tumors a...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>12</td>\n",
              "      <td>2015-10-13</td>\n",
              "      <td>0.044077</td>\n",
              "      <td>637</td>\n",
              "      <td>595.0</td>\n",
              "      <td>NA</td>\n",
              "      <td>SINGLE_GROUP</td>\n",
              "      <td></td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>A Study to Evaluate ABY-035 in Subjects With M...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This randomized, double-blinded dose-finding s...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Plaque Psoriasis</td>\n",
              "      <td>BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo</td>\n",
              "      <td>Proportion of subjects with a â‰¥90% improveme...</td>\n",
              "      <td>Number of treatment emergent Adverse Events, A...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>108</td>\n",
              "      <td>2021-12-03</td>\n",
              "      <td>0.133504</td>\n",
              "      <td>1367</td>\n",
              "      <td>385.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20676 rows × 20 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-9766335e-2346-4f75-b74b-65ef2ee29f4c')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-9766335e-2346-4f75-b74b-65ef2ee29f4c button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-9766335e-2346-4f75-b74b-65ef2ee29f4c');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-b853fa1a-8fc6-4e09-bfe2-44eab433ea3a\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b853fa1a-8fc6-4e09-bfe2-44eab433ea3a')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-b853fa1a-8fc6-4e09-bfe2-44eab433ea3a button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_63ab4845-50ad-428e-b720-3d0be197473f\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('data1')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_63ab4845-50ad-428e-b720-3d0be197473f button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('data1');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "data1",
              "summary": "{\n  \"name\": \"data1\",\n  \"rows\": 20676,\n  \"fields\": [\n    {\n      \"column\": \"Study Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20636,\n        \"samples\": [\n          \"CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.\",\n          \"Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy\",\n          \"IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"UNKNOWN\",\n          \"SUSPENDED\",\n          \"COMPLETED\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20528,\n        \"samples\": [\n          \"The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly (over 60 years of age).\",\n          \"The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).\",\n          \"This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-\\u00ce\\u00b4,\\u00ce\\u00b3, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"YES\",\n          \"NO\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 7860,\n        \"samples\": [\n          \"Infection, Bacterial\",\n          \"Connective Tissue Disease-Associated Pulmonary Arterial Hypertension\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 18217,\n        \"samples\": [\n          \"DRUG: siremadlin|DRUG: venetoclax|DRUG: azacitidine\",\n          \"DIETARY_SUPPLEMENT: Probiotic\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20437,\n        \"samples\": [\n          \"Cmax Day 1, Maximum concentration, Day 1 for the first dose (8:00 AM dose)|AUC (AUCDay 3, 0-24hr), Area under the concentration-time curve, Day 3 from 8:00 AM to 8:00 AM from 0 to 24 hr\",\n          \"Phase 1b: Number of Participants With Adverse Events as Per Severity, An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event., Day 1 up to 45.2 months|Phase 2: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\\\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\\\>=90% or to less than (\\\\<) 200 milligrams (mg) per 24 hours. If the serum and urine M-protein were not measurable, a decrease of \\\\>=50% in the difference between involved and uninvolved free light chain (FLC) levels was required in place of the M-protein criteria. If serum and urine M-protein were not measurable, and serum free light assay was also not measurable, \\\\>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow PC percentage was \\\\>=30%. In addition to the above criteria, if present at baseline, a \\\\>=50% reduction in the size of soft tissue plasmacytomas was also required., Day 1 up to 45.2 months\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Secondary Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 17646,\n        \"samples\": [\n          \"AUC0-2hr for L-dopa, Area under the Plasma Concentration-time Curve for L-dopa from Time = 0 to Time = 2 hours post dose. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 min|Cmax of L-dopa, Maximum Observed Plasma Concentration of L-dopa from Time = 0 to Time = 2 hours post dose. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Tmax of L-dopa, Time to Reach the Maximum Plasma Concentration (Cmax) of L-dopa, For L-dopa 35 mg, 70 mg, 140 mg plasma samples were taken at pre-dose, 30, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Mean Change From Baseline in MDS-UPDRS Score Over 2 Hours for C1, C2, C3 and Change From Baseline at 30, 60, 90, 120 Minutes for C4, in MDS-UPDRS Part III Score, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Maximum score is 132, minimum is zero. High score means worse outcome. For the L-dopa 35 mg, L-dopa 70 mg, L-dopa 140 mg treatment groups, assessment occurred at pre-dose, 15, 30, 45, 60, 90 and 120 minutes post-dose. For the L-dopa 70 mg/carbidopa 7 mg treatment arm, assessment occurred at pre-dose, 30, 60, 90 and 120 minutes post-dose., For L-dopa 35 mg, 70 mg, 140 mg, assessment occurred at pre-dose, 15, 30, 45, 60, 90 and 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, assessment occurred at pre-dose, 30, 60, 90 and 120 minutes post-dose.|Time to Response (Defined as Improvement of 30% in MDS-UPDRS Part III Score From Baseline), MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., 2 hours|Cumulative Number of Responders (Defined as Improvement of 30% in MDS-UPDRS Part III Score From Baseline), MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., From time = 0 to 2 hours post-dose|Area Under the Curve (AUC) of Change From Baseline in MDS-UPDRS Part III Scores, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe., For L-dopa 35 mg, 70 mg, 140 mg, assessments were made at pre-dose, 15, 30, 45, 60, 90, 120 minutes post-dose. For L-dopa 70 mg/carbidopa 7 mg, assessments were made at pre-dose, 50, 60, 90, 120 minutes post-dose.|Mean Maximum Change From Baseline in MDS-UPDRS Part III Score, MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. The total of the subscales has a maximum value of 132 and a minimum value of zero. Lower scores indicate better motor function. A negative change from baseline indicates improved motor function., From time = 0 to 2 hours post-dose|Subjective Time to \\\"ON\\\" as Evaluated by the Investigator, Investigators will evaluate subjects' fluctuations in motor functions at 15, 30, 45, 60, 90, 120, and 240 minutes post-dose to determine if they are \\\"ON\\\"., 4 hours|Assessment of Time to \\\"ON\\\" as Evaluated by Subject Self-assessment, Subjects were asked to provide self-assessments at 15, 30, 45, 60, 90, 120, and 240 minutes post-dose as to whether they considered themselves to be \\\"ON\\\"., 4 hours|AUC0-2h for Carbidopa, Area under the concentration time curve for carbidopa, Plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose and AUC calculated from these from time 0 to 120 minutes.|Cmax of Carbidopa, Maximum concentration of carbidopa, For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Tmax of Carbidopa, Time to reach the maximum concentration of carbidopa, For L-dopa 70 mg/carbidopa 7 mg, plasma samples were taken at pre-dose, 5, 10, 15, 30, 45, 60, 90 and 120 minutes post-dose.|Duration of Response, Where Response is Defined as an Improvement of 30% in MDS-UPDRS Part III Score From Baseline., MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society with high internal consistency. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III, motor examination (18 items). The subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Maximum score is 132, minimum is zero. High score means worse outcome., 2 hours\",\n          \"Number of subject with adverse events, The toxic effects of the drug would be assessed from adverse events, vital signs and by clinically significant changes in the laboratory evaluations., up to 4 weeks after last dose|Objective response, Evaluation of Response: Clinical responses will be presented patient wise for different dose levels., up to approximately 24 months|AUC0-\\u00e2\\u02c6\\u017e, area under the concentration versus time curve (AUC) from time zero to infinity, up to approximately 4 weeks|AUC0-t, AUC from time zero to the time of the last quantifiable concentration time zero to the time of the last quantifiable concentration, up to approximately 4 weeks|Cmax, maximum observed plasma concentration, up to approximately 4 weeks|tmax, time of the maximum observed plasma concentration, up to approximately 4 weeks|t\\u00c2\\u00bd, apparent terminal elimination half-life, up to approximately 4 weeks|Vz/F, apparent volume of distribution, up to approximately 4 weeks\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"ALL\",\n          \"FEMALE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"ADULT, OLDER_ADULT\",\n          \"CHILD, ADULT\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"PHASE1|PHASE2\",\n          \"PHASE3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3534,\n        \"min\": 1,\n        \"max\": 477102,\n        \"num_unique_values\": 1341,\n        \"samples\": [\n          230,\n          273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Completion Date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2014-02-08 00:00:00\",\n        \"max\": \"2024-06-30 00:00:00\",\n        \"num_unique_values\": 3027,\n        \"samples\": [\n          \"2021-05-12 00:00:00\",\n          \"2020-06-25 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Recruitment Rate\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 47.61087701710453,\n        \"min\": 0.0011275127619133577,\n        \"max\": 4816.602870813397,\n        \"num_unique_values\": 17106,\n        \"samples\": [\n          0.9896963123644252,\n          21.433106967464703\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 669,\n        \"min\": -41927,\n        \"max\": 3787,\n        \"num_unique_values\": 2525,\n        \"samples\": [\n          903,\n          106\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Completion Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 527.2636176228543,\n        \"min\": 0.0,\n        \"max\": 3662.0,\n        \"num_unique_values\": 2277,\n        \"samples\": [\n          1207.0,\n          1124.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Allocation\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"RANDOMIZED\",\n          \"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention Model\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"SINGLE_GROUP\",\n          \"PARALLEL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Masking\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"NONE\",\n          \"SINGLE (OUTCOMES_ASSESSOR)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Purpose\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"SCREENING\",\n          \"PREVENTION\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Count NaN or empty values in each column\n",
        "nan_count = data1.isna().sum()  # Counts the NaN values in each column\n",
        "empty_count = (data1 == '').sum()  # Counts the empty string values in each column\n",
        "\n",
        "# Combine the NaN and empty count\n",
        "total_missing = nan_count + empty_count\n",
        "\n",
        "# Display the count of missing or empty values for each column\n",
        "print(total_missing)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PqAOlQDYWHzn",
        "outputId": "69aa9a51-ae44-4351-9a3b-ce622c042329"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Study Title                                0\n",
            "Study Status                               0\n",
            "Brief Summary                              0\n",
            "Study Results                              0\n",
            "Conditions                                 0\n",
            "Interventions                              0\n",
            "Primary Outcome Measures                   0\n",
            "Secondary Outcome Measures              2919\n",
            "Sex                                        6\n",
            "Age                                        0\n",
            "Phases                                     0\n",
            "Enrollment                                 0\n",
            "Completion Date                            1\n",
            "Study Recruitment Rate                     0\n",
            "Duration of Trial                          0\n",
            "Primary Completion Duration of Trial      46\n",
            "Allocation                                61\n",
            "Intervention Model                        29\n",
            "Masking                                    7\n",
            "Primary Purpose                            0\n",
            "dtype: int64\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Merge 'Primary Outcome Measures' and 'Secondary Outcome Measures' into a new column\n",
        "data1['Outcome Measures'] = 'Primary Outcomes: '+ data1['Primary Outcome Measures'].fillna('') + ' | ' +' Secondary Outcomes: '+ data1['Secondary Outcome Measures'].fillna('')\n",
        "\n",
        "# Drop the original columns if they are no longer needed\n",
        "data1 = data1.drop(columns=['Primary Outcome Measures', 'Secondary Outcome Measures'])\n",
        "\n",
        "# Display the updated DataFrame\n",
        "print(data1.head())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JaUwY7FJWKn-",
        "outputId": "7e8874cd-e91d-4b28-f90b-dc95a6256b7c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                         Study Title Study Status  \\\n",
            "0  QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
            "1  Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
            "2  A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
            "3  A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
            "4  Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
            "\n",
            "                                       Brief Summary Study Results  \\\n",
            "0  NK cells from patients with malignant diseases...            NO   \n",
            "1  The purpose of this study is to determine safe...           YES   \n",
            "2  This is a multi-site study with plerixafor in ...            NO   \n",
            "3  This study has the objective to demonstrate th...            NO   \n",
            "4  The purpose of this two part study is to test ...           YES   \n",
            "\n",
            "                                          Conditions  \\\n",
            "0                             Acute Myeloid Leukemia   \n",
            "1                                Diabetic Foot Ulcer   \n",
            "2  Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
            "3                        Poisoning by Scorpion Sting   \n",
            "4                                     Malaria, Vivax   \n",
            "\n",
            "                                       Interventions  Sex  \\\n",
            "0                  BIOLOGICAL: Neukoplastâ„¢ (NK-92)  ALL   \n",
            "1  DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...  ALL   \n",
            "2  DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...  ALL   \n",
            "3  BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...  ALL   \n",
            "4  DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...  ALL   \n",
            "\n",
            "                         Age         Phases  Enrollment Completion Date  \\\n",
            "0         ADULT, OLDER_ADULT         PHASE1           7      2015-06-02   \n",
            "1         ADULT, OLDER_ADULT  PHASE1|PHASE2          44      2015-10-17   \n",
            "2               CHILD, ADULT  PHASE1|PHASE2          46      2017-05-09   \n",
            "3                      CHILD  PHASE2|PHASE3          56      2018-11-15   \n",
            "4  CHILD, ADULT, OLDER_ADULT         PHASE2         851      2016-11-18   \n",
            "\n",
            "   Study Recruitment Rate  Duration of Trial  \\\n",
            "0                0.551598                386   \n",
            "1                0.443157                604   \n",
            "2                0.044558               1163   \n",
            "3                7.279202                117   \n",
            "4                1.969008                939   \n",
            "\n",
            "   Primary Completion Duration of Trial  Allocation Intervention Model  \\\n",
            "0                                 386.0          NA       SINGLE_GROUP   \n",
            "1                                 492.0  RANDOMIZED           PARALLEL   \n",
            "2                                1163.0  RANDOMIZED           PARALLEL   \n",
            "3                                 103.0  RANDOMIZED           PARALLEL   \n",
            "4                                 939.0  RANDOMIZED           PARALLEL   \n",
            "\n",
            "                                             Masking Primary Purpose  \\\n",
            "0                                               NONE       TREATMENT   \n",
            "1  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)       TREATMENT   \n",
            "2                                               NONE       TREATMENT   \n",
            "3  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "4  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "\n",
            "                                    Outcome Measures  \n",
            "0  Primary Outcomes: Determine the safety / maxim...  \n",
            "1  Primary Outcomes: Safety Outcome, Number of pa...  \n",
            "2  Primary Outcomes: Proportion of patients achie...  \n",
            "3  Primary Outcomes: To demonstrate the effective...  \n",
            "4  Primary Outcomes: Number of Participants With ...  \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1['Outcome Measures'][0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 174
        },
        "id": "bywQtA7EWSWA",
        "outputId": "243993b3-ab7f-4a49-dbee-26dfaa02ea37"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Primary Outcomes: Determine the safety / maximum tolerated dose of Neukoplastâ„¢ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia, 2016 |  Secondary Outcomes: Evaluate the therapeutic efficacy of Neukoplastâ„¢ in patients with refractory or relapsed acute myeloid leukemia, 2016|Determine the Neukoplastâ„¢ cell phenotype and cytotoxic activity at different time intervals after the Neukoplastâ„¢ cell infusion, 2016|Determine the presence of Neukoplastâ„¢ in the bone marrow, 2016|Determine the effects of Neukoplastâ„¢ on the host immune system, using flow cytometry and the LUMINEX multianalytic profiling system, at different time intervals after the Neukoplastâ„¢ infusion., 2016'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 19
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "0lBTuYwTWcOI",
        "outputId": "997cff33-123e-402a-93d7-3b1ca91db502"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                             Study Title Study Status  \\\n",
              "0      QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
              "1      Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
              "2      A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
              "3      A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
              "4      Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
              "...                                                  ...          ...   \n",
              "20671  A Single and Multiple Ascending-dose Trial of ...    COMPLETED   \n",
              "20672  A Study of Escalating Doses of DCDS0780A in Pa...    COMPLETED   \n",
              "20673  Clinical Trial of YYC301 for Treatment of Oste...    COMPLETED   \n",
              "20674   LGX818 for Patients With BRAFV600 Mutated Tumors   TERMINATED   \n",
              "20675  A Study to Evaluate ABY-035 in Subjects With M...    COMPLETED   \n",
              "\n",
              "                                           Brief Summary Study Results  \\\n",
              "0      NK cells from patients with malignant diseases...            NO   \n",
              "1      The purpose of this study is to determine safe...           YES   \n",
              "2      This is a multi-site study with plerixafor in ...            NO   \n",
              "3      This study has the objective to demonstrate th...            NO   \n",
              "4      The purpose of this two part study is to test ...           YES   \n",
              "...                                                  ...           ...   \n",
              "20671  This is a first-in-human study in adult health...            NO   \n",
              "20672  This open-label, multicenter, Phase 1/1b study...            NO   \n",
              "20673  A Multi-center, Double-blinded, Randomized, Ac...            NO   \n",
              "20674  The purpose of this signal seeking study is to...           YES   \n",
              "20675  This randomized, double-blinded dose-finding s...            NO   \n",
              "\n",
              "                                              Conditions  \\\n",
              "0                                 Acute Myeloid Leukemia   \n",
              "1                                    Diabetic Foot Ulcer   \n",
              "2      Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
              "3                            Poisoning by Scorpion Sting   \n",
              "4                                         Malaria, Vivax   \n",
              "...                                                  ...   \n",
              "20671                                 Healthy Volunteers   \n",
              "20672                             Non-Hodgkin's Lymphoma   \n",
              "20673                               Osteoarthritis, Knee   \n",
              "20674               Solid Tumor|Hematologic Malignancies   \n",
              "20675                                   Plaque Psoriasis   \n",
              "\n",
              "                                           Interventions  Sex  \\\n",
              "0                      BIOLOGICAL: Neukoplastâ„¢ (NK-92)  ALL   \n",
              "1      DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...  ALL   \n",
              "2      DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...  ALL   \n",
              "3      BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...  ALL   \n",
              "4      DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...  ALL   \n",
              "...                                                  ...  ...   \n",
              "20671                     DRUG: LEO 153339|DRUG: Placebo  ALL   \n",
              "20672  DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...  ALL   \n",
              "20673  DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...  ALL   \n",
              "20674                                       DRUG: LGX818  ALL   \n",
              "20675            BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo  ALL   \n",
              "\n",
              "                             Age         Phases  Enrollment Completion Date  \\\n",
              "0             ADULT, OLDER_ADULT         PHASE1           7      2015-06-02   \n",
              "1             ADULT, OLDER_ADULT  PHASE1|PHASE2          44      2015-10-17   \n",
              "2                   CHILD, ADULT  PHASE1|PHASE2          46      2017-05-09   \n",
              "3                          CHILD  PHASE2|PHASE3          56      2018-11-15   \n",
              "4      CHILD, ADULT, OLDER_ADULT         PHASE2         851      2016-11-18   \n",
              "...                          ...            ...         ...             ...   \n",
              "20671         ADULT, OLDER_ADULT         PHASE1         108      2022-07-18   \n",
              "20672         ADULT, OLDER_ADULT         PHASE1          66      2019-07-12   \n",
              "20673         ADULT, OLDER_ADULT         PHASE2         261      2020-09-07   \n",
              "20674         ADULT, OLDER_ADULT         PHASE2          12      2015-10-13   \n",
              "20675         ADULT, OLDER_ADULT         PHASE2         108      2021-12-03   \n",
              "\n",
              "       Study Recruitment Rate  Duration of Trial  \\\n",
              "0                    0.551598                386   \n",
              "1                    0.443157                604   \n",
              "2                    0.044558               1163   \n",
              "3                    7.279202                117   \n",
              "4                    1.969008                939   \n",
              "...                       ...                ...   \n",
              "20671                7.693208                427   \n",
              "20672                0.199434               1438   \n",
              "20673                1.074256                739   \n",
              "20674                0.044077                637   \n",
              "20675                0.133504               1367   \n",
              "\n",
              "       Primary Completion Duration of Trial      Allocation  \\\n",
              "0                                     386.0              NA   \n",
              "1                                     492.0      RANDOMIZED   \n",
              "2                                    1163.0      RANDOMIZED   \n",
              "3                                     103.0      RANDOMIZED   \n",
              "4                                     939.0      RANDOMIZED   \n",
              "...                                     ...             ...   \n",
              "20671                                 427.0      RANDOMIZED   \n",
              "20672                                1438.0  NON_RANDOMIZED   \n",
              "20673                                 621.0      RANDOMIZED   \n",
              "20674                                 595.0              NA   \n",
              "20675                                 385.0      RANDOMIZED   \n",
              "\n",
              "      Intervention Model                                            Masking  \\\n",
              "0           SINGLE_GROUP                                               NONE   \n",
              "1               PARALLEL  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)   \n",
              "2               PARALLEL                                               NONE   \n",
              "3               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "4               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "...                  ...                                                ...   \n",
              "20671           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20672           PARALLEL                                               NONE   \n",
              "20673           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20674       SINGLE_GROUP                                                      \n",
              "20675           PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "\n",
              "      Primary Purpose                                   Outcome Measures  \n",
              "0           TREATMENT  Primary Outcomes: Determine the safety / maxim...  \n",
              "1           TREATMENT  Primary Outcomes: Safety Outcome, Number of pa...  \n",
              "2           TREATMENT  Primary Outcomes: Proportion of patients achie...  \n",
              "3           TREATMENT  Primary Outcomes: To demonstrate the effective...  \n",
              "4           TREATMENT  Primary Outcomes: Number of Participants With ...  \n",
              "...               ...                                                ...  \n",
              "20671       TREATMENT  Primary Outcomes: Number of treatment-emergent...  \n",
              "20672       TREATMENT  Primary Outcomes: Number of Participants with ...  \n",
              "20673       TREATMENT  Primary Outcomes: 100mm Pain VAS, Subjects who...  \n",
              "20674       TREATMENT  Primary Outcomes: Clinical Benefit Rate (CBR) ...  \n",
              "20675       TREATMENT  Primary Outcomes: Proportion of subjects with ...  \n",
              "\n",
              "[20676 rows x 19 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-4fc26c73-055a-4fb7-a33b-8e2e8fca3c50\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Completion Date</th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "      <th>Duration of Trial</th>\n",
              "      <th>Primary Completion Duration of Trial</th>\n",
              "      <th>Allocation</th>\n",
              "      <th>Intervention Model</th>\n",
              "      <th>Masking</th>\n",
              "      <th>Primary Purpose</th>\n",
              "      <th>Outcome Measures</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>NK cells from patients with malignant diseases...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Acute Myeloid Leukemia</td>\n",
              "      <td>BIOLOGICAL: Neukoplastâ„¢ (NK-92)</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>7</td>\n",
              "      <td>2015-06-02</td>\n",
              "      <td>0.551598</td>\n",
              "      <td>386</td>\n",
              "      <td>386.0</td>\n",
              "      <td>NA</td>\n",
              "      <td>SINGLE_GROUP</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Determine the safety / maxim...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Clinical Investigation of GalnobaxÂ® for the T...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this study is to determine safe...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Diabetic Foot Ulcer</td>\n",
              "      <td>DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>44</td>\n",
              "      <td>2015-10-17</td>\n",
              "      <td>0.443157</td>\n",
              "      <td>604</td>\n",
              "      <td>492.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Safety Outcome, Number of pa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>A Combined Study in Pediatric Cancer Patients ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a multi-site study with plerixafor in ...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...</td>\n",
              "      <td>DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>46</td>\n",
              "      <td>2017-05-09</td>\n",
              "      <td>0.044558</td>\n",
              "      <td>1163</td>\n",
              "      <td>1163.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Proportion of patients achie...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>A Trial of Equine F (ab')2 Antivenom for Treat...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This study has the objective to demonstrate th...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Poisoning by Scorpion Sting</td>\n",
              "      <td>BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD</td>\n",
              "      <td>PHASE2|PHASE3</td>\n",
              "      <td>56</td>\n",
              "      <td>2018-11-15</td>\n",
              "      <td>7.279202</td>\n",
              "      <td>117</td>\n",
              "      <td>103.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: To demonstrate the effective...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this two part study is to test ...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Malaria, Vivax</td>\n",
              "      <td>DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>851</td>\n",
              "      <td>2016-11-18</td>\n",
              "      <td>1.969008</td>\n",
              "      <td>939</td>\n",
              "      <td>939.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of Participants With ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>A Single and Multiple Ascending-dose Trial of ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a first-in-human study in adult health...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Healthy Volunteers</td>\n",
              "      <td>DRUG: LEO 153339|DRUG: Placebo</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>108</td>\n",
              "      <td>2022-07-18</td>\n",
              "      <td>7.693208</td>\n",
              "      <td>427</td>\n",
              "      <td>427.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of treatment-emergent...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>A Study of Escalating Doses of DCDS0780A in Pa...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This open-label, multicenter, Phase 1/1b study...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Non-Hodgkin's Lymphoma</td>\n",
              "      <td>DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>66</td>\n",
              "      <td>2019-07-12</td>\n",
              "      <td>0.199434</td>\n",
              "      <td>1438</td>\n",
              "      <td>1438.0</td>\n",
              "      <td>NON_RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of Participants with ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>Clinical Trial of YYC301 for Treatment of Oste...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>A Multi-center, Double-blinded, Randomized, Ac...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Osteoarthritis, Knee</td>\n",
              "      <td>DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>261</td>\n",
              "      <td>2020-09-07</td>\n",
              "      <td>1.074256</td>\n",
              "      <td>739</td>\n",
              "      <td>621.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: 100mm Pain VAS, Subjects who...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20674</th>\n",
              "      <td>LGX818 for Patients With BRAFV600 Mutated Tumors</td>\n",
              "      <td>TERMINATED</td>\n",
              "      <td>The purpose of this signal seeking study is to...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Solid Tumor|Hematologic Malignancies</td>\n",
              "      <td>DRUG: LGX818</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>12</td>\n",
              "      <td>2015-10-13</td>\n",
              "      <td>0.044077</td>\n",
              "      <td>637</td>\n",
              "      <td>595.0</td>\n",
              "      <td>NA</td>\n",
              "      <td>SINGLE_GROUP</td>\n",
              "      <td></td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Clinical Benefit Rate (CBR) ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>A Study to Evaluate ABY-035 in Subjects With M...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This randomized, double-blinded dose-finding s...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Plaque Psoriasis</td>\n",
              "      <td>BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>108</td>\n",
              "      <td>2021-12-03</td>\n",
              "      <td>0.133504</td>\n",
              "      <td>1367</td>\n",
              "      <td>385.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Proportion of subjects with ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20676 rows × 19 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-4fc26c73-055a-4fb7-a33b-8e2e8fca3c50')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-4fc26c73-055a-4fb7-a33b-8e2e8fca3c50 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-4fc26c73-055a-4fb7-a33b-8e2e8fca3c50');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-e7f550e5-92ee-4243-b8e5-800539505c32\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e7f550e5-92ee-4243-b8e5-800539505c32')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-e7f550e5-92ee-4243-b8e5-800539505c32 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_51706582-e5b6-4f03-a0b7-703b3ccc899b\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('data1')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_51706582-e5b6-4f03-a0b7-703b3ccc899b button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('data1');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "data1",
              "summary": "{\n  \"name\": \"data1\",\n  \"rows\": 20676,\n  \"fields\": [\n    {\n      \"column\": \"Study Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20636,\n        \"samples\": [\n          \"CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.\",\n          \"Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy\",\n          \"IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"UNKNOWN\",\n          \"SUSPENDED\",\n          \"COMPLETED\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20528,\n        \"samples\": [\n          \"The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly (over 60 years of age).\",\n          \"The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).\",\n          \"This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-\\u00ce\\u00b4,\\u00ce\\u00b3, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"YES\",\n          \"NO\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 7860,\n        \"samples\": [\n          \"Infection, Bacterial\",\n          \"Connective Tissue Disease-Associated Pulmonary Arterial Hypertension\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 18217,\n        \"samples\": [\n          \"DRUG: siremadlin|DRUG: venetoclax|DRUG: azacitidine\",\n          \"DIETARY_SUPPLEMENT: Probiotic\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"ALL\",\n          \"FEMALE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"ADULT, OLDER_ADULT\",\n          \"CHILD, ADULT\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"PHASE1|PHASE2\",\n          \"PHASE3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3534,\n        \"min\": 1,\n        \"max\": 477102,\n        \"num_unique_values\": 1341,\n        \"samples\": [\n          230,\n          273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Completion Date\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": \"2014-02-08 00:00:00\",\n        \"max\": \"2024-06-30 00:00:00\",\n        \"num_unique_values\": 3027,\n        \"samples\": [\n          \"2021-05-12 00:00:00\",\n          \"2020-06-25 00:00:00\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Recruitment Rate\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 47.61087701710453,\n        \"min\": 0.0011275127619133577,\n        \"max\": 4816.602870813397,\n        \"num_unique_values\": 17106,\n        \"samples\": [\n          0.9896963123644252,\n          21.433106967464703\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 669,\n        \"min\": -41927,\n        \"max\": 3787,\n        \"num_unique_values\": 2525,\n        \"samples\": [\n          903,\n          106\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Completion Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 527.2636176228543,\n        \"min\": 0.0,\n        \"max\": 3662.0,\n        \"num_unique_values\": 2277,\n        \"samples\": [\n          1207.0,\n          1124.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Allocation\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"RANDOMIZED\",\n          \"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention Model\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"SINGLE_GROUP\",\n          \"PARALLEL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Masking\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 19,\n        \"samples\": [\n          \"NONE\",\n          \"SINGLE (OUTCOMES_ASSESSOR)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Purpose\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"SCREENING\",\n          \"PREVENTION\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20572,\n        \"samples\": [\n          \"Primary Outcomes: Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period, Central read F-VASI was assessed based on the facial photographs taken at the site. Central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. The higher score of F-VASI signified severer symptoms of non-segmental vitiligo. Percent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)\\u00c3\\u2014100. A negative percent change from baseline in central read F-VASI signified an improvement., Baseline, Week 24 (Baseline was defined as the last measurement prior to Study Day 18)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to Week 24 - DR Period, Adverse Event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator., 24 weeks|Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - DR Period, An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator.\\n\\nAn AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.\\n\\nBaseline was defined as the last measurement prior to first dosing (Day 1)., Baseline up to Week 24|Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile up to Week 24 - DR Period, Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator.\\n\\nBaseline was defined as the last measurement prior to first dosing (Day 1)., Baseline up to Week 24|Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - DR Period, Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin., 24 weeks|Number of Participants With TEAEs and SAEs - Extension (Ext) Period, AE was defined as any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; or that was considered to be an important medical event. Causality to study treatment was determined by the investigator., 24 weeks|Number of Participants With the TEAEs of Anaemia, Neutropenia, Thrombocytopenia and Lymphopenia - Ext Period, An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event did not necessarily need to have a causal relationship with the treatment or usage. The abnormal test findings, clinically significant signs and symptoms of anaemia, neutropenia, thrombocytopenia and lymphopenia were reported as AEs. The clinical significance was determined by the investigator.\\n\\nAn AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs., 24 weeks|Number of Participants With Clinically Meaningful Changes From Baseline in Lipid Profile - Ext Period, Participants had to abstain from all food and drink (except water and non-investigational products) for an 8-hour overnight fast prior to fasting lipid profile panel collection. Fasting lipid assessment included total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The clinical meaningfulness was determined by the investigator., 24 Weeks|Number of Participants With Liver Function Test Values Meeting the Protocol-Specified Discontinuation Criteria - Ext Period, Liver function tests included tests of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin., 24 weeks |  Secondary Outcomes: Percentage of Participants Achieving Central F-VASI75 at Week 24 - DR Period, This outcome measure was the percentage of participants achieving at least 75% improvement from baseline in central read F-VASI (F-VASI75) at Week 24. A negative percent change from baseline in central read F-VASI signified an improvement. The central read F-VASI75 response rate was analyzed by first treating the missing data (non-COVID-19 related) as non responders and then applying Chan and Zhang exact confidence interval (CI) method at Week 24.\\n\\nCentral read F-VASI75=1 if percent change from baseline \\u00e2\\u2030\\u00a575; central read F-VASI75=0 if percent change from baseline \\\\<75. Percent change from baseline in F-VASI=((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)\\u00c3\\u2014100. Baseline was defined as the last measurement prior to study Day 18., Week 24|Percentage of Participants Achieving T-VASI50 at Week 24 - DR Period, Total body VASI (T-VASI) was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: T-VASI= \\u00c6\\u00a9\\\\[Hand Units\\\\]\\u00c3\\u2014\\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding feet), and feet. The extent of depigmentation was expressed by percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The data below was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50) at Week 24. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Week 24|Percent Change From Baseline in T-VASI at Designated Time Points - DR Period, The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)\\u00c3\\u2014100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percent Change From Baseline in Central Read F-VASI at Designated Time Points - DR Period, The central read F-VASI was assessed based on the facial photographs taken at the site. The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area.\\n\\nPercent change from baseline in central read F-VASI = ((post-baseline central read F-VASI - baseline central read F-VASI)/baseline central read F-VASI)\\u00c3\\u2014100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18., Baseline, Weeks 4, 8, 16 and 24|Percent Change From Baseline in Local F-VASI at Designated Time Points - DR Period, The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0.00 4.00): Local F-VASI = \\\\[Digit Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\] \\u00c3\\u2014 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%.\\n\\nPercent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)\\u00c3\\u2014100. Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percent Change From Baseline in SA-VES at Designated Time Points - DR Period, The Self-Assessment Vitiligo Extent Score (SA-VES) was a validated patient report outcome measurement instrument to provide information about disease extent. Vitiligo Extent Score (VES) was a measure to express the overall vitiligo involvement of the body (extent). Clinical illustrations for 19 separate body areas that reflected different degrees of involvement (1%, 5%, 10%, 25%, 50% and 75% depigmentation) were chosen to represent the participant's skin lesions to get the total extent of the disease. VES was a sum of all surface measurement that was similar to VASI. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 16 and 24|Absolute Change From Baseline in T-VASI at Designated Time Points - DR Period, The T-VASI was calculated using a formula that included contribution from 6 different body regions (possible range, 0-100) with a modified method: VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 separate and mutually exclusive regions: face/neck, hands, upper extremities (excluding hands), trunk, lower extremities (excluding the feet), and feet. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%.\\n\\nThe absolute change from baseline in T-VASI was analyzed using the ANCOVA analysis. Negative change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving T-VASI50 at Designated Time Points - DR Period, T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 50% improvement from baseline in T-VASI (T-VASI50). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)\\u00c3\\u2014100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving T-VASI75 at Designated Time Points - DR Period, T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 75% improvement from baseline in T-VASI (T-VASI75). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)\\u00c3\\u2014100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving T-VASI90 at Designated Time Points - DR Period, T-VASI was calculated by a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. The outcome measure was the percentage of participants achieving at least 90% improvement from baseline in T-VASI (T-VASI90). Percent change from baseline in T-VASI=((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)\\u00c3\\u2014100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving T-VASI100 at Designated Time Points - DR Period, T-VASI was calculated using a formula that included contribution from 6 body regions (possible range, 0-100): T-VASI = \\u00c6\\u00a9 \\\\[Hand Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\]. One hand unit, which encompassed the palm plus the volar surface of all the digits, was approximately 1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. The body was divided into 6 mutually exclusive regions: face/neck, hands, upper extremities, trunk, lower extremities, and feet. The extent of depigmentation was expressed by the percentages: 0, 10%, 25%, 50%, 75%, 90% or 100%. This outcome measure was the percentage of participants achieving 100% improvement from baseline in T-VASI (T-VASI100). Percent change from baseline in T-VASI = ((post-baseline T-VASI - baseline T-VASI)/baseline T-VASI)\\u00c3\\u2014100. Negative percent change from baseline in T-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving Central Read F-VASI50 at Designated Time Points - DR Period, The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 50% improvement in central read F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18., Baseline, Weeks 4, 8, 16 and 24|Percentage of Participants Achieving Central Read F-VASI75 at Designated Time Points - DR Period, The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 75% improvement in central read F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18., Baseline, Weeks 4, 8, 16 and 24|Percentage of Participants Achieving Central Read F-VASI90 at Designated Time Points - DR Period, The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 90% improvement in central read F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18., Baseline, Weeks 4, 8, 16 and 24|Percentage of Participants Achieving Central Read F-VASI100 at Designated Time Points - DR Period, The central read F-VASI was calculated using a formula that included contribution of affected facial surface areas showing all 6 different depigmentation rates (0.1, 0.25, 0.5, 0.75, 0.9 and 1) with a modified method: F-VASI (central read)=\\u00c6\\u00a9 \\\\[Affected Facial Surface Area\\\\] \\u00c3\\u2014 4 \\u00c3\\u2014 \\\\[Depigmentation Rates\\\\]. Face was defined as the area from the hairline on top of the forehead to the jawline at the bottom of the cheeks. F-VASI (central read) ranged from 0.000 to 4.000 by defining the affected Facial Surface Area (expressed as the value between 0.0 to 1.0) being 4% of total Body Surface Area. Percent change from baseline in F-VASI = ((post-baseline F-VASI - baseline F-VASI)/baseline F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 100% improvement in central read F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to Study Day 18., Baseline, Weeks 4, 8, 16 and 24|Percentage of Participants Achieving Local F-VASI50 at Designated Time Points - DR Period, The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \\\\[Digit Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\] \\u00c3\\u2014 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 50% improvement in site assessment F-VASI from baseline (F-VASI50). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving Local F-VASI75 at Designated Time Points - DR Period, The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \\\\[Digit Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\] \\u00c3\\u2014 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 75% improvement in site assessment F-VASI from baseline (F-VASI75). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving Local F-VASI90 at Designated Time Points - DR Period, The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \\\\[Digit Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\] \\u00c3\\u2014 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving at least 90% improvement in site assessment F-VASI from baseline (F-VASI90). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Percentage of Participants Achieving Local F-VASI100 at Designated Time Points - DR Period, The site assessment of the F-VASI was calculated using a formula that included contribution from face (possible range, 0-4): Local F-VASI = \\\\[Digit Units\\\\] \\u00c3\\u2014 \\\\[Depigmentation\\\\] \\u00c3\\u2014 0.1. Scalp, neck, eyebrows, eyelashes, and vermilion were excluded from this calculation. The volar surface of 1 digit (the participant's thumb) was approximately 0.1% of the total body surface area and was used as a guide to estimate the baseline percentage of vitiligo involvement of face. The extent of depigmentation was expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Percent change from baseline in Local F-VASI = ((post baseline Local F-VASI - baseline Local F-VASI)/baseline Local F-VASI)\\u00c3\\u2014100. This outcome measure was the percentage of participants achieving 100% improvement in site assessment F-VASI from baseline (F-VASI100). Negative percent change from baseline in F-VASI signified an improvement. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 8, 12, 16, 20 and 24|Change From Baseline in Total VitiQoL Score at Designated Time Points - DR Period, The Vitiligo-Specific Quality of Life (VitiQoL) instrument was a reliable and validated vitiligo disease-specific health-related quality of life (HRQoL) instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from \\\"not at all\\\" (scored 0) to \\\"most of the time\\\" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL total score was calculated as sum of items 1-15.\\n\\nThe change from baseline in total VitiQoL score was analyzed using the mixed-effect models repeated measures (MMRM) analysis. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 16 and 24|Change From Baseline in VitiQoL Participation Limitation Domain Score at Designated Time Points - DR Period, The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from \\\"not at all\\\" (scored 0) to \\\"most of the time\\\" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Participation Limitation domain score was the sum of items 3, 4, 6, 9, 10, 11, 14 and ranged from 0 to 42.\\n\\nThe change from baseline in VitiQoL Participation Limitation Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 16 and 24|Change From Baseline in VitiQoL Stigma Domain Score at Designated Time Points - DR Period, The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from \\\"not at all\\\" (scored 0) to \\\"most of the time\\\" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Stigma domain score was the sum of items 1, 2, 5, 7 and 15, and ranged from 0 to 30.\\n\\nThe change from baseline in VitiQoL Stigma Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 16 and 24|Change From Baseline in VitiQoL Behaviors Domain Score at Designated Time Points - DR Period, The VitiQoL was a reliable and validated vitiligo disease specific HRQoL instrument which measured concepts relevant to vitiligo participants. The VitiQoL was a 15-item PRO measure which measured concepts of symptoms, daily activities, leisure activities, work, personal relationships and treatment. Responses ranged from \\\"not at all\\\" (scored 0) to \\\"most of the time\\\" (scored 6) and gave a minimum and maximum score from 0 to 90, with higher scores representing greater burden. The VitiQoL Behaviors domain score was the sum of items 8, 12 and 13, and ranged from 0 to 18.\\n\\nThe change from baseline in VitiQoL Behaviors Domain Score was analyzed using the MMRM analysis. Baseline was defined as the last measurement prior to first dosing (Day 1)., Baseline, Weeks 4, 16 and 24|Percentage of Participants Achieving sIGA 0 or 1 and at Least a 2-Point Improvement at Week 24 - DR Period, The percentage of participants achieving a static Investigator Global Assessment (sIGA) Score 0/1 and sIGA \\u00e2\\u2030\\u00a52-point improvement at Week 24 was presented in this outcome measure. The sIGA score ranged from 0 to 4.\\n\\nThe sIGA Score 0 represented \\\"Clear\\\" with no signs of loss of pigmentation with natural light or with Woods lamp examination.\\n\\nThe sIGA Score 1 represented \\\"Almost Clear\\\" with the following descriptors:\\n\\n* Faint, barely detectable loss of pigmentation mainly located on dorsal hands, feet, bony prominences, and/or limited areas.\\n* Approximately 90% pigmentation within lesions.\\n* No or rare signs of Koebner phenomenon, confetti like or trichrome lesions could be present.\\n\\nThe sIGA Scores 2, 3 and 4 represented \\\"Mild Vitiligo\\\", \\\"Moderate Vitiligo\\\" and \\\"Severe Vitiligo\\\", respectively., Week 24\",\n          \"Primary Outcomes: Daily \\\"Average Pain Over the Last 24 Hours\\\" Score at Week 4, At week 4, subjects were asked to rate their pain on an 11-point numerical scale where 0 = no pain, 10 = pain as bad as you can imagine., Week 4 |  Secondary Outcomes: Weekly Change From Baseline Score of \\\"Average Pain Over the Last 24 Hours\\\" From the mBPI-SF Pain Severity Subscale, Subjects were asked to rate their pain on an 11-point numerical scale where 0 = no pain, 10 = pain as bad as you can imagine., Weeks 1, 2 and 4|Average Daily \\\"Pain Right Now\\\" Score Collected by e-Diary, Subjects were asked to rate their pain on an 11-point numerical scale where 0 = no pain, 10 = pain as bad as you can imagine., 4 Weeks|Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Pain Subscale, The pain subscale consisted of 5 items: walking; stair climbing; nocturnal; at rest; weight bearing. The score for each item ranged from 0 (none) to 4 (extreme). The pain subscale score was obtained by adding the responses to the 5 items which could range from 0 to 20., 4 Weeks|Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Stiffness Subscale, The stiffness subscale consisted of 2 items; morning stiffness and stiffness occurring later in the day. The score for each item ranged from 0 (none) to 4 (extreme) and the stiffness subscale score was obtained by adding the responses to the 2 items which could range from 0 - 8., 4 Weeks|Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Physical Function Subscale, The physical function subscale consisted of 17 items: descending stairs; ascending stairs; rising from sitting; standing; bending to floor; walking on flat surface; getting into or out of car; going shopping; putting on socks; rising from bed; taking off socks; lying in bed; sitting; getting into or out of the bathtub; getting on or off the toilet; heavy domestic duties; light domestic duties. The score for each item ranged from 0 (none) to 4 (extreme) and the physical function subscale score was obtained by adding the responses to the 17 items which could range from 0 to 68., 4 Weeks|Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Total Score, The total score of the WOMAC consisted of 24 items (5 items from the pain subscale, 2 items from the stiffness subscale, and 17 items from the physical function subscale). The total score was obtained by adding the scores from these 3 subscales and could range from 0 to 96., 4 Weeks|Modified Brief Pain Inventory-Short Form (mBPI-SF) - Total Score (All Parts of 6 Questions), The mBPI-SF consists of 6 questions and is a self-administered questionnaire used to assess the severity of pain, and the interference of pain on daily functions. Subjects rated their severity of pain / interference of pain on a 0 (no pain / does not interfere) to 10 (as bad as you can imagine / completely interferes) numerical rating scale (NRS) The total score is the sum of all parts of the 6 questions and the total score range is 0 - 110., 4 Weeks|Modified Brief Pain Inventory-Short Form (mBPI-SF) Pain Severity Subscale Score, The mBPI-SF is a self-administered questionnaire. The pain severity subscale of the mBPI-SF consists of 4 questions which ask the subjects to rate their severity of pain on a 0 to 10 NRS for worst pain, least pain, average pain, and current pain. The severity of pain was computed as the mean of questions 1-4. The mean severity of pain scores could range from 0 to 10., 4 Weeks|Modified Brief Pain Inventory-Short Form (mBPI-SF) Pain Interference Subscale Score, The mBPI-SF is a self-administered questionnaire. The pain interference subscale of the mBPI-SF consists of Question 6 which has 7 parts, all of which ask the subjects to rate the impact/interference of their pain on various functions, ie, general activity, mood, walking, normal work, relations with others, sleep, and enjoyment of life on a 0 to 10 NRS where 0 = does not interfere and 10 = completely interferes. The mean interference of pain scores could range from 0 to 10., 4 Weeks|Responder to Treatment (Calculated as the Percentage Reduction of \\\"Average Pain Over the Last 24 Hours\\\") at Week 4, A subject's response to treatment was defined as the percentage reduction from the baseline \\\"average pain over the last 24 hours\\\" score to the week 4 pain score from the mBPI-SF pain severity subscale. Responders were defined as having \\\\> 0 % reduction; non-responders were defined as having \\u00e2\\u2030\\u00a4 0% reduction., Week 4|Medical Outcomes Study Short Form-36 (SF-36) - Physical Component Summary, The SF-36 is a generic health survey with 36 items that measure functional health and well-being from the subject's perspective. The survey is summarized into 8 dimensions/scales: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH).\\n\\nThe Physical Component Summary is derived from 4 of the 8 health dimensions (aggregate of PF, RP, BP, and GH scales). The minimum score is 0 and the maximum score is 100. A higher score indicates a better health state., 4 Weeks|Medical Outcomes Study Short Form-36 (SF-36) - Mental Component Summary, The SF-36 is a generic health survey with 36 items that measure functional health and well-being from the subject's perspective. The survey is summarized into 8 dimensions/scales: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH).\\n\\nThe Mental Component Summary is derived from 4 of the 8 health dimensions,(aggregate of VT, SF, RE, and MH scales). The minimum score is 0 and the maximum score is 100. A higher score indicates a better health state., 4 Weeks|European Quality of Life Scale - 5 Dimensions (EQ-5D-5L) to Measure Health Status, EQ-5D-5L is a standardized generic measure of health status for clinical and economic appraisal based on a descriptive system that defines health in terms of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It includes a visual analogue scale (VAS) with scores ranging from 0 (\\\"worst imaginable health state\\\") to 100 (\\\"best imaginable health state\\\")., 4 Weeks|Patient Global Impression of Change (PGIC), The PGIC is an ordinal scale which assesses the change in overall status relative to the start of the study. The scale has only 1 item, which measures global change of overall status by the subject on a 7-point scale (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse), where 1 = very much improved and 7 = very much worse. The number of subjects responding \\\"very much improved\\\" and \\\"much improved\\\" was summarized by treatment group., 4 Weeks|Supplemental Analgesic Medication Use, The average daily number of tablets of supplemental pain medication used during the double-blind period was summarized by treatment group., Up to 28 days|Number of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Score (C-SSRS), Suicidality was monitored throughout the study using the C-SSRS. The C-SSRS involves a series of probing questions to inquire about possible suicidal thinking and behavior. The composite endpoints (Suicidal Ideation, Suicidal Behavior, Suicidal Ideation or Behavior) included subjects who experienced any one of the events at least once during treatment., Baseline up to 4 Weeks|Change From Baseline to Week 4 in Hospital Anxiety and Depression Scale (HADS) Score, Safety assessment to evaluate the impact of V120083 on mood (anxiety \\\\[HADS-A\\\\] and depression \\\\[HADS-D\\\\]). The score for each subscale ranges from 0 (no anxiety or depression) to 21, with a score of 11 or higher indicating the probable presence of the mood disorder., Week 4\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "source": [
        "# @title Study Recruitment Rate\n",
        "\n",
        "from matplotlib import pyplot as plt\n",
        "data1['Study Recruitment Rate'].plot(kind='line', figsize=(8, 4), title='Study Recruitment Rate')\n",
        "plt.gca().spines[['top', 'right']].set_visible(False)"
      ],
      "cell_type": "code",
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 800x400 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ],
      "metadata": {
        "cellView": "form",
        "id": "9JShQ6e7ZLvW",
        "outputId": "8211408a-4e99-4cb2-fb28-620ea8a12edd",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 383
        }
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Drop rows with NaN or empty values in the specified columns\n",
        "data1 = data1[(data1['Allocation'].notna()) & (data1['Allocation'] != '') &\n",
        "              (data1['Intervention Model'].notna()) & (data1['Intervention Model'] != '') &\n",
        "              (data1['Masking'].notna()) & (data1['Masking'] != '')]\n",
        "\n",
        "# Display the updated DataFrame\n",
        "print(data1.head())\n"
      ],
      "metadata": {
        "id": "uxPSrRUcZBfi",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "053b8035-7a3f-4e26-8eb3-6c7f6bf93de4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                         Study Title Study Status  \\\n",
            "0  QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
            "1  Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
            "2  A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
            "3  A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
            "4  Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
            "\n",
            "                                       Brief Summary Study Results  \\\n",
            "0  NK cells from patients with malignant diseases...            NO   \n",
            "1  The purpose of this study is to determine safe...           YES   \n",
            "2  This is a multi-site study with plerixafor in ...            NO   \n",
            "3  This study has the objective to demonstrate th...            NO   \n",
            "4  The purpose of this two part study is to test ...           YES   \n",
            "\n",
            "                                          Conditions  \\\n",
            "0                             Acute Myeloid Leukemia   \n",
            "1                                Diabetic Foot Ulcer   \n",
            "2  Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
            "3                        Poisoning by Scorpion Sting   \n",
            "4                                     Malaria, Vivax   \n",
            "\n",
            "                                       Interventions  Sex  \\\n",
            "0                  BIOLOGICAL: Neukoplastâ„¢ (NK-92)  ALL   \n",
            "1  DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...  ALL   \n",
            "2  DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...  ALL   \n",
            "3  BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...  ALL   \n",
            "4  DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...  ALL   \n",
            "\n",
            "                         Age         Phases  Enrollment Completion Date  \\\n",
            "0         ADULT, OLDER_ADULT         PHASE1           7      2015-06-02   \n",
            "1         ADULT, OLDER_ADULT  PHASE1|PHASE2          44      2015-10-17   \n",
            "2               CHILD, ADULT  PHASE1|PHASE2          46      2017-05-09   \n",
            "3                      CHILD  PHASE2|PHASE3          56      2018-11-15   \n",
            "4  CHILD, ADULT, OLDER_ADULT         PHASE2         851      2016-11-18   \n",
            "\n",
            "   Study Recruitment Rate  Duration of Trial  \\\n",
            "0                0.551598                386   \n",
            "1                0.443157                604   \n",
            "2                0.044558               1163   \n",
            "3                7.279202                117   \n",
            "4                1.969008                939   \n",
            "\n",
            "   Primary Completion Duration of Trial  Allocation Intervention Model  \\\n",
            "0                                 386.0          NA       SINGLE_GROUP   \n",
            "1                                 492.0  RANDOMIZED           PARALLEL   \n",
            "2                                1163.0  RANDOMIZED           PARALLEL   \n",
            "3                                 103.0  RANDOMIZED           PARALLEL   \n",
            "4                                 939.0  RANDOMIZED           PARALLEL   \n",
            "\n",
            "                                             Masking Primary Purpose  \\\n",
            "0                                               NONE       TREATMENT   \n",
            "1  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)       TREATMENT   \n",
            "2                                               NONE       TREATMENT   \n",
            "3  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "4  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "\n",
            "                                    Outcome Measures  \n",
            "0  Primary Outcomes: Determine the safety / maxim...  \n",
            "1  Primary Outcomes: Safety Outcome, Number of pa...  \n",
            "2  Primary Outcomes: Proportion of patients achie...  \n",
            "3  Primary Outcomes: To demonstrate the effective...  \n",
            "4  Primary Outcomes: Number of Participants With ...  \n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Count NaN or empty values in each column\n",
        "nan_count = data1.isna().sum()  # Counts the NaN values in each column\n",
        "empty_count = (data1 == '').sum()  # Counts the empty string values in each column\n",
        "\n",
        "# Combine the NaN and empty count\n",
        "total_missing = nan_count + empty_count\n",
        "\n",
        "# Display the count of missing or empty values for each column\n",
        "print(total_missing)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gilUhxkdbTzd",
        "outputId": "673fa1fa-c5a8-4100-f2c5-e5791f49ffa6"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Study Title                              0\n",
            "Study Status                             0\n",
            "Brief Summary                            0\n",
            "Study Results                            0\n",
            "Conditions                               0\n",
            "Interventions                            0\n",
            "Sex                                      6\n",
            "Age                                      0\n",
            "Phases                                   0\n",
            "Enrollment                               0\n",
            "Completion Date                          1\n",
            "Study Recruitment Rate                   0\n",
            "Duration of Trial                        0\n",
            "Primary Completion Duration of Trial    46\n",
            "Allocation                               0\n",
            "Intervention Model                       0\n",
            "Masking                                  0\n",
            "Primary Purpose                          0\n",
            "Outcome Measures                         0\n",
            "dtype: int64\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Calculate the mean of the 'Primary Completion Duration of Trial' column, excluding NaN or empty values\n",
        "mean_value = data1['Primary Completion Duration of Trial'].replace('', np.nan).mean()\n",
        "\n",
        "# Fill NaN or empty values with the calculated mean\n",
        "data1['Primary Completion Duration of Trial'] = data1['Primary Completion Duration of Trial'].replace('', np.nan).fillna(mean_value)\n",
        "\n",
        "# Display the updated DataFrame\n",
        "print(data1.head())\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JX92bwfzbn_0",
        "outputId": "e282a1db-4331-41ed-c3f6-39b903015d83"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                                         Study Title Study Status  \\\n",
            "0  QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
            "1  Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
            "2  A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
            "3  A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
            "4  Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
            "\n",
            "                                       Brief Summary Study Results  \\\n",
            "0  NK cells from patients with malignant diseases...            NO   \n",
            "1  The purpose of this study is to determine safe...           YES   \n",
            "2  This is a multi-site study with plerixafor in ...            NO   \n",
            "3  This study has the objective to demonstrate th...            NO   \n",
            "4  The purpose of this two part study is to test ...           YES   \n",
            "\n",
            "                                          Conditions  \\\n",
            "0                             Acute Myeloid Leukemia   \n",
            "1                                Diabetic Foot Ulcer   \n",
            "2  Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
            "3                        Poisoning by Scorpion Sting   \n",
            "4                                     Malaria, Vivax   \n",
            "\n",
            "                                       Interventions  Sex  \\\n",
            "0                  BIOLOGICAL: Neukoplastâ„¢ (NK-92)  ALL   \n",
            "1  DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...  ALL   \n",
            "2  DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...  ALL   \n",
            "3  BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...  ALL   \n",
            "4  DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...  ALL   \n",
            "\n",
            "                         Age         Phases  Enrollment Completion Date  \\\n",
            "0         ADULT, OLDER_ADULT         PHASE1           7      2015-06-02   \n",
            "1         ADULT, OLDER_ADULT  PHASE1|PHASE2          44      2015-10-17   \n",
            "2               CHILD, ADULT  PHASE1|PHASE2          46      2017-05-09   \n",
            "3                      CHILD  PHASE2|PHASE3          56      2018-11-15   \n",
            "4  CHILD, ADULT, OLDER_ADULT         PHASE2         851      2016-11-18   \n",
            "\n",
            "   Study Recruitment Rate  Duration of Trial  \\\n",
            "0                0.551598                386   \n",
            "1                0.443157                604   \n",
            "2                0.044558               1163   \n",
            "3                7.279202                117   \n",
            "4                1.969008                939   \n",
            "\n",
            "   Primary Completion Duration of Trial  Allocation Intervention Model  \\\n",
            "0                                 386.0          NA       SINGLE_GROUP   \n",
            "1                                 492.0  RANDOMIZED           PARALLEL   \n",
            "2                                1163.0  RANDOMIZED           PARALLEL   \n",
            "3                                 103.0  RANDOMIZED           PARALLEL   \n",
            "4                                 939.0  RANDOMIZED           PARALLEL   \n",
            "\n",
            "                                             Masking Primary Purpose  \\\n",
            "0                                               NONE       TREATMENT   \n",
            "1  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)       TREATMENT   \n",
            "2                                               NONE       TREATMENT   \n",
            "3  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "4  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...       TREATMENT   \n",
            "\n",
            "                                    Outcome Measures  \n",
            "0  Primary Outcomes: Determine the safety / maxim...  \n",
            "1  Primary Outcomes: Safety Outcome, Number of pa...  \n",
            "2  Primary Outcomes: Proportion of patients achie...  \n",
            "3  Primary Outcomes: To demonstrate the effective...  \n",
            "4  Primary Outcomes: Number of Participants With ...  \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-24-8b2a032b31dc>:5: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  data1['Primary Completion Duration of Trial'] = data1['Primary Completion Duration of Trial'].replace('', np.nan).fillna(mean_value)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Count NaN or empty values in each column\n",
        "nan_count = data1.isna().sum()  # Counts the NaN values in each column\n",
        "empty_count = (data1 == '').sum()  # Counts the empty string values in each column\n",
        "\n",
        "# Combine the NaN and empty count\n",
        "total_missing = nan_count + empty_count\n",
        "\n",
        "# Display the count of missing or empty values for each column\n",
        "print(total_missing)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "04vfL-B4b26A",
        "outputId": "de7f22ad-b9b5-460a-f15b-37a1f8a51a8c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Study Title                             0\n",
            "Study Status                            0\n",
            "Brief Summary                           0\n",
            "Study Results                           0\n",
            "Conditions                              0\n",
            "Interventions                           0\n",
            "Sex                                     6\n",
            "Age                                     0\n",
            "Phases                                  0\n",
            "Enrollment                              0\n",
            "Completion Date                         1\n",
            "Study Recruitment Rate                  0\n",
            "Duration of Trial                       0\n",
            "Primary Completion Duration of Trial    0\n",
            "Allocation                              0\n",
            "Intervention Model                      0\n",
            "Masking                                 0\n",
            "Primary Purpose                         0\n",
            "Outcome Measures                        0\n",
            "dtype: int64\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1.drop(['Completion Date'],axis='columns',inplace=True)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LmfBKC4_b9d-",
        "outputId": "144bdfa8-1667-4c68-8f86-1f07ffc0040e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-26-9026e5ac341e>:1: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  data1.drop(['Completion Date'],axis='columns',inplace=True)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "rnZYtguNcWOM",
        "outputId": "7bd13f79-ed66-4780-eb43-d4a0116846e4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                             Study Title Study Status  \\\n",
              "0      QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...    COMPLETED   \n",
              "1      Clinical Investigation of GalnobaxÂ® for the T...    COMPLETED   \n",
              "2      A Combined Study in Pediatric Cancer Patients ...    COMPLETED   \n",
              "3      A Trial of Equine F (ab')2 Antivenom for Treat...    COMPLETED   \n",
              "4      Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...    COMPLETED   \n",
              "...                                                  ...          ...   \n",
              "20670  The Multiple Dose of PK/PD Study of SHR2285 Ta...    COMPLETED   \n",
              "20671  A Single and Multiple Ascending-dose Trial of ...    COMPLETED   \n",
              "20672  A Study of Escalating Doses of DCDS0780A in Pa...    COMPLETED   \n",
              "20673  Clinical Trial of YYC301 for Treatment of Oste...    COMPLETED   \n",
              "20675  A Study to Evaluate ABY-035 in Subjects With M...    COMPLETED   \n",
              "\n",
              "                                           Brief Summary Study Results  \\\n",
              "0      NK cells from patients with malignant diseases...            NO   \n",
              "1      The purpose of this study is to determine safe...           YES   \n",
              "2      This is a multi-site study with plerixafor in ...            NO   \n",
              "3      This study has the objective to demonstrate th...            NO   \n",
              "4      The purpose of this two part study is to test ...           YES   \n",
              "...                                                  ...           ...   \n",
              "20670  The study is a randomized, single-blind, place...            NO   \n",
              "20671  This is a first-in-human study in adult health...            NO   \n",
              "20672  This open-label, multicenter, Phase 1/1b study...            NO   \n",
              "20673  A Multi-center, Double-blinded, Randomized, Ac...            NO   \n",
              "20675  This randomized, double-blinded dose-finding s...            NO   \n",
              "\n",
              "                                              Conditions  \\\n",
              "0                                 Acute Myeloid Leukemia   \n",
              "1                                    Diabetic Foot Ulcer   \n",
              "2      Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...   \n",
              "3                            Poisoning by Scorpion Sting   \n",
              "4                                         Malaria, Vivax   \n",
              "...                                                  ...   \n",
              "20670                                           Thrombus   \n",
              "20671                                 Healthy Volunteers   \n",
              "20672                             Non-Hodgkin's Lymphoma   \n",
              "20673                               Osteoarthritis, Knee   \n",
              "20675                                   Plaque Psoriasis   \n",
              "\n",
              "                                           Interventions  Sex  \\\n",
              "0                      BIOLOGICAL: Neukoplastâ„¢ (NK-92)  ALL   \n",
              "1      DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...  ALL   \n",
              "2      DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...  ALL   \n",
              "3      BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...  ALL   \n",
              "4      DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...  ALL   \n",
              "...                                                  ...  ...   \n",
              "20670                 DRUG: SHR2285 tablet|DRUG: Placebo  ALL   \n",
              "20671                     DRUG: LEO 153339|DRUG: Placebo  ALL   \n",
              "20672  DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...  ALL   \n",
              "20673  DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...  ALL   \n",
              "20675            BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo  ALL   \n",
              "\n",
              "                             Age         Phases  Enrollment  \\\n",
              "0             ADULT, OLDER_ADULT         PHASE1           7   \n",
              "1             ADULT, OLDER_ADULT  PHASE1|PHASE2          44   \n",
              "2                   CHILD, ADULT  PHASE1|PHASE2          46   \n",
              "3                          CHILD  PHASE2|PHASE3          56   \n",
              "4      CHILD, ADULT, OLDER_ADULT         PHASE2         851   \n",
              "...                          ...            ...         ...   \n",
              "20670                      ADULT         PHASE1          36   \n",
              "20671         ADULT, OLDER_ADULT         PHASE1         108   \n",
              "20672         ADULT, OLDER_ADULT         PHASE1          66   \n",
              "20673         ADULT, OLDER_ADULT         PHASE2         261   \n",
              "20675         ADULT, OLDER_ADULT         PHASE2         108   \n",
              "\n",
              "       Study Recruitment Rate  Duration of Trial  \\\n",
              "0                    0.551598                386   \n",
              "1                    0.443157                604   \n",
              "2                    0.044558               1163   \n",
              "3                    7.279202                117   \n",
              "4                    1.969008                939   \n",
              "...                       ...                ...   \n",
              "20670               12.303371                 89   \n",
              "20671                7.693208                427   \n",
              "20672                0.199434               1438   \n",
              "20673                1.074256                739   \n",
              "20675                0.133504               1367   \n",
              "\n",
              "       Primary Completion Duration of Trial      Allocation  \\\n",
              "0                                     386.0              NA   \n",
              "1                                     492.0      RANDOMIZED   \n",
              "2                                    1163.0      RANDOMIZED   \n",
              "3                                     103.0      RANDOMIZED   \n",
              "4                                     939.0      RANDOMIZED   \n",
              "...                                     ...             ...   \n",
              "20670                                  89.0      RANDOMIZED   \n",
              "20671                                 427.0      RANDOMIZED   \n",
              "20672                                1438.0  NON_RANDOMIZED   \n",
              "20673                                 621.0      RANDOMIZED   \n",
              "20675                                 385.0      RANDOMIZED   \n",
              "\n",
              "      Intervention Model                                            Masking  \\\n",
              "0           SINGLE_GROUP                                               NONE   \n",
              "1               PARALLEL  TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)   \n",
              "2               PARALLEL                                               NONE   \n",
              "3               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "4               PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "...                  ...                                                ...   \n",
              "20670           PARALLEL                               SINGLE (PARTICIPANT)   \n",
              "20671           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20672           PARALLEL                                               NONE   \n",
              "20673           PARALLEL                 DOUBLE (PARTICIPANT, INVESTIGATOR)   \n",
              "20675           PARALLEL  QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...   \n",
              "\n",
              "      Primary Purpose                                   Outcome Measures  \n",
              "0           TREATMENT  Primary Outcomes: Determine the safety / maxim...  \n",
              "1           TREATMENT  Primary Outcomes: Safety Outcome, Number of pa...  \n",
              "2           TREATMENT  Primary Outcomes: Proportion of patients achie...  \n",
              "3           TREATMENT  Primary Outcomes: To demonstrate the effective...  \n",
              "4           TREATMENT  Primary Outcomes: Number of Participants With ...  \n",
              "...               ...                                                ...  \n",
              "20670       TREATMENT  Primary Outcomes: Number of subjects with adve...  \n",
              "20671       TREATMENT  Primary Outcomes: Number of treatment-emergent...  \n",
              "20672       TREATMENT  Primary Outcomes: Number of Participants with ...  \n",
              "20673       TREATMENT  Primary Outcomes: 100mm Pain VAS, Subjects who...  \n",
              "20675       TREATMENT  Primary Outcomes: Proportion of subjects with ...  \n",
              "\n",
              "[20586 rows x 18 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-6c40a00e-376c-49bb-8d78-d5cf4d0701f4\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Study Title</th>\n",
              "      <th>Study Status</th>\n",
              "      <th>Brief Summary</th>\n",
              "      <th>Study Results</th>\n",
              "      <th>Conditions</th>\n",
              "      <th>Interventions</th>\n",
              "      <th>Sex</th>\n",
              "      <th>Age</th>\n",
              "      <th>Phases</th>\n",
              "      <th>Enrollment</th>\n",
              "      <th>Study Recruitment Rate</th>\n",
              "      <th>Duration of Trial</th>\n",
              "      <th>Primary Completion Duration of Trial</th>\n",
              "      <th>Allocation</th>\n",
              "      <th>Intervention Model</th>\n",
              "      <th>Masking</th>\n",
              "      <th>Primary Purpose</th>\n",
              "      <th>Outcome Measures</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Tre...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>NK cells from patients with malignant diseases...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Acute Myeloid Leukemia</td>\n",
              "      <td>BIOLOGICAL: Neukoplastâ„¢ (NK-92)</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>7</td>\n",
              "      <td>0.551598</td>\n",
              "      <td>386</td>\n",
              "      <td>386.0</td>\n",
              "      <td>NA</td>\n",
              "      <td>SINGLE_GROUP</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Determine the safety / maxim...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Clinical Investigation of GalnobaxÂ® for the T...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this study is to determine safe...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Diabetic Foot Ulcer</td>\n",
              "      <td>DRUG: Esmolol hydrochloride|DRUG: Esmolol hydr...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>44</td>\n",
              "      <td>0.443157</td>\n",
              "      <td>604</td>\n",
              "      <td>492.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Safety Outcome, Number of pa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>A Combined Study in Pediatric Cancer Patients ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a multi-site study with plerixafor in ...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblast...</td>\n",
              "      <td>DRUG: plerixafor|DRUG: plerixafor|DRUG: plerix...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT</td>\n",
              "      <td>PHASE1|PHASE2</td>\n",
              "      <td>46</td>\n",
              "      <td>0.044558</td>\n",
              "      <td>1163</td>\n",
              "      <td>1163.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Proportion of patients achie...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>A Trial of Equine F (ab')2 Antivenom for Treat...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This study has the objective to demonstrate th...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Poisoning by Scorpion Sting</td>\n",
              "      <td>BIOLOGICAL: Equine F(ab')2 antivenom|OTHER: In...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD</td>\n",
              "      <td>PHASE2|PHASE3</td>\n",
              "      <td>56</td>\n",
              "      <td>7.279202</td>\n",
              "      <td>117</td>\n",
              "      <td>103.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: To demonstrate the effective...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Ph 2B/3 Tafenoquine (TFQ) Study in Prevention ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The purpose of this two part study is to test ...</td>\n",
              "      <td>YES</td>\n",
              "      <td>Malaria, Vivax</td>\n",
              "      <td>DRUG: Chloroquine 600mg|DRUG: Chloroquine 300m...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>851</td>\n",
              "      <td>1.969008</td>\n",
              "      <td>939</td>\n",
              "      <td>939.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of Participants With ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20670</th>\n",
              "      <td>The Multiple Dose of PK/PD Study of SHR2285 Ta...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>The study is a randomized, single-blind, place...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Thrombus</td>\n",
              "      <td>DRUG: SHR2285 tablet|DRUG: Placebo</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>36</td>\n",
              "      <td>12.303371</td>\n",
              "      <td>89</td>\n",
              "      <td>89.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>SINGLE (PARTICIPANT)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of subjects with adve...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20671</th>\n",
              "      <td>A Single and Multiple Ascending-dose Trial of ...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This is a first-in-human study in adult health...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Healthy Volunteers</td>\n",
              "      <td>DRUG: LEO 153339|DRUG: Placebo</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>108</td>\n",
              "      <td>7.693208</td>\n",
              "      <td>427</td>\n",
              "      <td>427.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of treatment-emergent...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20672</th>\n",
              "      <td>A Study of Escalating Doses of DCDS0780A in Pa...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This open-label, multicenter, Phase 1/1b study...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Non-Hodgkin's Lymphoma</td>\n",
              "      <td>DRUG: DCDS0780A|DRUG: Rituximab|DRUG: Obinutuz...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE1</td>\n",
              "      <td>66</td>\n",
              "      <td>0.199434</td>\n",
              "      <td>1438</td>\n",
              "      <td>1438.0</td>\n",
              "      <td>NON_RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>NONE</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Number of Participants with ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20673</th>\n",
              "      <td>Clinical Trial of YYC301 for Treatment of Oste...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>A Multi-center, Double-blinded, Randomized, Ac...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Osteoarthritis, Knee</td>\n",
              "      <td>DRUG: Celecoxib 200mg|DRUG: Tramadol 37.5Mg+ C...</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>261</td>\n",
              "      <td>1.074256</td>\n",
              "      <td>739</td>\n",
              "      <td>621.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>DOUBLE (PARTICIPANT, INVESTIGATOR)</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: 100mm Pain VAS, Subjects who...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20675</th>\n",
              "      <td>A Study to Evaluate ABY-035 in Subjects With M...</td>\n",
              "      <td>COMPLETED</td>\n",
              "      <td>This randomized, double-blinded dose-finding s...</td>\n",
              "      <td>NO</td>\n",
              "      <td>Plaque Psoriasis</td>\n",
              "      <td>BIOLOGICAL: ABY-035|BIOLOGICAL: Placebo</td>\n",
              "      <td>ALL</td>\n",
              "      <td>ADULT, OLDER_ADULT</td>\n",
              "      <td>PHASE2</td>\n",
              "      <td>108</td>\n",
              "      <td>0.133504</td>\n",
              "      <td>1367</td>\n",
              "      <td>385.0</td>\n",
              "      <td>RANDOMIZED</td>\n",
              "      <td>PARALLEL</td>\n",
              "      <td>QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTI...</td>\n",
              "      <td>TREATMENT</td>\n",
              "      <td>Primary Outcomes: Proportion of subjects with ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>20586 rows × 18 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-6c40a00e-376c-49bb-8d78-d5cf4d0701f4')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-6c40a00e-376c-49bb-8d78-d5cf4d0701f4 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-6c40a00e-376c-49bb-8d78-d5cf4d0701f4');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-ac1ea9e9-ec9b-4a06-ac73-de4920e19b7b\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ac1ea9e9-ec9b-4a06-ac73-de4920e19b7b')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-ac1ea9e9-ec9b-4a06-ac73-de4920e19b7b button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_b07242f9-52ab-473d-b973-cca4f19f0c24\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('data1')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_b07242f9-52ab-473d-b973-cca4f19f0c24 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('data1');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "data1",
              "summary": "{\n  \"name\": \"data1\",\n  \"rows\": 20586,\n  \"fields\": [\n    {\n      \"column\": \"Study Title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20546,\n        \"samples\": [\n          \"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread\",\n          \"Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6\",\n          \"Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 8,\n        \"samples\": [\n          \"UNKNOWN\",\n          \"SUSPENDED\",\n          \"COMPLETED\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Brief Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20438,\n        \"samples\": [\n          \"This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque psoriasis.\",\n          \"The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST\\u00c2\\u00ae) compared to PERFOROMIST\\u00c2\\u00ae, in a population of participants with moderate-to-very severe Chronic Obstructive Pulmonary Disease (COPD) over 21 days.\",\n          \"This is a first-in-human, Phase I, single-dose escalation and multiple-dose escalation clinical trial for FTP-198 conducted in Australian healthy volunteers. The safety, tolerability, and pharmacokinetics of FTP-198 suspension in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Results\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"YES\",\n          \"NO\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Conditions\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 7837,\n        \"samples\": [\n          \"Recurrent Kaposi Sarcoma|Skin Kaposi Sarcoma\",\n          \"Diabetes Mellitus, Type 2|Non-Alcoholic Fatty Liver Disease\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Interventions\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 18143,\n        \"samples\": [\n          \"DRUG: Pemigatinib|DRUG: Gemcitabine|DRUG: Pembrolizumab|DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Retifanlimab|DRUG: Cisplatin\",\n          \"BIOLOGICAL: CYP-001\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sex\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"ALL\",\n          \"FEMALE\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Age\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 6,\n        \"samples\": [\n          \"ADULT, OLDER_ADULT\",\n          \"CHILD, ADULT\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Phases\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"PHASE1|PHASE2\",\n          \"PHASE3\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Enrollment\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3541,\n        \"min\": 1,\n        \"max\": 477102,\n        \"num_unique_values\": 1341,\n        \"samples\": [\n          230,\n          273\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Study Recruitment Rate\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 47.709349724437075,\n        \"min\": 0.0011275127619133577,\n        \"max\": 4816.602870813397,\n        \"num_unique_values\": 17053,\n        \"samples\": [\n          0.11924507438681142,\n          0.06196158913550219\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 669,\n        \"min\": -41927,\n        \"max\": 3787,\n        \"num_unique_values\": 2522,\n        \"samples\": [\n          2035,\n          165\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Completion Duration of Trial\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 526.974666487615,\n        \"min\": 0.0,\n        \"max\": 3662.0,\n        \"num_unique_values\": 2278,\n        \"samples\": [\n          1977.0,\n          71.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Allocation\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"NA\",\n          \"RANDOMIZED\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Intervention Model\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"PARALLEL\",\n          \"FACTORIAL\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Masking\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 18,\n        \"samples\": [\n          \"NONE\",\n          \"TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Primary Purpose\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 9,\n        \"samples\": [\n          \"SCREENING\",\n          \"PREVENTION\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Outcome Measures\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 20482,\n        \"samples\": [\n          \"Primary Outcomes: Prostate-Specific Antigen (PSA) Response Greater Than or Equal to 50%, The primary endpoint is a PSA response at 8 weeks or greater from starting study treatment and with a minimum of 3 treatments administered.\\n\\nA PSA response is defined as a \\u00e2\\u2030\\u00a550% PSA decline at 8 weeks or greater from the time of starting study treatment. The two-stage minimax design of the study will be utilized to determine whether further investigation of the study drug is warranted., 8 Weeks, 6 months |  Secondary Outcomes: PSA Progression-free Survival (PFS), PSA progression-free survival (pPFS) defined as the time from enrollment until PSA progression by Prostate Cancer Working Group 3 (PCWG3) or death, whichever occurs earlier. Subjects without pPFS at the time of data cut-off will be censored at the date of last adequate cancer assessment. PSA progression-free survival will be reported using Kaplan-Meier estimates, with 95% confidence interval for median time-to-event., pPFS will be assessed 12 months after enrollment of last subject.|Radiographic Progression-free Survival (PFS), Radiographic progression-free survival (rPFS) defined as the time from enrollment until radiographic progression by PCWG3 or death, whichever occurs earlier. Subjects without rPFS at the time of data cut-off will be censored at the date of last known to be alive. Radiographic progression-free survival will be reported using Kaplan-Meier estimates, with 95% confidence interval for median time-to-event., rPFS will be assessed 12 months after enrollment of last subject.|Overall Survival (OS), Overall survival (OS) defined as the time from enrollment until death on study. Subjects who are alive at the time of data cut-off will be censored at the date of last known to be alive. OS will be reported using Kaplan-Meier estimates, with 95% CI for median time-to-event., Overall survival with be assessed at 3 years from time of enrollment of last study subject.\",\n          \"Primary Outcomes: MTD, The primary objective of this study is to determine the maximum tolerated dose (MTD) of TTC-352 for the treatment of metastatic ER+ breast cancer progressing after endocrine therapy, 24 months |  Secondary Outcomes: Best response to treatment, Determine patient best response to treatment (complete response, partial response, stable disease or disease progression) after at least two 28-day cycles of treatment with TTC 352., 24 months|PFS, Determine durations of progression-free survival after at least two 28-day cycles of treatment with TTC 352, 24 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Treatment-related adverse events as assessed by CTCAE v4.0 will be collected in presented in tabular form at the end of study., 24 months|Maximum Plasma Concentration (Cmax), Blood samples will be collected at the following Cycle 1 time points:\\n\\nDay 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).\\n\\nDay 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.\\n\\nTTC-352 blood levels will be measured at above time points and Cmax will be calculated., 24 months|Half life, Blood samples will be collected at the following Cycle 1 time points:\\n\\nDay 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).\\n\\nDay 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.\\n\\nTTC-352 blood levels will be measured at above time points and half life of TTC-352 will be calculated., 24 months|Area Under the Curve (AUC), Blood samples will be collected at the following Cycle 1 time points:\\n\\nDay 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).\\n\\nDay 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.\\n\\nTTC-352 blood levels will be measured at above time points and AUC will be calculated., 24 months\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 27
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Save the DataFrame to an Excel file\n",
        "data1.to_excel('updated_data1.xlsx', index=False)\n",
        "\n",
        "# Confirm the file is saved\n",
        "print(\"Data has been saved as 'updated_data1.xlsx'\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cCMYGY02cYzR",
        "outputId": "e3c4c12e-cb35-4bff-99bf-3a19670865e8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Data has been saved as 'updated_data1.xlsx'\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.preprocessing import StandardScaler"
      ],
      "metadata": {
        "id": "2BcG8Sz30U2u"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "scaler = StandardScaler()\n",
        "data1[numerical_cols] = scaler.fit_transform(data1[numerical_cols])"
      ],
      "metadata": {
        "id": "mbkLSgss0T2-",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "95c25c7e-df41-48bf-e84a-9e2013479228"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-30-938c1ac55b65>:2: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame.\n",
            "Try using .loc[row_indexer,col_indexer] = value instead\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  data1[numerical_cols] = scaler.fit_transform(data1[numerical_cols])\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.model_selection import train_test_split # Import train_test_split from the correct module"
      ],
      "metadata": {
        "id": "2OCrPZoQcmJw"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.model_selection import train_test_split\n",
        "\n",
        "# Assuming 'target' is your target variable column name and 'data1' contains your features\n",
        "X = data1.drop('Study Recruitment Rate', axis=1)  # Features (exclude the target column)\n",
        "y = data1['Study Recruitment Rate']  # Target variable\n",
        "\n",
        "# Split the data into training and testing sets\n",
        "X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state=42)\n",
        "\n",
        "# random_state ensures consistent splitting for reproducibility\n",
        "\n",
        "# Print the shapes of the resulting datasets to verify the split\n",
        "print(\"X_train shape:\", X_train.shape)\n",
        "print(\"X_test shape:\", X_test.shape)\n",
        "print(\"y_train shape:\", y_train.shape)\n",
        "print(\"y_test shape:\", y_test.shape)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6eULufmsgzWs",
        "outputId": "cf838063-e7b9-44a8-a057-cf499489d701"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "X_train shape: (16468, 17)\n",
            "X_test shape: (4118, 17)\n",
            "y_train shape: (16468,)\n",
            "y_test shape: (4118,)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data1.columns"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xOjFKZ2jhL2g",
        "outputId": "21fd0d56-5876-4a3b-8bd4-25002181f444"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Index(['Study Title', 'Study Status', 'Brief Summary', 'Study Results',\n",
              "       'Conditions', 'Interventions', 'Sex', 'Age', 'Phases', 'Enrollment',\n",
              "       'Study Recruitment Rate', 'Duration of Trial',\n",
              "       'Primary Completion Duration of Trial', 'Allocation',\n",
              "       'Intervention Model', 'Masking', 'Primary Purpose', 'Outcome Measures'],\n",
              "      dtype='object')"
            ]
          },
          "metadata": {},
          "execution_count": 33
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "numerical_cols = ['Enrollment', 'Study Recruitment Rate', 'Duration of Trial', 'Primary Completion Duration of Trial']\n",
        "textual_cols = ['Study Title', 'Study Status', 'Brief Summary', 'Study Results',\n",
        "       'Conditions', 'Interventions', 'Sex', 'Age', 'Phases','Allocation',\n",
        "       'Intervention Model', 'Masking', 'Primary Purpose', 'Outcome Measures']"
      ],
      "metadata": {
        "id": "l8tOR8SiqUlO"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Correct numerical_cols to exclude the target column\n",
        "numerical_cols = ['Enrollment', 'Duration of Trial', 'Primary Completion Duration of Trial']\n",
        "\n",
        "# Split the data into features and target\n",
        "X_train, X_test, y_train, y_test = train_test_split(\n",
        "    data1[textual_cols + numerical_cols],  # Features (textual + numerical columns)\n",
        "    data1['Study Recruitment Rate'],       # Target column\n",
        "    test_size=0.2,\n",
        "    random_state=42\n",
        ")\n",
        " # Adjust as needed"
      ],
      "metadata": {
        "id": "e3G1QIlYm0uG"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "X_train, X_test, y_train, y_test = train_test_split(\n",
        "    data1[textual_cols + numerical_cols],  # Features (textual + numerical columns)\n",
        "    data1['Study Recruitment Rate'],       # Target column\n",
        "    test_size=0.2,\n",
        "    random_state=42\n",
        ")"
      ],
      "metadata": {
        "id": "W2dGSg5UpMze"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"X_train shape:\", X_train.shape)\n",
        "print(\"X_test shape:\", X_test.shape)\n",
        "print(\"y_train shape:\", y_train.shape)\n",
        "print(\"y_test shape:\", y_test.shape)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7ParPGQCqiTK",
        "outputId": "ce034c4a-e5b0-456e-d765-0e4a5fce039a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "X_train shape: (16468, 17)\n",
            "X_test shape: (4118, 17)\n",
            "y_train shape: (16468,)\n",
            "y_test shape: (4118,)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install transformers datasets torch sklearn"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Lgkyn_EBqmyb",
        "outputId": "d35cb3ae-28c2-4e6d-d243-8df960d28257"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.10/dist-packages (4.47.0)\n",
            "Collecting datasets\n",
            "  Downloading datasets-3.2.0-py3-none-any.whl.metadata (20 kB)\n",
            "Requirement already satisfied: torch in /usr/local/lib/python3.10/dist-packages (2.5.1+cu121)\n",
            "Collecting sklearn\n",
            "  Downloading sklearn-0.0.post12.tar.gz (2.6 kB)\n",
            "  \u001b[1;31merror\u001b[0m: \u001b[1msubprocess-exited-with-error\u001b[0m\n",
            "  \n",
            "  \u001b[31m×\u001b[0m \u001b[32mpython setup.py egg_info\u001b[0m did not run successfully.\n",
            "  \u001b[31m│\u001b[0m exit code: \u001b[1;36m1\u001b[0m\n",
            "  \u001b[31m╰─>\u001b[0m See above for output.\n",
            "  \n",
            "  \u001b[1;35mnote\u001b[0m: This error originates from a subprocess, and is likely not a problem with pip.\n",
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25herror\n",
            "\u001b[1;31merror\u001b[0m: \u001b[1mmetadata-generation-failed\u001b[0m\n",
            "\n",
            "\u001b[31m×\u001b[0m Encountered error while generating package metadata.\n",
            "\u001b[31m╰─>\u001b[0m See above for output.\n",
            "\n",
            "\u001b[1;35mnote\u001b[0m: This is an issue with the package mentioned above, not pip.\n",
            "\u001b[1;36mhint\u001b[0m: See above for details.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install datasets\n",
        "import torch\n",
        "from sklearn.preprocessing import StandardScaler\n",
        "from sklearn.model_selection import train_test_split\n",
        "from transformers import AutoTokenizer, AutoModelForSequenceClassification, Trainer, TrainingArguments\n",
        "from datasets import Dataset # Change the import to datasets\n",
        "import pandas as pd\n",
        "from torch.utils.data import Dataset as TorchDataset"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Oj3MzmzZrPfk",
        "outputId": "16193480-04b9-4de5-da76-9c9c67267ae9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting datasets\n",
            "  Using cached datasets-3.2.0-py3-none-any.whl.metadata (20 kB)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from datasets) (3.16.1)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.10/dist-packages (from datasets) (1.26.4)\n",
            "Requirement already satisfied: pyarrow>=15.0.0 in /usr/local/lib/python3.10/dist-packages (from datasets) (17.0.0)\n",
            "Collecting dill<0.3.9,>=0.3.0 (from datasets)\n",
            "  Downloading dill-0.3.8-py3-none-any.whl.metadata (10 kB)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (from datasets) (2.2.2)\n",
            "Requirement already satisfied: requests>=2.32.2 in /usr/local/lib/python3.10/dist-packages (from datasets) (2.32.3)\n",
            "Requirement already satisfied: tqdm>=4.66.3 in /usr/local/lib/python3.10/dist-packages (from datasets) (4.67.1)\n",
            "Collecting xxhash (from datasets)\n",
            "  Downloading xxhash-3.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (12 kB)\n",
            "Collecting multiprocess<0.70.17 (from datasets)\n",
            "  Downloading multiprocess-0.70.16-py310-none-any.whl.metadata (7.2 kB)\n",
            "Collecting fsspec<=2024.9.0,>=2023.1.0 (from fsspec[http]<=2024.9.0,>=2023.1.0->datasets)\n",
            "  Downloading fsspec-2024.9.0-py3-none-any.whl.metadata (11 kB)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from datasets) (3.11.10)\n",
            "Requirement already satisfied: huggingface-hub>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from datasets) (0.27.0)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from datasets) (24.2)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from datasets) (6.0.2)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (2.4.4)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.3.2)\n",
            "Requirement already satisfied: async-timeout<6.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (4.0.3)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (24.3.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (0.2.1)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.18.3)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->datasets) (4.12.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (2024.12.14)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2024.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2024.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas->datasets) (1.17.0)\n",
            "Downloading datasets-3.2.0-py3-none-any.whl (480 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m480.6/480.6 kB\u001b[0m \u001b[31m16.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading dill-0.3.8-py3-none-any.whl (116 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m116.3/116.3 kB\u001b[0m \u001b[31m12.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading fsspec-2024.9.0-py3-none-any.whl (179 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m179.3/179.3 kB\u001b[0m \u001b[31m15.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading multiprocess-0.70.16-py310-none-any.whl (134 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m134.8/134.8 kB\u001b[0m \u001b[31m14.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading xxhash-3.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (194 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m194.1/194.1 kB\u001b[0m \u001b[31m21.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: xxhash, fsspec, dill, multiprocess, datasets\n",
            "  Attempting uninstall: fsspec\n",
            "    Found existing installation: fsspec 2024.10.0\n",
            "    Uninstalling fsspec-2024.10.0:\n",
            "      Successfully uninstalled fsspec-2024.10.0\n",
            "\u001b[31mERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.\n",
            "gcsfs 2024.10.0 requires fsspec==2024.10.0, but you have fsspec 2024.9.0 which is incompatible.\u001b[0m\u001b[31m\n",
            "\u001b[0mSuccessfully installed datasets-3.2.0 dill-0.3.8 fsspec-2024.9.0 multiprocess-0.70.16 xxhash-3.5.0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Load BioBERT tokenizer\n",
        "tokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-v1.1\")\n",
        "\n",
        "# Function to tokenize textual columns\n",
        "def tokenize_function(text_data):\n",
        "    return tokenizer(text_data, padding='max_length', truncation=True, max_length=512)\n",
        "\n",
        "# Tokenizing the textual columns\n",
        "X_train_tokenized = X_train[textual_cols].apply(lambda row: ' '.join(row.astype(str)), axis=1)\n",
        "X_test_tokenized = X_test[textual_cols].apply(lambda row: ' '.join(row.astype(str)), axis=1)\n",
        "\n",
        "train_encodings = tokenizer(list(X_train_tokenized), padding=True, truncation=True, max_length=512)\n",
        "test_encodings = tokenizer(list(X_test_tokenized), padding=True, truncation=True, max_length=512)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 269,
          "referenced_widgets": [
            "2302b059b0094e94896cff7d6e6f2db0",
            "126be6dbc52d4d79b3ced479a27f5739",
            "7984e4b259ab4679bc293bd004f9d0b2",
            "2147e1746ebe425f8118d3a722bc967e",
            "bb8feea3590c4493a2b3bc0a730279f3",
            "7d6ef8ba218b4466ae3d260c27fea432",
            "5aa69f7724654f9d9b0471591e543faa",
            "f716de48c1ee4b9b833f459e41fd7560",
            "a71c4ada43ac4e088883654f352af207",
            "82d32670d7b541579a4e99e349c108d7",
            "e6b859fe978640eeb9b52f2959514320",
            "36a39041fcb9418ba77771d31b632cad",
            "60e5133645d241e1ac8433041e20ad41",
            "8e155c3522484a2bbe594c8d22efd9c1",
            "8fa10b7f24cb44788c2e5ce43709d05b",
            "3cf5897c4d274fad80065df9d477e029",
            "87201dbab4624b71b4651f47991b762e",
            "02404362752c43a2bcba806d851298ec",
            "7677487f2fd14c82abe137048356c7bd",
            "12a9ff1599564a6c85a74825ca06fc06",
            "0c69059325ec4b1e9671cd1e83574c2b",
            "60d25f1eeed44459bcc8e1294dee2616",
            "aa72a9c4d048432bb28e3fc494e8440b",
            "59838d16e4bf4e5eab2054fba0aa5c76",
            "2e030ddedcfc4d2dbe4fd4d9a5d8be07",
            "e3d6729d540842fd8c065d933a2b5448",
            "d0b5c3f078134bd1b275f32665cff826",
            "cd67b959b37546ec8795448a264eab33",
            "e0c7fcfc44744d7f94fe60898b8d4dd8",
            "12e7bf8a4cb04be6ac41333ce1f2ca41",
            "7961ad44532c4fa8b6a1f99363b0b957",
            "c07eb7ab296d4a8e81dd6c87dace00a3",
            "7333a2fab91b4baf99b822d513399b68",
            "3881c68bd8064fbe8963a038fce9455c",
            "9eb17f7511a44254acb3078b2eefd4fa",
            "f4135e59b7aa42f0af35a00726641f0e",
            "5fe8e2f627bf4a0ea1f64818218fb930",
            "9b6e0dc1d8fd49528608131220316121",
            "edb7b73285d44f3a92f7fed42148e82e",
            "cdea772afffd4cfca62a01514b8e54cc",
            "bdf6b240e87f42549843612897670819",
            "98babaab1ffc47ff98284a7742180c90",
            "8ce2cb82a5f74f7d905bd4c953e3ee63",
            "243d39a3150b4d69bb1d90358c3dc09e"
          ]
        },
        "id": "pyoPa5F4rVZH",
        "outputId": "2567d583-4cb0-463f-e27f-4c14300214c0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/49.0 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "2302b059b0094e94896cff7d6e6f2db0"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/462 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "36a39041fcb9418ba77771d31b632cad"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.txt:   0%|          | 0.00/213k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "aa72a9c4d048432bb28e3fc494e8440b"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "3881c68bd8064fbe8963a038fce9455c"
            }
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Add numerical columns to the tokenized text\n",
        "class CustomDataset(TorchDataset):\n",
        "    def __init__(self, encodings, numerical_data, labels):\n",
        "        self.encodings = encodings\n",
        "        self.numerical_data = numerical_data\n",
        "        self.labels = labels\n",
        "\n",
        "    def __getitem__(self, idx):\n",
        "        item = {key: torch.tensor(val[idx]) for key, val in self.encodings.items()}\n",
        "        # Access numerical features directly by index and ensure they are float32\n",
        "        item['numerical_features'] = self.numerical_data[idx].type(torch.float32)  # Change to float32\n",
        "        item['labels'] = torch.tensor(self.labels[idx], dtype=torch.float32) # Change to float32\n",
        "        return item\n",
        "\n",
        "    def __len__(self):\n",
        "        return len(self.labels)\n",
        "\n",
        "# Ensure numerical data is included\n",
        "numerical_train = X_train[numerical_cols]\n",
        "numerical_test = X_test[numerical_cols]\n",
        "\n",
        "# Standardize numerical features (already done, assuming they're scaled)\n",
        "# Ensure numerical data is float32\n",
        "numerical_train = torch.tensor(numerical_train.values, dtype=torch.float32)  # Change to float32\n",
        "numerical_test = torch.tensor(numerical_test.values, dtype=torch.float32)  # Change to float32\n",
        "\n",
        "# Create the train and test datasets\n",
        "train_dataset = CustomDataset(train_encodings, numerical_train, y_train.values)\n",
        "test_dataset = CustomDataset(test_encodings, numerical_test, y_test.values)"
      ],
      "metadata": {
        "id": "53D1IKcLr0HV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Load BioBERT model\n",
        "model = AutoModelForSequenceClassification.from_pretrained(\"dmis-lab/biobert-v1.1\", num_labels=1)\n",
        "\n",
        "# Define the training arguments\n",
        "training_args = TrainingArguments(\n",
        "    output_dir='./results',          # output directory\n",
        "    num_train_epochs=3,              # number of training epochs\n",
        "    per_device_train_batch_size=8,   # batch size for training\n",
        "    per_device_eval_batch_size=8,    # batch size for evaluation\n",
        "    warmup_steps=500,                # number of warmup steps for learning rate scheduler\n",
        "    weight_decay=0.01,               # strength of weight decay\n",
        "    logging_dir='./logs',            # directory for storing logs\n",
        "    logging_steps=10,\n",
        "    evaluation_strategy=\"epoch\",     # evaluate after each epoch\n",
        "    save_strategy=\"epoch\",           # save checkpoint after each epoch\n",
        "    load_best_model_at_end=True      # load the best model when finished training\n",
        ")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 138,
          "referenced_widgets": [
            "cd5a937bd0794a238482e7f0bef529d9",
            "716f43bca3d94aa88152c22d97b66921",
            "95957a9e2c454ca2ace9964d8d62a865",
            "80a079a8fdda4cf59b9036cda2d67629",
            "0652aa8e74fd4548a804db34b8fe8a8b",
            "9e5c99b638a44dce98d632ab8da859d4",
            "9c61c8a7a04e4021bd5d8a31a00f2be5",
            "7eac63f340ae4e7b9b73667b24b34cf4",
            "3458853c665c40a583766717f4f35058",
            "612305bc53854bb9a17481c3d95ecfb1",
            "4028065cc4eb4daf9871facde97a3922"
          ]
        },
        "id": "uYh_dFNer9De",
        "outputId": "53ec85e9-0b96-499c-ae61-0eafa265c507"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "pytorch_model.bin:   0%|          | 0.00/433M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "cd5a937bd0794a238482e7f0bef529d9"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Some weights of BertForSequenceClassification were not initialized from the model checkpoint at dmis-lab/biobert-v1.1 and are newly initialized: ['classifier.bias', 'classifier.weight']\n",
            "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n",
            "/usr/local/lib/python3.10/dist-packages/transformers/training_args.py:1575: FutureWarning: `evaluation_strategy` is deprecated and will be removed in version 4.46 of 🤗 Transformers. Use `eval_strategy` instead\n",
            "  warnings.warn(\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Create the Trainer\n",
        "trainer = Trainer(\n",
        "    model=model,                         # the instantiated 🤗 transformers model to be trained\n",
        "    args=training_args,                  # training arguments, defined above\n",
        "    train_dataset=train_dataset,         # training dataset\n",
        "    eval_dataset=test_dataset            # evaluation dataset\n",
        ")\n",
        "\n",
        "# Train the model\n",
        "trainer.train()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 360
        },
        "id": "_JCCrNojsCsm",
        "outputId": "4cd27d94-1018-49dd-efba-50bb2fb3c42d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "        window._wandbApiKey = new Promise((resolve, reject) => {\n",
              "            function loadScript(url) {\n",
              "            return new Promise(function(resolve, reject) {\n",
              "                let newScript = document.createElement(\"script\");\n",
              "                newScript.onerror = reject;\n",
              "                newScript.onload = resolve;\n",
              "                document.body.appendChild(newScript);\n",
              "                newScript.src = url;\n",
              "            });\n",
              "            }\n",
              "            loadScript(\"https://cdn.jsdelivr.net/npm/postmate/build/postmate.min.js\").then(() => {\n",
              "            const iframe = document.createElement('iframe')\n",
              "            iframe.style.cssText = \"width:0;height:0;border:none\"\n",
              "            document.body.appendChild(iframe)\n",
              "            const handshake = new Postmate({\n",
              "                container: iframe,\n",
              "                url: 'https://wandb.ai/authorize'\n",
              "            });\n",
              "            const timeout = setTimeout(() => reject(\"Couldn't auto authenticate\"), 5000)\n",
              "            handshake.then(function(child) {\n",
              "                child.on('authorize', data => {\n",
              "                    clearTimeout(timeout)\n",
              "                    resolve(data)\n",
              "                });\n",
              "            });\n",
              "            })\n",
              "        });\n",
              "    "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\u001b[34m\u001b[1mwandb\u001b[0m: Appending key for api.wandb.ai to your netrc file: /root/.netrc\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "Tracking run with wandb version 0.19.1"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "Run data is saved locally in <code>/content/wandb/run-20241219_222054-stqqux4m</code>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "Syncing run <strong><a href='https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface/runs/stqqux4m' target=\"_blank\">./results</a></strong> to <a href='https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface' target=\"_blank\">Weights & Biases</a> (<a href='https://wandb.me/developer-guide' target=\"_blank\">docs</a>)<br>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              " View project at <a href='https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface' target=\"_blank\">https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface</a>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              " View run at <a href='https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface/runs/stqqux4m' target=\"_blank\">https://wandb.ai/shauryasphinx-iiit-ranchi/huggingface/runs/stqqux4m</a>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "    <div>\n",
              "      \n",
              "      <progress value='6177' max='6177' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
              "      [6177/6177 1:31:06, Epoch 3/3]\n",
              "    </div>\n",
              "    <table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              " <tr style=\"text-align: left;\">\n",
              "      <th>Epoch</th>\n",
              "      <th>Training Loss</th>\n",
              "      <th>Validation Loss</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <td>1</td>\n",
              "      <td>0.015500</td>\n",
              "      <td>3.045868</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>2</td>\n",
              "      <td>0.232000</td>\n",
              "      <td>3.045332</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>3</td>\n",
              "      <td>0.005600</td>\n",
              "      <td>3.031166</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table><p>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "TrainOutput(global_step=6177, training_loss=0.45483387495929783, metrics={'train_runtime': 5480.9853, 'train_samples_per_second': 9.014, 'train_steps_per_second': 1.127, 'total_flos': 1.2998621868576768e+16, 'train_loss': 0.45483387495929783, 'epoch': 3.0})"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "trainer.evaluate()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 124
        },
        "id": "XaGl2MKRsHAQ",
        "outputId": "7c72ec68-ade6-44d9-b7f9-7cc58217728f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "    <div>\n",
              "      \n",
              "      <progress value='515' max='515' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
              "      [515/515 02:01]\n",
              "    </div>\n",
              "    "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'eval_loss': 3.0311660766601562,\n",
              " 'eval_runtime': 122.1154,\n",
              " 'eval_samples_per_second': 33.722,\n",
              " 'eval_steps_per_second': 4.217,\n",
              " 'epoch': 3.0}"
            ]
          },
          "metadata": {},
          "execution_count": 45
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Save the fine-tuned model\n",
        "output_dir = \"./fine_tuned_biobert\"\n",
        "model.save_pretrained(output_dir)\n",
        "\n",
        "# Save the tokenizer\n",
        "tokenizer.save_pretrained(output_dir)\n",
        "\n",
        "print(f\"Model and tokenizer saved to {output_dir}\")"
      ],
      "metadata": {
        "id": "8-E38bvnyqcU",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "95c75dd7-1525-4b26-86c0-cad31734f542"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Model and tokenizer saved to ./fine_tuned_biobert\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Specify the directory on your D drive\n",
        "output_dir = \"D:/fine_tuned_biobert\"\n",
        "\n",
        "# Save the model and tokenizer\n",
        "model.save_pretrained(output_dir)\n",
        "tokenizer.save_pretrained(output_dir)\n",
        "\n",
        "print(f\"Model and weights saved to {output_dir}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2QPJpeLqYiXb",
        "outputId": "3dbac7d0-6927-41da-9e6f-716b4e4a347f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Model and weights saved to D:/fine_tuned_biobert\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Loading the Saved Model Later\n",
        "from transformers import AutoModelForSequenceClassification, AutoTokenizer\n",
        "\n",
        "# Load the fine-tuned model and tokenizer\n",
        "model = AutoModelForSequenceClassification.from_pretrained(output_dir)\n",
        "tokenizer = AutoTokenizer.from_pretrained(output_dir)\n",
        "\n",
        "print(\"Model and tokenizer successfully loaded!\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "73iwm1G6XVaw",
        "outputId": "4e6d3150-57a8-409e-edd6-588be0111b3d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Model and tokenizer successfully loaded!\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "output_dir = \"./fine_tuned_biobert\"\n",
        "\n",
        "# Save the model and tokenizer\n",
        "model.save_pretrained(output_dir)\n",
        "tokenizer.save_pretrained(output_dir)\n",
        "\n",
        "print(f\"Model and tokenizer saved to {output_dir}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "aF1mJH2zXj1l",
        "outputId": "92a6979f-6650-4865-bed6-d767eb1b0a8f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Model and tokenizer saved to ./fine_tuned_biobert\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import shutil\n",
        "\n",
        "# Zip the model directory\n",
        "shutil.make_archive(output_dir, 'zip', output_dir)\n",
        "print(f\"Model and tokenizer zipped as {output_dir}.zip\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6lSS1mM_a3mr",
        "outputId": "6d03eec3-e6df-4ac2-8923-9599bf1283ae"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Model and tokenizer zipped as ./fine_tuned_biobert.zip\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import files\n",
        "\n",
        "# Download the zipped file\n",
        "files.download(f\"{output_dir}.zip\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "SiTjG88Ya41U",
        "outputId": "c3be0215-9ed2-4b4a-d681-7932593ed8de"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_1a015e74-f444-4b9c-be7f-cc32ed12141f\", \"fine_tuned_biobert.zip\", 401864300)"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "8YfMnpMUbDba"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}